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A2780cis  cisplatin-sensitive human ovarian carcinoma cell line 
A2780R  cisplatin-resistant human ovarian carcinoma cell line 
A549   lung cancer cell line 
bpy   2,2’-bipyridine 
cod   cyclooctadiene 
COSY   Correlation Spectroscopy 
d   doublet 
DMF   dimethylformamide 
DMSO   dimethylsulfoxide 
DNA   deoxyribonucleic acid 
dtdeg   bis[4’-(2,2’:6’,2”-terpyridyl)]-diethyleneglycolether 
H4edta   ethylene diamine tetraacetic acid 
en   ethylene diamine 
EPR   electron paramagnetic resonance spectroscopy 
ESI-MS  electrospray ionization mass spectroscopy 
EtOH   ethanol 
9egua   9-ethylguanine 
FAAS   flameless atomic absorption spectroscopy 
FBS   fetal bovine serum 
GSH   glutathione 
HBL-100  non tumorigenic epithelial cell line 
HCT-15  colorectal cancer cell line 
hr   hour 
Hs683   glioblastoma cell line 
IC50   concentration of a compound that induces 50 % of growth inhibition of 
   cells compared to untreated cells 
J   couplin constant in NMR 
KB   carcinoma cell line 
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L1210/0  cisplatin-sensitive mouse leukemia cell line 
L1210/2  cisplatin-resistant mouse leukemia cell line 
LoVo   colorectal cancer cell line 
M   molar 
MCF-7  breast cancer cell line 
MeOH   methanol 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide 
m/z   mass to charge ratio 
NMR   nuclear magnetic resonance 
NOE   nuclear Overhauser effect 
NOESY  nuclear Overhauser effect spectroscopy 
OD   optical density 
PBS   phosphate buffered saline 
ppm   parts per million 
q   quartet 
qpy   4’-pyridyl-2,2’:6’,2”-terpyridine 
RT   room temperature 
s   singlet, or second 
SAR   structure-activity relationships 
t   triplet 
T1   nuclear longitudinal relaxation time 
T2   nuclear transverse relaxation time 
tpy   2,2:6’,2”-terpyridine 
U-373MG  glioblastoma cell line 
UV-VIS  ultraviolet visible 














Metals are often considered to be toxic for living systems. However, many metal ions are vital 
for the human body, since they play a diversity of important roles in biological processes. As 
already stated by Paracelsus (1493-1541): “Dosis sola facit venenum” (“Only the dose makes 
the poison”), any toxicity of metal ions depends on the actual concentration present. This 
knowledge has opened the way for medicinal application of metal ions. Metals in medicine 
hold great promise, since positively charged metal centers can interact with negatively 
charged biomolecules, and the constituents of proteins and nucleic acids supply good ligands 
for binding to metal ions. Especially complexes of the second- and third-row transition metals 
offer excellent perspectives for use as drugs, because of their slow ligand exchange, which 
usually provides reactivity only after hydrolysis. Because of the success of the anticancer drug 
cisplatin, which is introduced in the next section, a large variety of platinum and ruthenium 
compounds have been produced in search for new anticancer agents. The main achievements 
within this field of inorganic medicinal chemistry are summarized in this chapter. The 
research described in this thesis has been dealing with the development of homo- and 
heteropolynuclear platinum and ruthenium complexes, the potential of which as anticancer 









1.2 Development of metal-based anticancer drugs 
 
Cancer, one of the major causes of death in the western world, is treated by conventional 
therapies such as surgical excision, chemotherapy and radiation, and more recently also by 
immunotherapy.[1] In chemotherapy, cisplatin, cis-[Pt(NH3)2Cl2] or cis-diamminedichloro-
platinum(II) (1, Figure 1.1), is frequently used in combination with other anticancer drugs. It 
is one of the most used anticancer drugs, and is especially effective against testicular and 
ovarian carcinomas, bladder tumors and tumors of the head and neck. For testicular cancer, 
cure rates have been reported to be greater than 90 %.[2] It is generally believed that the 
ultimate target of the drug is DNA.[3] The DNA adducts formed interfere with DNA 






Figure 1.1 Cisplatin (1) and carboplatin (2). 
 
The serendipitous discovery of cisplatin,[5] and its clinical success have been a tremendous 
impetus for the design of metal-based anticancer drugs.[6-9] Over the years, much attention has 
been focused on developing direct cisplatin analogues (section 1.3.4) to limit the serious side 
effects (vide infra) that result from reaction of cisplatin with cellular components of healthy 
tissues. However, so far only cis-[diammine(1,1-cyclobutane-dicarboxylato)platinum(II)], 
carboplatin (2, Figure 1.1), has received worldwide approval, thanks to its reduced toxicity to 
kidney cells and the nervous system (nephrotoxicity and neurotoxicity, respectively). 
Unfortunately, no significant improvement was achieved in the spectrum of activity compared 
to cisplatin, apparently owing to the similar type of DNA adducts formed by this cisplatin 
analogue. 
To achieve anticancer activity in a broader range of tumors, alternative platinum complexes 
that can bind to DNA in a fundamentally different manner, have been developed. These 
include trans-platinum(II) complexes,[10] sterically hindered cis-diamine platinum(II) 
complexes[11] and platinum(IV) complexes (section 1.3.5).[12] Metals other than platinum have 
also been used for the design of anticancer agents.[13, 14] Among these are the ruthenium(II) 
and ruthenium(III) complexes (section 1.4), which probably function differently due to their 
octahedral structure as opposed to the square-planar geometry of cisplatin.[15] A completely 












complexes[16] (section 1.5), which have been shown to form long-range DNA adducts. The 
concept of polynuclear anticancer agents has also been applied to ruthenium complexes, 
although to a lesser extent (section 1.6). A challenging extension of the polynuclear concept 
has been the syntheses of heteropolynuclear complexes to achieve selective specificity and 
reactivity at each metal center (section 1.7). 
 
1.3 “Classical” and “non-classical” mononuclear platinum complexes 
 
1.3.1 Cisplatin and its mechanism of action 
 
Cisplatin is administered by intravenous injection or infusion.[4, 8, 17] In the bloodstream, 
cisplatin remains intact owing to the relatively high chloride ion concentration of 100 mM, 
which suppresses hydrolysis of the drug. It enters cells by passive diffusion although some 
evidence indicates the involvement of active transport mechanisms.[18] Very recently, it was 
proposed that cisplatin uptake is mediated by the copper transporter Ctr1 in yeast and 
mammals.[19] Inside the cell, the low chloride ion concentration of 4 mM is known to promote 
hydrolysis of the drug.[4, 8, 17] The resulting activated hydrolysis products of cisplatin[20] can 
react rapidly with a wide variety of cellular molecules,[3, 21] but it is widely accepted that DNA 
damage is the decisive effect by which cisplatin exerts its antitumor activity. The major DNA 
adducts formed are intrastrand crosslinks to adjacent purines, which causes significant 
bending and unwinding of the helical structure of DNA.[4] Subsequently, DNA replication and 
transcription are inhibited, which eventually result in programmed cell death, i.e. apoptosis.[4] 
The 1,2-d(GpG) crosslink is thought to be primarily responsible for cell death, as it is not 
effectively repaired by the nucleotide excision repair (NER) system.[22] It has been 
suggested[4] that the specific adduct is being shielded from repair enzymes by binding of high-
mobility group (HMG) domain proteins. Another hypothesis states[4] that the specific adduct 
hijacks the HMG domain proteins away from their normal binding sites, thereby disrupting 
DNA transcription. These two mechanisms are not mutually exclusive and could work in 
concert to affect cisplatin cytotoxicity. 
 
1.3.2 Cisplatin’s side effects 
 
Several toxic side effects may occur during treatment with cisplatin in anticancer 
chemotherapy.[8] Patients treated with cisplatin have shown serious signs of nephrotoxicity, 
neurotoxicity and ototoxicity (loss of hear). Other side effects are severe nausea and vomiting, 
diarrhea and an elevated blood pressure. Intravenous hydration and diuresis can reduce the 
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level of nephrotoxicity,[23] and 5-HT3-receptor blockers control nausea and vomiting.[24] The 
recently approved[8] chemoprotective agent amifostine (WR-2721), which is co-administered 
with cisplatin, alleviates nephro- and neurotoxicity by reducing the effects on normal tissues 
without compromising antitumor efficacy. 
 
1.3.3 Cisplatin resistance 
 
The major clinical problem of cisplatin, which limits its applicability to a narrow range of 
tumors, is the cellular resistance to the drug. Drug resistance can be either intrinsic or 
acquired, which develops after exposure to the drug. In general, the mechanism of resistance 
consists of mechanisms restricting the formation of DNA adducts, and of mechanisms 
operating downstream of the DNA adduct to promote cell survival.[4, 25]  The first include 
reduced uptake and enhanced efflux of the drug resulting in reduced accumulation inside the 
cell, and inactivation of cisplatin by reaction with intracellular thiols such as glutathione 
(GSH). Interestingly, regulation of the intracellular GSH level appears to be a promising 
strategy to circumvent cisplatin resistance.[26] Increased capability of cells to repair cisplatin-
damaged DNA, and increased tolerance of the DNA damage are involved in the second group 
of mechanisms. The tumor suppressor protein p53 has been hypothesized to influence 
sensitivity or resistance of tumor cells to cisplatin through its regulation of other proteins 
involved in cell cycle control, DNA repair and apoptosis.[27] 
 
1.3.4 Direct cisplatin analogues 
 
Since the introduction of cisplatin in 1971, thousands of platinum compounds have been 
synthesized and evaluated as potential antitumor active agents. The majority of them adhered 
to the set of structure-activity relationships originally stated for platinum complexes to display 
antitumor activity.[28] Platinum(II) and platinum(IV) complexes should have cis geometries 
with the general formula of cis-[PtX2(Am)2] or cis,trans-[PtX2Y2(Am)2], where X is the 
leaving group and Am is an inert amine with at least one N-H moiety. The leaving group X 
should be an anion with intermediate binding strength to platinum and have a weak trans-
effect to avoid labilizing the amine. Complexes with labile leaving groups such as ClO4- or 
NO3- are highly toxic, while complexes with inert leaving groups are generally inactive. The 
N-H moiety should be present to afford hydrogen bonding upon binding of the drug to DNA, 
and to stabilize the DNA adduct. 
The development of direct cisplatin analogues has resulted in only a few clinically useful 
complexes, one of which is carboplatin (2, Figure 1.1). It displays the same spectrum of 
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activity against cancer cell lines as cisplatin, but displays a more tolerable toxicological 
profile. Bone marrow toxicity is the dose-limiting factor in carboplatin treatment.[29] The 
lower toxicity is attributed to its higher stability and lower reactivity due to the relative 
inertness of the didentate carboxylate ligand. Because of the milder toxicity, but equivalent 
efficacy, it has largely replaced cisplatin in therapies of ovarian, non-small cell and small cell 
lung cancers.[6, 8] 
Nedaplatin (3, Figure 1.2) is only clinically used in Japan.[6] It is cross-resistant to cisplatin, 
but shows improved toxicological properties.[30] As no studies directly compared nedaplatin 
with carboplatin yet, no clear evidence is available for any distinct advantage of the former 
over the latter. 
Oxaliplatin (4, Figure 1.2) was the first platinum drug to show clinical activity in a tumor with 
primary resistance to cisplatin.[31] Oxaliplatin forms adducts at DNA sites that are nearly 
identical to cisplatin DNA adducts.[32] However, the conformation of the major DNA adduct 
formed (the 1,2-GG intrastrand crosslink) shows some distinct features,[33] and these have 
been suggested to influence further processing of the crosslink in the cell.[34] Oxaliplatin has 
been approved for clinical use in Europe, Asia and Latin America for the first-line treatment 
and in the United States for the secondary treatment of metastatic colorectal cancers in 







Figure 1.2 The direct cisplatin analogues nedaplatin (3) and oxaliplatin (4).       
 
 
1.3.5 New approaches 
 
More recently, new concepts in designing platinum-based antitumor drugs with a broader 
spectrum of activity and less side effects have been introduced. Platinum prodrugs have been 
designed, which are only activated in solid tumors with low pH.[38] Targeted platinum drugs 
have been developed to accumulate in certain tissues.[8] Kinetically inert octahedral 
platinum(IV) complexes, for which reduction by extracellular and intracellular agents to 
platinum(II) is necessary for activation, have been receiving increased interest.[8, 12] 














great promise in Phase I and II clinical trials.[39] It represented the first platinum drug, which 
was suitable for oral administration because of favorable physicochemical properties. 
However, it was abandoned from Phase III trials due to variability in drug uptake.[12] The drug 
is supposedly too readily reduced to platinum(II) in the blood stream. It has been suggested 
that the consequent loss of its lipophilicity accounts for the disparity in activity between in 
vitro and in vivo systems.[40] 
Cis-platinum complexes with bulky ligands have been designed to broaden the spectrum of 
anticancer activity, as it is believed that cisplatin resistance can be circumvented by sterically 
hindering inactivating reactions with glutathione and other cellular thiols.[11] A lead 
compound within this series of complexes is ZD0473 (cis-amminedichloro(2-
methylpyridine)platinum(II), 6, Figure 1.3). Its crystal structure has confirmed that the methyl 
group is imposing steric hindrance for associative substitution reactions on the square-planar 
platinum(II), as the 2-methylpyridine ring is tilted nearly perpendicular with respect to the 
PtN2Cl2 plane.[41] The complex shows a unique pattern of response, and has shown lower 
resistance factors than cisplatin in cell lines, which represent different mechanisms of 
resistance.[42] Initiation of phase-III clinical trials in patients with ovarian cancer has been 








Figure 1.3 The non-classical mononuclear platinum complexes satraplatin (5), ZD0473 
(6) and JM335 (7). 
 
Trans-platinum complexes have also been developed using bulky ligands to reduce kinetic 
reactivity inherent to the inactive complex transplatin, trans-[Pt(NH3)2Cl2], thereby 
decreasing susceptibility to deactivating side reactions on route to the DNA.[8, 10] It is believed 
that trans-platinum complexes can overcome cisplatin resistance, as they form DNA adducts 
which are different from those formed by cisplatin. The three main series of trans-platinum 
complexes can be classified in those using planar aromatic amines, iminoethers or aliphatic 
amines, the latter being used in designing trans-platinum(IV) as well as trans-platinum(II) 
compounds. The first type of complexes form a high portion of interstrand adducts[44] and 




























account for the higher activity compared to the cis analogues, and for the lack of cross-
resistance with cisplatin.[46] Stable monofunctional DNA adducts are most likely responsible 
for the cytotoxic activity of the iminoether class of complexes.[47] The specific activity of the 
most promising trans-platinum(IV) complex[48], JM335 or trans-ammine(dichlorocyclohexyl-
amine)dihydroxoplatinum(IV) (7, Figure 1.3), has been found to correlate with the inability of 
gene-specific repair[49] of its DNA interstrand adducts.[50] 
 




Many ruthenium complexes have been evaluated for the treatment of cancer,[15] in part 
because ruthenium(II) and ruthenium(III) complexes exhibit relatively low ligand exchange 
rates, which are comparable to those of platinum(II) complexes.[51] Slow ligand exchange may 
ensure that the drug reaches its biological target without being modified. Moreover, the 
various oxidation states (II, IIII and IV) of ruthenium are all accessible under physiological 
conditions.[52] In these oxidation states the ruthenium center is predominantly hexacoordinated 
with octahedral geometry in contrast to the square-planar geometry of platinum(II). The 
octahedral geometry of ruthenium compounds imposes different steric effects upon 
interaction with biomolecules, which in turn may cause a different anticancer profile from 
cisplatin. 
 
1.4.2 Hypotheses on the mechanism of action 
 
In the blood, ruthenium mimics iron in binding to certain biomolecules, such as albumin and 
transferrin.[52] Specific intake of ruthenium(III) and ruthenium(II) ions might be mediated by 
the transferrin-based iron transport system.[53, 54] The serum transferrin system specifically 
recognizes iron(III) (and not iron(II)) along with a synergistic anion (usually carbonate).[54] 
Transferrin binds strongly to its receptor when it is loaded with two iron(III) ions, after which 
it is internalized by cells. Release of iron(III) from transferrin is induced at low pH. The 
protein is then recirculated into the blood. There is potential for use of this transport 
mechanism in cancer therapy, as high levels of transferrin receptors are expressed by many 
solid tumor cells, due to their higher iron requirement than normal cells. Moreover, the 
relatively low pH of tumor cells facilitates readily the release of transferrin-bound metal ions. 
Selective tumor toxicity may also be reached by what is known as the “activation by 
reduction” mechanism. It has been suggested that ruthenium(III) complexes may serve as 
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prodrugs, which are activated by reduction in vivo to coordinate more rapidly to biomolecules, 
since ruthenium(II) species are usually less inert than the corresponding ruthenium(III) 
complexes.[14, 15, 55] The low oxygen content and low pH in tumor cells cause a relatively low 
electrochemical potential inside tumors. Therefore, the reduction of ruthenium(III) to 
ruthenium(II) is favored in tumors relative to normal tissue. In vivo, reduction of 
ruthenium(III) species can occur by glutathione and redox proteins available in the cell. 
Glutathione, which appears to contribute to cisplatin resistance in tumor cells (section 1.3.3), 
may also be involved in the metabolism of many types of ruthenium pharmaceuticals. GSH 
has been shown to bind to ammineruthenium(III) complexes, and depending on its 
concentration it either facilitates or inhibits ruthenium coordination to DNA.[56] In general, 
cytotoxicity of ruthenium complexes correlates with their ability to coordinate to DNA.[15] 
 
1.4.3 Ruthenium anticancer compounds: state of the art 
 
A number of ammine and amine ruthenium complexes, as well as complexes with 
monodentate and chelating heterocyclic ligands have been synthesized for anticancer 
purposes.[9, 14, 15] The tetrachlororuthenium(III) complexes of the type (HL)[RuCl4L2] (where 
L is imidazole (im) or indazole (ind)) have emerged as promising compounds as they display 
activity against a number of cancer cell lines,[57] and in particular against colorectal tumors.[58-
61] Human colon cancer is the second highest occurring cancer after bronchial carcinomas.[62] 
The complex (Hind)[RuCl4(ind)2] (KP1019 (8), Figure 1.4) is highly active against a model of 
colorectal cancer,[63] which has been used as sometimes only weak activity is observed against 
colorectal tumors using conventional treatments.[59] KP1019 is completely devoid of side 
effects and drug induced lethality at active dosages, and it has shown a better therapeutic 
index than the imidazole derivative.[60] The complex has been announced[38] to enter phase I 
clinical trials. Results have demonstrated that the transferrin-bound species of both KP1019 
and its imidazole analogue, as well as the apotransferrin form of (Him)[RuCl4(im)2] exhibit 
anticancer activity superior to that of the protein-free complexes.[64] Therefore, the low 
toxicity of 8 presumably stems from a transferrin-mediated accumulation in tumor cells.[65] 
An “activation by reduction mechanism”, and a different DNA binding mode compared to 
cisplatin have been proposed to account for the unique cytotoxicity in tumor cells.[61, 66] 
The first ruthenium complex, i.e. NAMI-A (trans-(H2im)[RuCl4(dmso)(Him)] (9), Figure 
1.4), has recently accomplished phase I clinical trials.[67, 68] The complex belongs to the class 
of ruthenium dimethylsulfoxide complexes. It is relatively nontoxic in vitro against tumor 
cells,[69] and shows a remarkable high efficiency in vivo against lung metastasis,[70] a common 
feature of many human tumors. Because of the S-bonded dmso ligand, NAMI-A is easily 
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reduced to the corresponding ruthenium(II) species by biological reducing agents under 
physiological conditions.[71, 72] It has been proven that these reduced species maintain their 
anticancer activities. Interestingly, the antimetastatic activity appears not to be related to DNA 
binding,[73] even though the complex interacts with DNA in vitro.[71] Instead, NAMI-A 
interferes with fibrous collagen of the lung and with basement membrane collagen type IV.[67] 
It significantly increases the thickness of connective tissue around the tumor capsule and 
around tumor blood vessels, thereby probably hindering blood flow to the tumor.[74] The 
inhibition of angiogenesis has been attributed to induction of apoptosis, as has recently been 
shown in ECV304 cells.[75] Since angiogenesis is crucial for metastasis formation, and in 
particular for metastases growth, it is likely that the inhibition of this process is relevant for 
the activity of NAMI-A against metastasis. 
Organometallic ruthenium(II) complexes with arene ligands represent a relatively new group 
of water-soluble ruthenium compounds with antitumor activity displayed in vitro and in 
vivo.[76] No cross-resistance has been observed in cisplatin-resistant cells, but did occur in the 
multi-drug-resistant cell line 2780AD. The most hydrophobic arene species 
[(η6-C6H5C6H5)RuCl(en)](PF6) (10, Figure 1.4) and [(η6-C6H5C6H5)RuCl(en-Et)]PF6 (en = 
ethylenediamine, and en-Et = N-ethylethylenediamine), in which a phenyl is substituent at the 
arene ligand, showed the highest tumor-inhibiting activity. It has been suggested that the 
presence of the hydrophobic planar arene ligand facilitates recognition and transport of these 
complexes through cell membranes. The relative conformational flexibility of the arene ligand 












Figure 1.4 The ruthenium(III) pharmaceuticals KP1019 (8) and NAMI-A (9), and the 










































1.5 Polynuclear platinum complexes 
 
1.5.1 A new paradigm 
 
Polynuclear platinum complexes represent a completely new paradigm in the development of 
novel anticancer agents.[9, 16, 77] They are probably the most distinctively different from 
cisplatin of all “third generation” platinum complexes developed. These polynuclear 
complexes consist of two or more linked platinum centers that can each interact with DNA. 
Consequently, they are capable of DNA interactions which are not possible for their 
mononuclear counterparts. 
It is believed[77] that polynuclear platinum complexes of long and flexible α,ω-diaminoalkane 
linkers can overcome both acquired and intrinsic resistance to the antitumor drug cisplatin by 
their ability to form long-range DNA adducts (vide infra). From studies with these complexes, 
chain length and flexibility, hydrogen-bonding capacity and charge of the linker, and finally 
the position of the leaving group (usually chloride) relative to the linker chain appear to be 
major factors in designing polynuclear platinum antitumor drugs. However, very short and 
rigid linked polynuclear platinum complexes have also shown promising biological activity 
(vide infra). It appears that the class of polynuclear platinum agents is too diverse to infer 
general structure-activity relationships for this new series of anticancer drugs. Therefore, it is 
of great importance to understand the mechanisms of action within a particular series of 
polynuclear complexes. Results reported so far are summarized below. 
 
1.5.2 Polynuclear complexes with alkanediamine linkers 
 
The first polynuclear platinum antitumor agents reported[78] were dinuclear complexes based 
upon the linking of two cisplatin-like, or transplatin-like, centers by long and flexible α,ω-
diaminoalkane linkers of variable length, i.e. [{cis-PtCl2(NH3)}2(H2N(CH2)nNH2)]Cl2, 2,2/c,c 
(11) and [{trans-PtCl2(NH3)}2(H2N(CH2)nNH2)]Cl2, 2,2/t,t, (12) (Figure 1.5), in which 





Figure 1.5 The tetrafunctional dinuclear cis- and trans-platinum complexes 2,2/c,c (11) 




















The tetrafunctional nature of the compounds (after chloride dissociation) allows for a complex 
array of inter- and intrastrand crosslinks upon reaction with DNA. The 2,2/c,c complexes 
have been shown to be particularly active in cells resistant to cisplatin, whereas the 2,2/t,t 
isomers did not show significantly improved cytotoxicity over their mononuclear analogue, 
transplatin.[79, 80]  Of specific interest was the fact that the complexes produce a large number 
of interstrand DNA crosslinks.[81] The activity of the mixed cis,trans species 2,2/c,t in both 
cisplatin sensitive and resistant cell lines, indicated that only one cisplatin-like unit is 
necessary for activity. The nature of the second platinum coordination sphere appeared not to 
be critical, as long as interstrand crosslinks are formed.[79] 
DNA-binding studies of dinuclear complexes with monofunctional platinum centers of 
general formula [{PtCl(NH3)2}2(H2N(CH2)nNH2)]Cl2 (1,1/c,c (13) and 1,1/t,t (14), Figure 1.6) 
showed that DNA interstrand crosslinking is more efficient for the 1,1/t,t complexes than for 
the 2,2/c,c isomers.[82] Apparently, interstrand crosslinks are easily formed by bifunctional 
coordination of two independent monofunctional platinum moieties as in the 1,1/t,t isomers. 
The latter are deficient of many of the steric requirements faced when two nucleobases are 
bound to one platinum center. Studies using relatively bulky ligands, confirmed steric 
hindrance to affect relative tendencies to form inter- or intrastrand crosslinks or 
monoadducts.[83, 84] The higher activity of the 1,1/t,t complexes compared to the 2,2/c,c 
complexes observed in cisplatin resistant cells[82] stressed that the contribution of the 
interstrand crosslink to the biological effects is independent of any involvement from the 
cisplatin-like intrastrand crosslink.  
As opposed to the dinuclear complexes with bifunctional coordination spheres, this series of 
dinuclear platinum complexes induces unique DNA conformational changes,[82, 85] which 
include B → Z conformational changes in poly(dG-dC)·poly(dG-dC).[86] Ionic charges have 
been stated to be necessary to induce the B → Z transition. Coordination appears to be of 
importance for locking DNA in the induced Z form.[87] In contrast, cisplatin supports the B 
form of DNA,[88] and does not attack alternating purine-pyrimidine sequences.[82] Although 
the role of Z DNA in vivo has not yet been firmly established,[89] these differences may have 





Figure 1.6 The bifunctional dinuclear cationic platinum complexes 1,1/c,c (13) and 1,1/t,t 





















Within the series, the trans isomer is more active in cisplatin-resistant cell lines, the highest 
activity in vitro being observed for n = 6.[77, 90] The high activity has been attributed to the fact 
that the trans isomer forms predominantly long-range interstrand adducts[91] (~ 50 % versus ~ 
5 % for cisplatin[92]). Although the cis isomer is a more effective interstrand crosslinker (~ 
80 %), it forms structurally more diverse adducts, also short-range cross links and even an 
interstrand cross link between a cytosine and guanine on the same base pair have been 
observed.[77, 93] The sterically more constrained adducts of the cis isomer are more readily 
repaired in cisplatin resistant cells, thereby probably reducing the ability to circumvent 
cisplatin resistance.[94] 
The formation of the long-range 1,4-interstrand adduct of 14 with DNA has been studied.[95] 
Initial electrostatic association of the intact 1,1/t,t (n = 6) isomer with the DNA duplex has 
been found to occur. Subsequently, the complex is monoaquated to form the monoaqua-
monochloroplatinum(II) species.  On the contrary, the mono-aquated cisplatin derivative pre-
associates with DNA.[96] Furthermore, monofunctional coordination of 1,1/t,t to the duplex 
was found, while the unbound platinum moiety remained electrostatically bound to the 
duplex. The electrostatic interaction probably ensures fast fixation of the crosslink, which 
finally results in two conformers of the 1,4-adduct. These results point out the importance of 
the positive charge of the complex. The charge is likely to cause the higher rate of 
bifunctional DNA binding in comparison with cisplatin. The 1,4-interstrand crosslink is not 
efficiently recognized by HMG proteins,[97] which may be caused by the conformational 
flexibility of the crosslink and the consequent lack of a directed bend of DNA. 
Concluding, results summarized for the dinuclear platinum complexes so far provide strong 
evidence for the hypothesis that platinum drugs, which bind to DNA in a fundamentally 
different way compared to cisplatin, have different pharmacological properties. This 
statement is being emphasized by recent studies of the two isomeric trifunctional dinuclear 
platinum complexes of formula [{PtCl(NH3)2}(µ-H2N(CH2)6NH2){PtCl2(NH3)}]+ (1,2/c,c 





Figure 1.7 The trifunctional dinuclear cationic platinum complexes 1,2/c,c (15) and 
1,2/t,c (16). 
 
Protein binding to the complex might occur after formation of a long-range interstrand 



































activity in cisplatin resistant cell lines and exhibit a unique profile of activity compared to 
cisplatin, as well as within the class of polynuclear platinum complexes with 
α,ω-diaminoalkane linkers.[99] 
The most promising agent within this new structural class of polynuclear anticancer drugs, is 
the trinuclear complex [{trans-PtCl(NH3)2}2{µ-trans-Pt(NH3)2(H2N(CH2)6NH2)2}]4+ 
(1,0,1/t,t,t), or BBR3464 (17, Figure 1.8). The complex can bifunctionally bind to DNA with 
the two terminal monofunctional platinum units. The positively charged inert tetraamine 
platinum linker provides water solubility and high DNA affinity. BBR3464 was the first 
polynuclear platinum complex to enter clinical trials and has recently undergone Phase II 
clinical trials for treatment of a variety of cancers.[7, 25] In Phase I clinical trials, short-lasting 
neutropenia and diarrhea appeared to be dose-limiting.[100] Neither neurotoxicity nor renal 
toxic effects were observed, and nausea and vomiting were found to be rare. BBR3464 has 
been shown to be able to overcome acquired and intrinsic cisplatin resistance at remarkable 
low concentrations in a number of cancer cell lines,[101, 102] including p53-mutant 
xenografts.[103] It has been suggested that apoptosis induced in tumor cells by BBR3464 is not 
mediated by p53. “Bypassing” of the p53 pathway may have its origin in the specific DNA-
binding mode of this trinuclear agent.[104] 
Interestingly, interstrand cross-linking efficiency for BBR3464 is only 20 % and intrastrand 
DNA adducts are equally being formed.[105] Both inter- and intrastrand crosslinks of 
BBR3464 are not recognized by HMG proteins. However, only the major 1,4-interstrand 
crosslink is not effectively removed by the NER system, which suggests its relevance to the 
antitumor effects of the drug.[106] It has been shown that the 1,4-interstrand adduct extends 
over the phosphate backbone by preassociation of the central tetraamine linker in the minor 
groove through electrostatic interactions, and subsequent coordination of the two outer 
platinum atoms in the major groove.[107] This novel mode of DNA binding may account for 
the difference in antitumor activity between BBR3464 and the dinuclear analogues that lack 
the charged central linker. Conformational flexibility of the 1,4-interstrand adduct has also 
been observed for BBR3464, but the conformers are not interconvertable. This delocalization 









1.5.3 Linkers exhibiting special features 
 
The polyamines spermidine (H2N(CH2)3NH(CH2)4NH2) and spermine 
(H2N(CH2)3NH(CH2)4NH(CH2)3NH2) have been used as linkers for the syntheses of 
polynuclear platinum complexes, as they are known to play essential roles in normal cell 
growth and differentiation in eukarytotic cells.[108] Since they are protonated at physiological 
pH, their polycationic character can provide electrostatic and hydrogen-bonding interactions 
with negatively charged nucleic acids.[109] Moreover, these ligands can induce significant 
structural changes like B → Z and B → A transitions in DNA.[110] The first polyamine 
complexes reported were the di- and trinuclear cis-dichloroplatinum(II) and platinum(IV) 
spermine and spermidine compounds, [{cis-PtCl2}2(H2N(CH2)3NH(CH2)4NH(CH2)3NH2)] 
and [{cis-PtCl2}(cis-PtCl2(H2N(CH2)3NH(CH2)4NH2))2], respectively. The central secondary 
amino groups of the polyamines were also involved in coordination to platinum, thereby 
forming chelates.[111, 112] Cytotoxic activity has been demonstrated against breast carcinoma, 
leukemia cells[112] and epithelial-type cells.[113] 
Very promising results have been revealed by bifunctional dinuclear trans platinum(II) 
complexes in which linear coordinated spermine and spermidine are incorporated, i.e. [{trans-
PtCl(NH3)2}2(µ-spermine-N1,N12)]Cl4 (BBR3535) and [{trans-PtCl(NH3)2}2(µ-spermidine-
N1,N8)]Cl3 (BBR3571, 18, Figure 1.9), respectively. The flexibility of the linker and the 
distance between the metal centers is not reduced by the linear coordination of the polyamine 





Figure 1.9 The spermidine dinuclear cationic platinum complex BBR3571 (18). 
 
In particular, the spermidine complex 18 showed remarkable cytotoxicity against cisplatin 
resistant leukemia cells,[114] which rather closely matched that of BBR3464 (17).[101] 
Comparative studies suggested that the charge and hydrogen-bonding capabilities of the 
spermidine linker of 18, and the tetraamineplatinum linker of BBR3464 (17), contribute 
significantly to the anticancer profiles of both complexes.[101, 115] Moreover, cellular uptake, 
cytotoxicity, and antitumor activity are greatly enhanced in comparison to the 1,1/t,t 
derivative 14, in which a “simple” diamine linker is utilized. Compared to 17, DNA binding is 
more rapid for the polyamine complexes and significantly more interstrand crosslinks are 











It has been suggested that 17 is sterically more demanding in comparison with the polyamine 
complexes, which may hamper ready access to the minor groove and consequently decreases 
the DNA-binding rate. Moreover, the formation of a bifunctional interstrand crosslink from a 
monofunctional adduct may require larger conformational distortions for 17 than for the 
polyamine linked complexes. 
Irreversible B → Z conformational changes as well as B → A transitions induced by the 
polyamine complexes at low doses[117] have been proposed to contribute to the lack of repair 
observed in mouse leukemia cells.[118] Preclinical investigations confirm the potency of the 
polyamine species, showing cytotoxicities in the nanomolar range.[119] However, the 
remarkable potency has resulted in a relatively narrow therapeutic index. Therefore “prodrug” 
delivery of less toxic and better tolerated derivates has been investigated by use of blocking 
carbamates with different structures and acid susceptibility.[120] 
A tetranuclear trans platinum complex 19 has been synthesized using a branched polyamine 
to link the platinum moieties (Figure 1.10). The polyamine ligand has, however, not been 
reported to display specific interactions with DNA. The complex showed low cytotoxicity 
against several cell lines.[121] The highly charged and branched structure has been suggested to 









Figure 1.10 The dendritic tetranuclear cationic platinum complex 19. 
 
Chiral non-racemic bis(dichloro)platinum complexes have been prepared from R and/or S 
1,2,4-triaminobutane units, in which the amino groups at position 1 and 2 are part of the 
chelate rings and are linked at position 4 as mono- or bisamides or ureides (20, 21 and 22, 
respectively, Figure 1.11).[122, 123] Only the dinuclear platinum complexes of the bisamide type 
exhibited activity close to that of cisplatin against cisplatin-sensitive mouse leukemia L1210 
cells.[123] This observation is consistent with the fact that they form a high amount of 
interstrand crosslinks,[124] which may be related to the length and nature of the bisamide 
linker. The chirality of the different isomeric forms is, however, of no influence on the 






























Figure 1.11 Mono- and bisamides (20 and 21, respectively) and ureide (22) linking two 
1,2,4-triaminobutane-N4 units. 
 
Thiourea-bridged dinuclear platinum ethylenediamine (en) and trans-cyclohexane-1,2-
diamine (dach) complexes, in which the S-donor ligand may alter the metabolism of  the 
complex, were shown to display moderate to low activity in cisplatin-sensitive and -resistant 
leukemia cells, respectively.[125] 
Bisplatinum complexes in which two trans platinum moieties are linked using intercalating 
diaminoanthraquinone ligands (23, Figure 1.12) were found to be sensitive to the resistance 
mechanisms of cisplatin-resistant human ovarian cancer cells.[126] It has been discovered that 
the platinum complexes accumulate in acidic vesicles in contrast to the free ligand by 
monitoring the fluorescent anthraquinones using fluorescence microscopy. The accumulation 
appears to be unrelated to the mechanism of deactivation of platinum compounds by 
glutathione.[127] Dinuclear platinum complexes bridged by oxa-diaza crown ether ligands (one 
example is 24, Figure 1.12) have been prepared to increase DNA interaction by the formation 
of cationic complexes with ions that are abundant in cells, such as sodium or potassium. 











Figure 1.12 Dinuclear cationic platinum complexes of linking anthraquinones (23) and 



























































1.5.4 Short and (semi) rigid linkers 
 
A series of highly rigid double-bridged dinuclear platinum chloride and mixed 
chloride/hydroxide complexes, with both square planar and octahedral geometries, have been 
synthesized by linking two cisplatin-like centers through the 4,4’-dipyrazolylmethane ligand 
dpzm (an example is 25, Figure 1.13).[129] From the more flexible single-bridged series with 
two chlorides cis or trans and either an amine or dmso ligand coordinated to platinum, the 
complex [{cis-PtCl2(NH3)}2(µ-dpzm)] exhibits higher cytotoxicity than the double-bridged 
complexes in three cancer cell lines.[130] However, [{cis-PtCl2(NH3)}2(µ-dpzm)] did not show 
any advantage over cisplatin due to its poor water solubility. 
Subsequently, the single-bridged dinuclear and trinuclear species [{trans-Pt(NH3)2Cl}2(µ-
dpzm)]Cl2 (26, Figure 1.13) and [{trans-Pt(NH3)2Cl}2(µ-Pt(NH3)2(dpzm)2]Cl4, respectively, 
have been developed. The monofunctional trans-platinum centers provide an overall charge of 
2+ and 4+, respectively.[131, 132] The complexes form high levels of DNA interstrand 
crosslinks (50 %), which has been proposed to be due to the rigid nature of the dpzm ligand 
that prevents the complexes from forming short-range intrastrand adducts. The bifunctional 
dinuclear complex 26 was shown to bind preferentially at adenine residues,[133] probably 
because of pre-association in the minor groove at A/T rich regions.[134] Pre-association in the 
minor groove at G/C rich regions has been found to occur as well, but at a lower rate.[135] The 
complexes do show cytotoxicity, but are not as active as their aliphatic equivalents, i.e. 1,1/t,t 
and BBR3464.[131] The specific type of interstrand crosslink formed, and the preference for 
adenine binding may account for the difference in activity. 
Recent studies of 26 encapsulated in cucurbit[7]uril (Q[7]) indicated that this molecular host 
Q[7] slowed down reactions rates by at least 3-fold, whereas only a small effect on 







Figure 1.13 Double dpzm-linked dinuclear platinum complex 25, and single dpzm-linked 
cationic platinum complex 26. 
 
Dinuclear platinum complexes bridged by 4,4’-dipyridylselenide or 4,4’-dipyridylsulfide (27, 

























drugs, as selenium and sulfur containing compounds are known for their chemoprotective 
activity.[138] The bifunctional cis derivatives have shown significant cytotoxicity, the 
complexes containing sulfur exhibiting an activity superior to their selenium analogues.[139] 
DNA-binding studies indicated that the complex [{cis-Pt(NH3)2Cl}2(µ-4,4’-
dipyridylsulfide)](NO3)2 binds bifunctionally to DNA in a non-intercalative mode. The 
complex shows a lower interstrand crosslinking efficiency compared to the aliphatic analogue 
1,1/c,c and is not able to induce the B → Z transition in poly(dG-dC)·poly(dG-dC).[140] It has 
been suggested that the trans derivatives have different DNA-binding properties in 
comparison to the cis complexes.[141] Dinuclear organoplatinum complexes with relatively 
“simple” 4,4’-dipyridyl and 1,2-bis(4’-pyridyl)ethane bridging ligands were also synthesized, 
but no biological data have been reported.[84] 
Figure 1.14 Dipyridyl-linked dinuclear cationic platinum complexes (27) with X = S or Se 
and R = H or CH3. 
 
A series of very short and rigid pyrazole- and hydroxo- bridged dinuclear platinum 
complexes, in which the hydroxide acts as a leaving group, were produced to mimic cisplatin 
binding.[142, 143] They were anticipated to form 1,2-intrastrand adducts without major 
distortions of the DNA, thereby avoiding recognition and repair of the adduct. A crystal 
structure of the bis(9-ethylguanine) adduct of [{cis-Pt(NH3)2}2(µ-OH)(µ-pyrazolate)](NO3)2 
(28, Figure 1.15), illustrates that the platinum atoms are close enough to form a stable adduct 
to neighboring guanines on the DNA.[142] 
The rate of reaction of the azolato-bridged complexes with 9egua,[144] GMP[145] or DNA[146] 
has been shown to be relatively slow. However, once the five-membered ring is opened via 
nucleophilic attack of the first base, the second platinum center reacts faster with a second 
base. After binding of one 9egua to the triazolato derivatives 29 (Figure 1.15), migration of 
the platinum atom from N2 to N3 occurs.[144] The fact that a widely opened platinum 
coordination sphere results may explain why 29 not only serves as an intrastrand crosslinker, 
but also generates interstrand GC crosslinks,[146] whereas complex 28 yields only the 
1,2-intrastrand GG adduct on a hairpin stabilized double-stranded DNA. The significant 
cytotoxicity of 28 and 29 on several human tumor cell lines (compared to cisplatin),[143] as 
well as of 29 against cisplatin-resistant mouse leukemia cells,[144] have been postulated to be 


















Figure 1.15 Pyrazole-bridged and triazolato-bridged dinuclear cationic platinum complexes 
28 and 29, respectively, with R = H or phenyl. 
 
In general, azine-bridged dinuclear platinum(II) complexes[148, 149] (30, 31 and 32, Figure 
1.16), and more bulky derivatives, show lower cytotoxicity than cisplatin in several human 
tumor cell lines. However, activity is comparable or higher against mouse leukemia cells 
sensitive or resistant to cisplatin.[148] The complexes have been shown to undergo substitution 
of both chlorides by 9egua, except for complex 30. Reaction of the latter with GMP results in 







Figure 1.16 Azine-bridged dinuclear cationic platinum complexes 30, 31 and 32. 
 
 
1.5.5 Heterocylic coordinating ligands 
 
Based upon the corresponding cytotoxic mononuclear complexes,[150, 151] heterocyclic ligands 
capable of intercalation like 2,2’-bipyridine (bpy) and 2,2’:6’,2”-terpyridine (tpy) have also 
been used for the synthesis of dinuclear platinum complexes. Compounds capable of 
“stapling” DNA by intramolecular bis-intercalation are considered to have higher antitumor 
activity than the mononuclear analogues.[152] For dinuclear bipyridine platinum(II) complexes 
different chelating bis(amino) acids were used as linkers to induce additional weak DNA 
interactions (an example is 33, Figure 1.17).[153] Short linkers resulted in low activity against 
P388 lymphocytic leukemia cells. Interestingly, binding to calf thymus DNA has been 
proposed not to occur by intercalation (or coordination), but rather by hydrogen bonding and 



















































1.17) and cyclobutane dicarboxylic acid (CBDCA) imine platinum complexes, were 
developed by linking three imine platinum centers through a central benzene group.[154] 
 
Figure 1.17 The dinuclear cationic platinum bipyridine complex 33 (n = 2 and 4) and the 
trinuclear imine complex 34. 
 
Dinuclear terpyridine platinum(II) complexes, in which the platinum centers are joined by a 
long and flexible linker attached at the 4’ position of the tpy ligand, do not show high activity 
against several human ovarian carcinoma cell lines.[150] Dinuclear 6-phenyl-2,2’-bipyridine 
organoplatinum(II) complexes, in which a long and flexible linker is attached at the 4 position 
of a fourth coordinating pyridine ligand, do not show activity either.[155] The low activity of 
the latter is in agreement with the inactivity of the parental mononuclear complex. 
Cytotoxicity is displayed by platinum terpyridine complexes that are bridged through more 
rigid coordinating dipyridyl linkers. The linkers contain ethynyl bonds of variable length with 
or without phenyl groups in between, or a charged dipyridyl diamine-platinum coordination 
center, or contain no substituent at all (35, Figure 1.18).[156] Studies indicated that increasing 
the length of the linker does not improve antitumor activity. The complex with the shortest 
linker length is the most effective against several cancer cell lines showing no or little cross-
resistance to cisplatin.[150] However, high activity is displayed by a trinuclear platinum 
complex in which the linker contains a tetraamine-platinum center. Its cytoxicity points out 
that the charge on each platinum center may be of importance for activity. Intercalation of 
these complexes has not been demonstrated. 
A 1,3-substituted xylylthiolate-bridged dinuclear platinum terpyridine complex (36, Figure 
1.18) has been reported to interact strongly with DNA by intercalation in comparison to the 
1,4-substituted analogue.[157] The latter has been suggested to be less flexible for 











































Figure 1.18 Polynuclear cationic platinum terpyridine complexes 35, 36, and 37, in which 
X and R are different substituents and linkers (see text), respectively. 
 
Bisintercalation of dinuclear dithiolatoalkane-linked terpyridine platinum complexes has been 
shown for complexes that are linked by α,ω-dithioalkanes with n = 5, 6, and 7, whereas those 
with n = 8 and 10 form mono- and bisadducts by intercalation with either one or two platinum 
units.[158]  However, enhanced sequence specificity compared to the mononuclear derivative is 
not displayed.[159] It has been suggested that the length and flexibility of the used linkers is not 
sufficient for bisintercalation at remote sites. Intercalation to two nearby binding sites may 
interrupt the geometry of DNA, thereby leading to a loss of specificity.  
A new antitumor strategy has been implied for shorter thiolato-linked dinuclear platinum 
terpyridine complexes, which interact with two different intracellular targets, i.e. DNA and 
the selenoenzyme thioredoxin reductase (TrxR).[160] Reduced thioredoxin provides reducing 
equivalents for a number of processes including the formation of deoxyribonucleotides by 
ribonucleotide reductase, one of the key steps in DNA synthesis. The complexes show very 
high specificity for human thioredoxin, which has been considered to be due to the high 
affinity of thiols for thiolato-platinum(II) complexes. Cytotoxic activity of complex 37 
(Figure 1.18) has been shown against different glioblastoma, and head-and-neck squamous 
carcinoma cells.[160] Only for a mononuclear derivative, reduced activity of TrxR was shown 









































In comparison to the field of anticancer polynuclear platinum complexes, the field of 
polynuclear ruthenium complexes has been relatively unexplored. Dinuclear analogues of the 
antimetastatic ruthenium complex NAMI-A, in which different bridging (poly)pyridyl ligands 
are used, have been studied in some detail.[67] A few complexes bridged by rather short linkers 
have been investigated. Attention has been focused mostly on the extension of substitution-
inert mononuclear ruthenium polypyridyl complexes, designed as photo-probes and photo-
reagents of DNA, to dinuclear photoreactive complexes. 
 
1.6.2 Substitution-labile polynuclear ruthenium complexes 
 
A new series of anticancer ruthenium complexes structurally mimics the antimetastatic 
compound NAMI-A (9) by the linkage of two (NAMI-A)-type moieties through heterocyclic 
ligands, such as pyrazine (pyz), pyrimidine (pym) and 4,4’-bipyridine (bipy) and derivatives 
thereof.[67, 161]  The complexes NH4[{RuCl4(dmso-S)}2(µ-pyz){RuCl3(dmso-S)(dmso-O)}] 
and Na2[{RuCl4(dmso-S)}2(µ-bpy)] (38 and 39, respectively, Figure 1.19) have been shown to 
modify cell cycle distribution of human and murine carcinoma cells similarly to the parental 
mononuclear complex. An intracellular ruthenium concentration threshold, which imparted 
cell cycle arrest, was reached.[162] The dinuclear complexes have been shown to form 
interstrand crosslinks with linearized plasmid DNA more actively then NAMI-A.[163] They 
exhibit promising activity of inhibition of gelatinase MMP-9, an enzyme that degrades the 
















































Unfortunately, in vivo activity of the dinuclear complexes appeared not to be superior to that 
of NAMI-A.[164] Moreover, higher liver and kidney toxicity contributes to a less favorable 
therapeutic index relative to NAMI-A. 
The ruthenium atoms in the mixed-valent dinuclear complexes of the type [Ru2(RCO2)4Cl2]2– 
(R = CH3 or CH3CH2) are linked by the four carboxylate ligands. The complexes have been 
demonstrated to bind to two 9-ethylguanine molecules in an unusual N7,O6-bridging mode 
with the bases in a head-to-tail fashion,[165] and have shown good activity against P388 
lymphocyte leukemia cells.[166] The trinuclear µ-oxo bridged complex ruthenium red, 
[(NH3)5Ru(III)ORu(IV)(NH3)4ORu(III)(NH3)5]6+, has long been known to affect calcium 
metabolism, which has been linked to inhibition of tumor growth.[167] However, it is the 
dinuclear impurity µ-O-[X(NH3)4Ru]23+ (X = Cl or OH) that has later been shown to be 
responsible for most of the inhibition of Ca2+ uptake in mitochondria.[168] The dinuclear 
analogue µ-O-[(H2O)(bpy)2Ru(III)]24+ has been indicated to coordinate to DNA at relatively 
low levels with low stereoselectivity forming interstrand crosslinks.[169]  
 
1.6.3 Photoreactive polynuclear ruthenium(II) species 
 
In photodynamic therapy (PDT) light is used to kill undesired cells in the body. The activity 
of PDT agents depends on their ability to associate with biopolymers or aggregates, such as 
cell membranes and DNA. DNA damage can occur by photoinduced electron transfer from 
the DNA to the excited state of the PDT molecule. Light absorption by a photosensitizing 
molecule can also lead to energy transfer to activate another molecule, such as O2 to its 
excited singlet state. Ruthenium(II) complexes with polypyridine ligands have attracted 
considerable attention for studies aimed at photodynamic therapy, because of their rich 
photophysical repertoire.[15] In contrast to mononuclear complexes, dinuclear ruthenium(II) 
complexes are greater in size, and charge, and vary more in shape. This may lead to increased 
DNA-binding affinity and specificity, which can be useful in the development of new 
photoprobes and stereochemical probes of nucleic acids. 
Dinuclear systems, in which two [Ru(bpy)3]2+ or [Ru(phen)3]2+ (phen = 1,10-phenantroline) 
moieties are linked by long and flexible alkane linkers, have been found to exhibit higher 
DNA binding affinity, more efficient photocleavage properties, and less sensitivity to ionic 
strength than their parental mononuclear analogues.[170] DNA binding mainly occurs through 
electrostatic interactions. The linker length has been reported to be crucial for binding 
efficiency. 
Dinuclear complexes based on [Ru(dpq)2(phen)]2+ (dpq = dipyrido[3,2-d:2’,3’-f]-quinoxaline) 
(40, Figure 1.20), have been shown to bind to DNA with high affinity through intercalation of 
 32
the terminal dpq ligands.[171] The position of attachment of the long and flexible 
mercaptoethyl ether linker to the phenanthroline ligands appears to have a profound effect on 
the binding size. 
A dinuclear complex linked by 1,5-dipyridopentane, but with only one terminal ligand of 
extended aromaticity per moiety (i.e. dipyrido-[3,2-a:2’,3’-c]-phenazine), does not show 









Figure 1.20 Dinuclear cationic ruthenium(II) dpq complex (40) linked by a long and 
flexible linker. 
 
An interesting mode of DNA interaction has been suggested for the dinuclear ruthenium 
complex 41 (Figure 1.21), in which two [Ru(phen)2dppz]2+ (dppz = dipyrido-[3,2-a:2’,3’-c]-
phenazine) moieties are joined through the phenazine ligand by a long and flexible alkane 
linker. The complex binds between base pairs of the DNA by bis-intercalation of the linked 
dppz moieties, thereby placing the ruthenium centers in the minor groove and the alkylamide 
linker in the major groove.[173, 174] Kinetic results support a threading mechanism, in which the 
ruthenium moieties pass through the core of the DNA, rather than a mechanism in which the 
flexible linker is slinging itself around dissociated base pairs.[173] The two enantiomers ∆-∆ 
and Λ-Λ both show high DNA affinities, but dissociation is markedly faster and also more 
dependent on the ionic strength for the Λ-Λ than for the ∆-∆ enantiomer. Each entity of the 
dinuclear complex binds to DNA almost identically to the monomer.[174] The ∆-∆ enantiomer 
has been shown to be non-toxic for V79 Chinese hamster cells.[175] 
The semi-rigid dinuclear analogues (42, Figure 1.21) show even higher affinity for DNA.[176] 
The initial binding of all three stereoisomers, including the meso form, is in the major 
groove.[177] Subsequently, the isomers force one of their metal moieties through the DNA to 
slowly reach[178] their final intercalative binding geometries. The final adducts have the 
bridging dppz ligand sandwiched between the DNA bases. The two metal centers are placed 
in opposite grooves.[177] One is situated deeply in the minor groove. The enantiomeric forms 


















may provide a probe for stereoselectivity. The Λ part is deeply intercalated in the minor 

















Figure 1.21 Long and flexible versus semi-rigid dinuclear cationic ruthenium(II) dppz 
complexes 41 and 42, respectively. 
 
DNA intercalation of the bridging ligand has also been suggested for dinuclear bipyridine 
complexes with semi-rigid phenanthroline linking ligands (i.e. bis([1,10]-
phenanthroline[5,6-f]-imidazol-2-yl)).[179] Dinuclear bipyridine complexes with an 
asymmetric phenanthroline linking ligand (i.e. 3-(pyrazin-2-yl)-as-triazino[5,6-f]1,10-
phenanthroline) have been shown to bind to DNA only through electrostatic interactions.[180] 
The dinuclear and trinuclear analogues, in which phenanthroline has been used for the 
terminal ligands, have also been reported.[181] Groove-binding behavior has been 
demonstrated by dinuclear bipyridine complexes, which are linked by 4,4’-bipyridine-like 
ligands (i.e. 2,2’-bis(1,2,4-triazin-3-yl)-4,4’-bipyridine ligands with different substituents at 
the triazine).[182-184] Some showed enantioselectivity.[182, 183] Increasing the size of the plane of 
the bridging ligand, and thereby the hydrophobicity, resulted in stronger binding to DNA.[183] 
Rigid dinuclear phenanthroline complexes, that share the short ligand HAT (HAT = 
1,4,5,8,9,12-hezaazatriphenylene) (43, Figure 1.22) as  the linking ligand, have been shown to 
bind weakly to DNA. Some preference for denatured or deformed segments along the DNA 





































as the mononuclear parental complex.[185] The interaction with purine mononucleotides and 
denatured CT-DNA appeared to be stereoselective and in favor of the meso form in both the 
excited and ground state.[186] Stereoselectivity in DNA binding has also been seen for rigid 
dinuclear bipyridine complexes for which the short linking ligand 2,2’-bipyrimidine has been 
used.[187, 188] These complexes have been shown to bind selectively to the minor groove[187] at 
adenine bulge sites.[188, 189] For dinuclear dpb complexes (2,3-bis(2-
pyridyl)benzo[g]quinoxaline), the size of the spectator ligands has been shown to be of 








Figure 1.22 Short-bridged dinuclear cationic ruthenium HAT complex 43. 
 
 




Heteropolynuclear complexes of ruthenium and platinum have been developed to achieve 
selective reactivity at each metal center. Since ruthenium and platinum anticancer complexes 
display different mechanisms of action, the combination of the different metals may result in a 
unique profile of activity. The preparation of only a few ruthenium-platinum polynuclear 
complexes have been described, but biological activity has not been reported so far. 
 
1.7.2 Heterodinuclear ruthenium platinum complexes 
 
The complex [{cis-RuCl2(dmso)3}(H2N(CH2)4NH2){cis-PtCl2(NH3)}] (44, Figure 1.23), in 
which the two metal centers are linked by a long and flexible α,ω-diaminoalkane linker, was 
the first heterodinuclear ruthenium-platinum complex reported.[191, 192] The complex has been 
found to form DNA crosslinks at which repair-proteins are associated. The DNA lesion 
responsible for efficient DNA-protein crosslinking is most probably a DNA-DNA interstrand 
















crosslinks were suggested to act as potential suicide adducts by hijacking away critical 
proteins from their functions inside the cell. Unfortunately, the complex has been found to be 
too reactive for use as a probe, due to its light sensitivity and rapid hydrolysis.[192] 
Heterodinuclear ruthenium-platinum compounds have also been devised to photoreact with 
DNA. Systems, in which a ruthenium light-absorbing unit has been linked to a reactive 
platinum moiety, have been synthesized using short bridging heterocyclic ligands. The 
ruthenium unit provides water solubility and electrostatic interaction with DNA by its positive 
charge. The systems can be photoactivated through light absorption of the ruthenium unit, 
thereby imparting reactivity at the platinum unit. The latter may then coordinate to DNA. 
The bridging ligand of the complex [(bpy)2Ru(dpb)PtCl2]Cl2 (45, Figure 1.23), affords an 
extra interaction with DNA by intercalation.[193] Results have indicated that the complex 
primarily forms intrastrand crosslinks by coordination of the platinum unit, but a higher 
percentage of interstrand crosslinks than cisplatin has also been found. The system has been 
extended to complexes with 2,2’:6’,2”-terpyridine as the terminal ligand on ruthenium to 
eliminate enantiomeric forms, and with either chloride or PEt2Ph as the sixth ligand.[194] A 
variety of bridging ligands with different aromaticity, such as 2,2’-bipyrimidine, 2,3-bis(2-
pyridyl)pyrazine and dpq, have been used to tune the spectroscopic and redox properties of 
the complexes. All have been shown to avidly bind to DNA, but photoreactivity has not been 
reported for these complexes. 
Dinuclear dimethyltriazolopyrimidine ruthenium-platinum complexes have been prepared by 









Figure 1.23 The long and flexible linked heterodinuclear ruthenium(II)-platinum(II) 




































1.8 Aim and contents of the thesis 
 
The development of polynuclear platinum complexes in search for anticancer agents, which 
are effective against cisplatin resistant tumors, appears to be a productive field of research. 
Polynuclear ruthenium complexes on the other hand have not yet extensively been studied for 
their anticancer activities, and the synthesis of anticancer heteropolynuclear ruthenium-
platinum complexes still presents a great challenge. The aim of the research described in this 
thesis has been the syntheses of polynuclear ruthenium polypyridyl complexes, as well as of 
heteropolynuclear ruthenium-platinum polypyridyl complexes as potential anticancer agents. 
These complexes have been designed to overcome cisplatin resistance. Their development has 
mainly been based upon the mononuclear complexes [Ru(tpy)Cl3] and [Pt(tpy)Cl]Cl (tpy = 




          
 
 
Figure 1.24 The mononuclear ruthenium(III) terpyridine complex 46, and the mononuclear 
cationic platinum(II) terpyridine complex 47. 
 
The mononuclear ruthenium(III) complex [Ru(tpy)Cl3] has been shown to display 
cytotoxicity and antitumor activity, which have been postulated to result from the interstrand 
binding to two guanines of the DNA in a trans position.[196, 197] The mononuclear platinum(II) 
complex [Pt(tpy)Cl]Cl has been found[150] to display cytotoxicity against a number of cancer 
cell lines, which has been ascribed to its ability to intercalate into DNA, as well as to 
coordinate to DNA.[198] 
The dinuclear ruthenium(III) complex [Cl3Ru(dtdeg)RuCl3] (48, Figure 1.25), in which the 
long and flexible ligand di[4’-(2,2’:6’,2”-terpyridyl)]-diethyleneglycolether links two 
trichlororuthenium(III) moieties, has previously been synthesized.[195] However, the complex 
has been found to be poorly soluble in aqueous solutions. Poor water solubility is a major 
problem for the development of clinically active compounds, and is the main reason for the 
fact that the mononuclear complex [Ru(tpy)Cl3] has not been developed any further. 
Chapter 2 addresses the synthesis and characterization of a water-soluble dinuclear 
ruthenium dtdeg complex containing one trichloroterpyridylruthenium(III) moiety. The 














water solubility and DNA affinity by its 2+ charge. Besides electrostatic DNA interactions, 
substitution-inert ruthenium polypyridyl complexes are also known to be capable of binding 
to DNA by surface binding, or partial intercalation.[199] 1H NMR resonances of the 
paramagnetic ruthenium(II)-ruthenium(III) complex are significantly broadened and shifted, 
due to the unpaired electron on the ruthenium(III) center. A unique approach to characterize 
the paramagnetic complex is presented. 
In Chapter 3 dinuclear ruthenium(II) polypyridyl complexes are described, in which the 
number of potential DNA coordination sites of each metal moiety has been varied by 
substitution of the relatively labile chloride ions with the inert ligands 2,2-bipyridine (bpy) or 
2,2’:6’,2”terpyridine. The mononuclear analogue [Ru(tpy)(bpy)Cl]Cl has been reported[197] to 
bind monofunctionally to DNA. The dinuclear complex [Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2 (49, 
Figure 1.25) has earlier been shown[195] to bind bifunctionally to the small biomolecules 
methylimidazole and methylbenzimidazole. In this Chapter, the coordination of the DNA-
model base 9-ethylguanine (9egua) to the dinuclear complex 49 is presented. The rotational 
behavior of coordinated 9egua is demonstrated by 1H NMR techniques at variable 
temperatures. Biological experiments have been performed on these complexes, as well as on 
the dinuclear ruthenium complex reported in Chapter 2, to obtain structure-activity-
relationships (SAR). 
 











Figure 1.25 Dinuclear ruthenium polypyridyl complexes 48 and 49. 
 
The syntheses and characterization of heterodinuclear ruthenium(II)-platinum(II) dtdeg 
complexes are described in Chapter 4. The ruthenium moiety of these complexes has been 
modified by coordination of three labile chloride ligands, or the inert ligands bipyridine and 
































moiety not to be hindered for intercalation by the dangling ruthenium center. 1H NMR data 
prove that coordination of platinum to 9-ethylguanine is feasible. The complexes have been 
tested for their cytotoxicity. 
The syntheses and characterization of trinuclear and tetranuclear ruthenium(II)-ruthenium(III) 
and ruthenium(II)-platinum(II) dtdeg complexes, as well as their precursors, are illustrated in 
Chapter 5. These polynuclear complexes display appreciable cytotoxicity. Interestingly, 
cisplatin sensitive human ovarian cells adhere together and form clots upon incubation with 
the tetranuclear ruthenium compound. This behavior indicates that migration and metastasis 
of these cells may be hampered under influence of this complex in particular. 
The short and semi-rigid bridging ligand 4’-pyridyl-2,2’:6’,2”-terpyridine (qpy) has been 
applied for the syntheses of the dinuclear and trinuclear ruthenium(II)-platinum(II) 
compounds presented in Chapter 6. According to 1H NMR data, coordination of 9-
ethylguanine to the ethylenediamine platinum unit occurs without hydrolysis. Inhibition of 
cell growth is substantially higher for the bifunctional trinuclear quaterpyridine complex than 
the monofunctional dinuclear derivative. However, the complexes do not show cytotoxicity. 
The final chapter of this thesis summarizes the research described in this work. A general 
conclusion is given and future prospects for the development of polynuclear anticancer 
complexes are discussed. 
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A paramagnetic dinuclear ruthenium(II)-ruthenium(III) 
complex: synthesis and strategy for 1H NMR studies 
 
 
Abstract – The terpyridyl-ruthenium(II) complex [(tpy)Ru(dtdeg)]Cl2 (1) (tpy = 2,2’:6’,2”-
terpyridine, dtdeg = bis[4’-(2,2’:6’,2”-terpyridyl)]-diethyleneglycolether) has been produced 
for the synthesis of the dinuclear ruthenium(II)-ruthenium(III) complex 
[(tpy)Ru(dtdeg)RuCl3]Cl2 (2). A straightforward strategy to fully characterize the 
paramagnetic species 2 by 1D and 2D 1H NMR is reported. Complex 2 represents the first 
example of a paramagnetic ruthenium complex, which has been fully characterized using 1D 
NOE difference experiments. Plots of the observed chemical shifts versus the reciprocal 
temperatures indicate Curie behavior. Both contact and dipolar interactions are suggested to 
contribute to the hyperfine shift and nuclear relaxation. Delocalization of unpaired-spin 
density into the central pyridine ring, which is coordinated to the paramagnetic ruthenium(III) 
center, probably occurs by a spin polarization mechanism. The chemical shifts of the protons 
of the diamagnetic ruthenium(II) moiety are also affected by the unpaired electron. The 















Polynuclear platinum complexes represent a new class of anticancer agents.[1] It is believed 
they can overcome resistance to the anticancer drug cisplatin, as they are capable of 
distinctive interactions with DNA, which is generally believed to be the ultimate target of 
platinum anticancer agents.[2] Ruthenium complexes are also known for their anticancer 
activity, and polynuclear derivatives are under study.[3] The synthesis of a series of dinuclear 
ruthenium complexes has been inspired by the mononuclear antimetastatic complex 
NAMI-A.[4] Dinuclear photoreactive ruthenium complexes have been designed, as it is 
thought that the greater size, charge and variation in shape increase DNA-binding affinity and 
specificity relative to mononuclear complexes.[5] The octahedral geometry of most ruthenium 
complexes is thought to impose unique interactions with biomolecules, which may cause a 
different anticancer profile from square-planar cisplatin.[6] Moreover, ruthenium(III) 
complexes may serve as prodrugs, which are activated by reduction in vivo to coordinate more 
rapidly to biomolecules.[3, 7] Selective tumor toxicity can be reached by the low oxygen 
content and the low pH in tumor cells, which are known to promote reduction.[3] 
A challenge in the investigation of ruthenium(III) complexes is their characterization by 1H 
NMR, because of the presence of an unpaired electron in the t2g orbital of the low-spin d5 
ruthenium(III) ions. Paramagnetism induces hyperfine shifts of 1H NMR signals and 
shortening of nuclear longitudinal (T1) and transverse (T2) relaxation times, which exclude 
characterization by standard 1H NMR techniques used for diamagnetic molecules. Proton 
NMR studies of paramagnetic compounds have become increasingly useful in applications 
such as probing metalloprotein active-site structure and mechanism.[8, 9] However, for 
relatively small paramagnetic inorganic complexes, 1H NMR has not been used intensively. It 
can be applied to small paramagnetic complexes in cases where the relaxation time of the 
unpaired electron is short enough, such that reasonably sharp 1H NMR signals are observed. 
For low-spin ruthenium(III) complexes relatively short electronic relaxation rates of 10–11 s–1 
have been reported,[10] which might make characterization by 1H NMR possible. 
In this Chapter, the synthesis and characterization of the ruthenium(II) complex 
[(tpy)Ru(dtdeg)]Cl2 (1) (tpy = 2,2’:6’,2”-terpyridine, dtdeg = bis[4’-(2,2’:6’,2”-terpyridyl)]-
diethyleneglycolether) and of the paramagnetic dinuclear ruthenium(II)-ruthenium(III) 
complex [(tpy)Ru(dtdeg)RuCl3]Cl2 (2, Figure 2.1) are presented. The synthesis of 2 has been 
based upon the cytotoxic and antitumor active complex[11] [Ru(tpy)Cl3], and the dinuclear 
derivative[12] [Cl3Ru(dtdeg)RuCl3]. These complexes have not been developed as possible 
anticancer drugs, because of their poor water solubility. The double positive charge of the 
bis(terpyridyl)-ruthenium(II) moiety of 2 is thought to increase water solubility. Moreover, 
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the positive charge of the ruthenium(II) moiety can direct 2 to the negatively charged DNA. 
Subsequently, the ruthenium(III) unit may coordinate to the DNA in a similar fashion[11, 13] as 
the parental mononuclear complex [Ru(tpy)Cl3]. 
The ruthenium(III) moiety of 2 is paramagnetic, as is its mononuclear derivative. 1H NMR 
studies have already been performed[12] on the latter and [Cl3Ru(dtdeg)RuCl3]. In this 
Chapter, a straightforward strategy is presented to fully characterize 2 by 1H NMR 
experiments. It is shown for the first time that high-resolution 1H 1D NOE NMR can be 
applied to low-spin ruthenium(III) complexes. To understand the relative weight of the 
different interactions between the unpaired electron and the nuclei on the hyperfine shift and 








Figure 2.1 The dinuclear cationic ruthenium(II)-ruthenium(III) complex 2. 
 
 
2.2 Experimental section 
 
2.2.1 General methods and starting materials 
 
Elemental analyses on C, H and N were performed on a Perkin Elmer series II CHNS/O 
Analyzer 2400. Electrospray mass spectra were recorded on a Finnigan TSQ-quantum 
instrument with an electrospray interface (ESI). Hydrated RuCl3·xH2O (x ~ 3) was used as 
received from Johnson & Matthey. The ligand tpy was obtained from Sigma. The ligand 
4’-chloro-2,2’:6’,2”-terpyridine and the complex [Ru(tpy)Cl3] have been synthesized 
according to known procedures.[14] The complex [(tpy)Ru(dtdeg)]Cl2 has been synthesized 
according to a modified procedure for cationic [Ru(L1)(L2)]2+ complexes in which L 
represents different tridentate heterocyclic ligands.[15] The acidic ruthenium(III) chloride 
solution and the ligand dtdeg have been synthesized[12] previously, but their synthesis will 


















2.2.2 1H NMR measurements 
 
1H NMR spectra were mainly acquired on a Bruker DPX 300 spectrometer. 1D 1H NOE 
difference spectra were measured on a Bruker DMX 600 spectrometer. Spectra were recorded 
in deuterated DMSO, and calibrated on the residual solvent peak at δ 2.49 ppm. 1D 1H spectra 
of 2 were obtained using a 100 ppm spectral width. Longitudinal relaxation times were 
measured by the standard inversion-recovery method, with 7 s relaxation delay and a spectral 
width of 100 ppm. Variable delays ranged from 50 µs to 500 ms to define the T1 values for 
the proton signals of the paramagnetic ruthenium(III) moiety, and from 100 ms to 5000 ms to 
define the T1 values for the proton signals of the diamagnetic ruthenium(II) moiety. 
Magnetization recovery was exponential within experimental error. T2 values were estimated 
from the peak half-widths. The COSY spectrum was obtained by collecting 1024 F2 x 1024 F1 
data points with a relaxation delay of 20 ms. 1D NOE experiments were carried out according 
to published procedures.[16] These procedures include a WEFT pulse sequence, which was not 
applied here. The irradiation time used for the 1D NOE experiment was 500 ms, and the 




0.1 M ruthenium(III) solution:[12] RuCl3·xH2O (1.20 g; ~ 5.0 mmol) was refluxed for 3 
hours in 50 mL of a mixture of a 1 M HCl aqueous solution and EtOH (v:v = 1:1). The 
mixture was filtered and the filtrate was reduced in vacuo to 10 mL. A 1 M HCl aqueous 
solution (40 mL) was added to result in 50 mL of the required acidified ~ 0.1 M 
ruthenium(III) solution. 
Dtdeg:[12] A mixture of 4’-chloro-2,2’:6’,2”-terpyridine (2.05 g; 7.6 mmol), diethyleneglycol 
(0.45 g; 4.2 mmol) and KOH (1.22 g; 21.7 mmol) was stirred in 185 mL of DMSO for 24 
hours at 338 K, under a moisture-free atmosphere. 160 mL of water was added to the mixture 
at RT, which resulted in a white precipitate. The mixture was filtered and the residue was 
dried on air. The residue was dissolved in 350 mL of EtOH 98 % by reflux for ~ 1 hour. The 
desired product was precipitated upon cooling of the solution in an ice bath for 0.5 hour. The 
mixture was filtered and the residue was washed twice with a small amount (~ 5 mL) of ice 
cold EtOH 98 %. The product was dried on air. Yield: 1.75 g (80 %). 
[(tpy)Ru(dtdeg)]Cl2, (1): An excess of AgBF4 (4.5 g; 23.1 mmol) was dissolved in 200 mL 
of acetone and filtered. [Ru(tpy)Cl3] (0.800 g; 1.815 mmol) was added to the filtrate and the 
mixture was refluxed in the dark for 16 hours to remove the chloride ions from ruthenium. 
After filtration to remove precipitated AgCl, the filtrate was evaporated in vacuo, which 
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resulted in a green oil (~ 6 mL).  The ligand dtdeg (1.700 g; 2.993 mmol) was added and the 
mixture was refluxed for 1.5 hours in 200 mL of DMF, which acted as the reducing agent. 
The reaction mixture was filtered and the red filtrate was evaporated in vacuo, which resulted 
in ~ 6 mL of an oil. To synthesize the chloride salt of the product, 75 mL of a saturated LiCl 
solution in EtOH was added to the oil. The desired product was obtained by precipitation with 
a large amount of acetone (~ 2 L). Complex 1 was separated from [(tpy)Ru(dtdeg)Ru(tpy)]Cl4 
by column chromatography on neutral alumina with acetone/MeOH/EtOH (v:v:v = 8:1:1). 
The first orange band contained pure product. Yield: 0.899 g (51 %). Elemental analysis (%) 
calculated for C49H39Cl2N9O3Ru·6H2O (water, originating from the used solvents, was used to 
fit the elemental analysis as the C/N ratio of the analysis corresponds to the structural formula 
of the complex): C 54.40, N 11.65, H 4.75. Found: C 54.51, N 11.96, H 4.95. ESI-MS: m/z: 
452 [M2+], 301 [M2++H+]. 1H NMR (300 MHz, DMSO, 298 K): δ = 8.61 (d, 2H; I33”), 7.99 
(t, 2H; I44”), 7.48 (t, 2H; I55”), 8.67 (d, 2H; I66”), 8.03 (s, 2H; I3’5’), 4.51 (t, 2H; 1), 4.06 
(t, 2H; 2), 8.87 (d, 2H; I’33”), 7.97 (t, 2H; I’44”), 7.21 (t, 2H; I’55”), 7.36 (d, 2H; I’66”), 8.87 
(s, 2H; I’3’5’), 4.77 (t, 2H; 1’), 4.15 (t, 2H; 2’), 8.83 (d, 2H; II33”), 7.98 (t, 2H; II44”), 7.25 
(t, 2H; II55”), 7,51 (d, 2H; II66”), 9.08 (d,2H; II3’5’), 8.48 ppm (t, 1H; II4’). 
[(tpy)Ru(dtdeg)RuCl3]Cl2, (2): 1 (0.190 g; 0.195 mmol) was dissolved in 60 mL of MeOH. 
At reflux temperature, 4 mL of the 0.1 M ruthenium(III) solution (0.4 mmol) was added to the 
solution. The mixture was refluxed for 3 hours and the resulting precipitate was filtered off at 
RT. The residue was dissolved in 1000 mL of hot MeOH and filtered to remove any insoluble 
species (probably ruthenium-oxo species). The filtrate was concentrated in vacuo, and the 
product was precipitated with diethyl ether. After filtration of the mixture, the residue was 
extensively washed with diethyl ether, which resulted in pure product. Yield: 0.082 g (36 %). 
Elemental analysis (%) calculated for C49H39Cl5N9O3Ru2·8H2O·0.5HCl (Besides water (vide 
supra), HCl was used to fit the elemental analysis, as the product precipitates from an acidic 
solution and an aqueous solution of the product is slightly acidic): C 43.80, N 9.38, H 
4.16, Cl 14.51. Found: C 43.45, N 9.17, H 3.28, Cl 14.60. 1H NMR (300 MHz, DMSO, 
320 K): δ = –8.44 (s, 2H; I33”), 0.94 (s, 2H; I44”), –9.89 (s, 2H; I55”), –30.19 (s, 2H; I66”), 
4.79 (s, 2H; I3’5’), 14.43 (s, 2H; 1), 4.12 (s, 2H; 2), 9.26 (s, 2H; I’33”), 8.09 (s, 2H; I’44”), 
7.27 (s, 2H; I’55”), 7.82 (s, 2H; I’66”), 9.44 (s, 2H; I’3’5’), 5.26 (s, 2H; 1’), 4.41 (s, 2H; 2’), 
8.90 (d, 2H; II33”), 8.09 (s, 2H; II44”), 7.27 (s, 2H; II55”), 7.53 (d, 2H; II66”), 9.15 (d,2H; 































2.3 Results and discussion 
 
2.3.1 Characterization of the diamagnetic precursor 1 by 1H NMR spectroscopy 
 
Complex 1 is water soluble. However, the 1H NMR spectrum of 1 is shown in dmso-d6 for 
comparison with 2 (Figure 2.2, assignments are reported in the experimental section). The 
appearance of four individual resonances in the region between 4 and 5 ppm for the linker 
protons 1, 2, 1’ and 2’ clearly indicates the presence of a non-symmetric species consisting of 
two different moieties. This is further confirmed by the fact that three sets of signals are 
recognized for the three inequivalent terpyridine ligands I, I’ and II in the aromatic region by 
2D 1H NMR experiments (data not shown). Symmetry is displayed within each unit due to the 
occurrence of a C2 symmetry axis, which is aligned along the linking diethylene glycolether 
chain and passes through the ruthenium center. Therefore, only half of the resonances for each 
terpyridine ligand are observed. The signals for the 66” protons have been identified by the 
small J value as compared to that of the 33” protons (~ 5 Hz versus ~ 9 Hz for the 66” and 33” 
protons, respectively). The terpyridine ligand II has been distinguished from the other 
terpyridine ligands by the signal for the II4’ proton, since it is the only signal with a relative 
intensity of 1. The terpyridine ligands I and I’ have been differentiated by the chemical shift 
of the 66” protons. The I’66” resonance is shifted upfield compared to the I66” signal, due to 













Figure 2.2 Schematic representation and 1D 1H NMR spectrum of the cation of 1 in 
DMSO-d6 at 298 K with some assignments. The numbering scheme given for terpyridine 
ligand I is also applicable to ligands I’ and II. 
 
2.3.2 1H NMR assignment strategy for the paramagnetic complex 2 
 
Complex 2 is, like its precursor 1, soluble in water. Since hydrolysis of 2 occurs in water, its 
1D 1H NMR spectrum is shown in dmso-d6 (Figure 2.3). The spectrum has been acquired at 
320 K. At this temperature, the “paramagnetic” signals, i.e. the resonances of the 
paramagnetic ruthenium(III) moiety, do not overlap. The effect of the unpaired electron of the 
paramagnetic species 2 is clearly recognized in the 1H NMR spectrum. Most signals are 
observed in the normal diamagnetic envelope from 0 to 12 ppm, but some signals are greatly 
shifted upfield or downfield. The unpaired electron influences the magnetic field sensed by a 
proton, since a significant magnetic dipolar field is associated with the large magnetic 
moment of the unpaired electron, which is 658 times that of a proton.[8] The broadened and 
shifted resonances, which also display relatively short longitudinal relaxation times, have 
been classified as signals of protons of the paramagnetic trichlororuthenium(III) moiety. The 
signal at 4.79 ppm has also been established as a “paramagnetic” signal, since it exhibits short 
T1 and T2 values. Only 5 resonances are observed for the ruthenium(III) unit, because of the 
C2 symmetry. The resonances appearing in the aromatic region have been assigned to the 
protons of the diamagnetic ruthenium(II) unit. This is fully consistent with the fact that the 
unpaired electron resides on the ruthenium(III) ion, and influences the nuclei closest to it the 
most. The striking similarities in chemical shift between the resonances for the terpyridine 
ligand I protons and the analogues resonances of the mononuclear parental complex 





























Figure 2.3 Schematic representation and 1D 1H NMR spectrum of the cation of 2 in 
DMSO-d6 at 320 K with some assignments. The numbering scheme given for terpyridine 
ligand I is also applicable to terpyridine ligands I’ and II. 
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At 320 K, nine resonances, of which two have a relative intensity of 4, are observed in the 
aromatic region of the 1H NMR spectrum of 2 (Figure 2.4). Thus, a total of eleven resonances 
are identified, which agrees with the structure and C2 symmetry of the bis(terpyridyl)-
ruthenium(II) moiety. The resonances of the terminal terpyridine ligand II appear as doublets 
and triplets, with exception of those that overlap with resonances of the I’ terpyridine ligand. 
In contrast, all the resonances of the terpyridine ligand I’ are significantly broadened. These 
signals also display relatively short longitudinal relaxation times. Fast relaxation rates result 
in a loss of magnetization during the various steps of the sequences of NMR experiments, 
which may cause a dramatic decrease in signal intensity.[8] For a 2D 1H COSY NMR 
experiment of 2, a relaxation delay of 20 ms resulted in a best signal-to-noise ratio in the 
aromatic region, as well as in the upfield region where most paramagnetic signals occur (vide 
infra). Since short acquisition times are a consequence of a short relaxation delay, a larger 
number of points (1024 in both dimensions) have been acquired in the same experimental 
time ensuing better resolution and signal intensity as well. 
The resonances of the terpyridine ligand II have been assigned starting from its II4’ proton, 
which displays a relative intensity of 1, using 2D 1H COSY and NOESY experiments (data 
not shown). The I’3’5’ resonance has been identified at 9.44 ppm, because no crosspeaks 
appear in the 2D COSY 1H NMR. From the two signals at 9.26 and 7.81 ppm, the first most 
likely originates from the I’33” protons. The more upfield shifted signal at 7.81 ppm is 
expected to arise from the I’66” protons, since these protons are shielded by the terpyridine 
ligand II. A NOE between the I’3’5’ and I’33” signals is not observed in 2D 1H NOESY 
experiments, because the resonance positions are too close to resolve the crosspeak from the 
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For the most “paramagnetic” signals of the paramagnetic species 2, the success of a COSY 
experiment can be severely hampered by short transverse relaxation times T2.[8] Indeed, the 
signal at –30.19 ppm appears to be too broad (T2 = 1/π(fwh), in which fwh is the full width at 
half height) to show crosspeaks in a 1H COSY NMR spectrum. The signal is expected to arise 
from the I66” protons, since these protons are closest to the paramagnetic ruthenium(III) ion. 
This signal is not only shifted and broadened the most, but also displays the shortest 
relaxation time T1. The assumption is confirmed by 1D NOE experiments (vide infra). 
In the upfield portion of the 2D COSY 1H NMR spectrum a three-spins system is displayed 
(Figure 2.5). Taking into account the above assignment, the considered resonances can be 
assigned to the I33”, I44” and I55” protons. The resonance at 0.94 ppm must arise from the 
I44” protons, as it displays crosspeaks to both resonances at –8.44 and –9.89 ppm. The latter 






















Figure 2.5 2D 1H COSY NMR spectrum of 2 in DMSO-d6 at 320 K with some 
assignments and crosspeaks indicated. 
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An additional spin-spin connectivity patterns involves the resonances at 14.43 and 4.12 ppm, 
which assigns these signals to the protons of the diethylene glycolether linker. The signal at 
14.43 ppm is attributed to the 1 protons, i.e. the linker protons, which are closest to the 
ruthenium(III) ion. 
Further assignments cannot be achieved without specific chemical substitution, which would 
require laborious syntheses, or interpretation of proton longitudinal relaxation times in 
correlation with distances between protons and the ruthenium(III) center. The latter are 
available from an earlier published[17] crystal structure of [Ru(tpy)Cl3]. However, the distance 
to the metal determined for a proton using T1 values may appear shorter than it really is when 
delocalized spin density is effective in relaxing the nucleus,[8] as may be the case for 2 (vide 
infra). 1D steady-state NOE studies are likely to be the only resource for examining dipolar 
contacts of the protons close to the metal, since a maximum intensity of the NOE is obtained. 
The mixing time of a 2D NOESY experiment is relative short, and therefore the 2D NOESY 
response is less than that of a 1D NOE. 1D NOE difference experiments are often used to 
probe metalloprotein active-site structures, but have scarcely been used to study paramagnetic 
metal complexes. The NOE intensity for paramagnetic compounds is proportional to the 
rotational correlation time and inversely proportional to the longitudinal relaxation rate.[8] 
Therefore, the relatively small size and small T1 values of paramagnetic complexes usually 
prevent the use of NOE techniques. 
However, 1D NOE difference experiments have successfully been applied to characterize the 
paramagnetic ruthenium(III) complex 2. Upon irradiation of the “paramagnetic” signal at 4.79 
ppm, negative NOEs are displayed by the resonances at 14.43 and –8.44 ppm (upper 
spectrum, Figure 2.6). These signal enhancements clearly prove that the irradiated resonance 
originates from the I3’5’ protons, and that the resonances exhibiting NOEs arise from the 
linker 1 protons and the I33” protons, respectively. Using a 10 mM concentration and a great 
number of scans, irradiation of the I66” signal produces a signal enhancement at –9.89 ppm 
despite its short T1 value. The NOE unambiguously confirms the assignment of the I66” 
protons, as well as that of the I55” protons, and completes successfully the full 
characterization of the paramagnetic species 2 by 1H NMR. All “paramagnetic” signals have 
been irradiated and the observed NOEs confirm the assignments done by 2D COSY NMR. 
For the I3’5’ and I66” signals, NOEs are only observed upon irradiation of these resonances, 
but are not displayed upon irradiation of the I33” or 1 resonance, and the I55” signal, 
respectively. It has been recognized that larger NOEs occur upon saturation of the signal with 











Figure 2.6 1D 1H NOE difference NMR spectra (upper and center), and 1D 1H NMR 
spectrum (bottom) of 2 in DMSO-d6 at 320 K. Irradiated signals are indicated with an arrow. 
NOEs are indicated with an asterisk. 
 
 
2.3.3 Temperature dependence of the chemical shift 
 
Spectra of 2 were monitored by variable-temperature measurements over the temperature 
range 300 to 360 K (Figure 2.7). The chemical shifts of the paramagnetic protons are all 
temperature sensitive. They shift to the diamagnetic region upon an increase of the 
temperature. 
The observed chemical shifts of the paramagnetic signals of 2 have been plotted against 1/T 
over the temperature range from 300 to 360 K (Figure 2.8). This Figure illustrates that the 
hyperfine shift linearly decreases upon a stepwise decrease of 1/T, which indicates Curie 
behavior. Curie’s law (M = constant × H/T) states that magnetization (M) increases with an 














Figure 2.7 Variable temperature 1D 1H NMR spectra for 2 in DMSO-d6 in the 
temperature range from 300 to 360 K. 
 
The equations (3) and (4) for the contact and dipolar shift, respectively (vide infra), indicate 
the linear dependency between the shift and the inverse of the temperature. From both 
equations it can be inferred that the observed chemical shift will approach the diamagnetic 
value as 1/T approaches zero. This behavior is also specified by the Curie law, which predicts 
zero magnetism at infinite temperatures. The intercepts obtained after extrapolation to infinite 
temperature for most of the signals differ only slightly from the expected diamagnetic shifts, 
which are in the aromatic region from 7 to 10 ppm. However, some intercepts deviate 
appreciably from their diamagnetic values. For example, the intercepts for I66” and I55” are 
20.65 and 15.29 ppm, respectively. The reasons for a deviation from Curie behavior have not 
been studied here. 
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Figure 2.8 Plots of the chemical shift versus 1/T for 2. 
 
 
2.3.4 The hyperfine shift 
 
For a proton of a paramagnetic species the observed 1H chemical shift is different from its 
diamagnetic value because of the interaction between the proton nucleus and the unpaired 
electron, i.e. the hyperfine interaction (equation (1)). Contact (through bond) and dipolar 
(through space) couplings contribute to the hyperfine shift (equation (2)). The contact 
contribution to the hyperfine or isotropic shift is given[8] by equation (3), where A is the 
contact coupling constant, ge is the free electron g-value, µB is the Bohr magneton, S is the 
spin quantum number of the spinning electron, h is Planck’s constant divided by 2π, γI is the 
proton gyromagnetic ratio, kB is the Boltzmann constant and T is the absolute temperature. 
The contact shift is given by an additional magnetic field, which is generated at the nucleus by 
spin delocalization of the unpaired electron. The unpaired spin density is transmitted through 
antibonding molecular orbitals of the complex. Spin density may reach the nucleus by two 
different mechanisms. Direct spin delocalization occurs owing to the hydrogen contribution to 
the molecular orbitals that have unpaired electrons. The contribution to the hyperfine shift 
through this mechanism decreases rapidly as the number of chemical bonds between the metal 
and the resonating nucleus increases. Spin polarization arises, because the presence of an 
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orbital. Spin polarization can result in alternating positive and negative shifts in an aromatic 
system to yield zero spin density over the entire system per doubly occupied MO. Both the 
direct delocalization and polarization mechanism can occur through σ and π orbitals. 
The dipolar or pseudocontact shift is given by equation (4), which is defined[8] for axially 
symmetric systems. The unpaired electron is considered to be localized on the metal in a 
paramagnetic complex. The shift is evaluated by expressing the principal molecular magnetic 
susceptibility values as a function of the principal g values, which holds when the spin 
multiplet ground state is well isolated from excited electronic states and zero-field splitting is 
negligible. µ0 is the magnetic permeability of a vacuum, gll and g⊥ are the principal parallel 
and perpendicular g values, respectively, r is the metal-proton distance, and θ is the angle 
between the metal-nucleus vector r and the z component of the magnetic susceptibility tensor. 
 
 δobserved =  δdiamagnetic + δhyperfine     (1) 
 
 δhyperfine =  δcontact + δdipolar      (2) 
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 (3 cos2 θ – 1)  (4) 
 
 
2.3.5 Contact and dipolar contributions to the chemical shifts of 2 
 
The I33”, I44”, I55” and I66” protons of the trichlororuthenium(III) moiety of 2 display 
hyperfine shifts which agree with the metal-proton distances, as well as with the number of 
chemical bonds to the metal center. The protons closest to the paramagnetic ruthenium(III) 
ion (i.e. the I66” protons) display the largest hyperfine shift, whereas the protons furthest 
away from the unpaired electron (the I44” protons) show a relatively small hyperfine shift. 
These observations suggest that dipolar interactions or direct delocalization of spin density (or 
both) influences the shifts of these protons. In contrast, the I3’5’ protons of the central 
pyridine ring of ligand I display a downfield shift with respect to the I33” and I55” signals, 
for which the metal-proton distances are approximately similar to that of the I3’5’ protons. 
The shift of the I3’5’ resonance agrees with[12] the signal of the same protons of the 
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mononuclear complex [Ru(tpy)Cl3]. Interestingly, the 4’ proton of the latter displays[12] a 
large upfield shift (–20.99 ppm) in comparison to its 44” signal, and the I44” resonance of 2. 
Upfield shifts for ortho and para protons versus downfield shifts for meta protons have been 
observed before in six-membered π systems of paramagnetic molecules.[18] The shifts indicate 
that spin delocalization into the central pyridine ring of trichlororuthenium(III) terpyridyl 
complexes at least partly occurs by a spin polarization mechanism. 
The unpaired electron of the low-spin ruthenium(III) ion occupies one of the t2g orbitals, 
which have the correct symmetry for π bonding. Therefore, π delocalization of spin density is 
likely to occur. Once some unpaired spin density is present in a π system, it can spin-polarize 
the electrons of the C–H σ bond. The alternating chemical shifts of the pyridyl (Chapter 6) 
and phenyl[12] protons of [Ru(qpy)Cl3] and [Ru(phtpy)Cl3] (qpy = 4’-pyridyl-2,2’:6’2”-
terpyridine and phtpy = 4’-phenyl-2,2’:6’2”-terpyridyl), support that spin polarization occurs 
in the central part of the terpyridine ligand. 
Direct delocalization of spin density may occur into the outer pyridines of the terpyridine 
ligand I, because the ruthenium(III)-nitrogen coordination bonds are not orthogonal. The 
N-Ru-N” angle has been found[17] to be ~ 158.3(3)° for [Ru(tpy)Cl3]. Therefore, overlap is 
expected between the ruthenium-nitrogen molecular orbitals and the t2g metal orbital, which is 
located in the plane of the terpyridine ligand. Such overlap may cause transfer of unpaired 
spin density through σ bonds. 
The relative weight of the dipolar or pseudocontact shift can be evaluated when both g values 
and structural information are available. For low-spin, d5 metal complexes of octahedral 
symmetry EPR spectra can only be seen at temperatures close to liquid helium, because of the 
large spin-orbit coupling present. At the time of writing, no such measurements could be 
performed for 2. However, EPR data of [Ru(tpy)Cl3] have shown two g values (2.36 and 
1.86), which indicates pseudo-axial symmetry. From the crystal structure of [Ru(tpy)Cl3], 
which has previously been published,[17] metal-proton distances can be derived (Table 2.1). 
Hence, the contribution to the dipolar shift can be estimated. Using the known parameters of 
equation (4) gives δdipolar = 162.31/r3 (g 2ll – g
2
⊥ ) (3 cos
2 θ – 1) ppm at 320 K (with r in Å). 
Taking into account that the geometric factor (3 cos2 θ – 1) can have a maximum value of 2, 
appreciable contributions to the pseudocontact shifts are possible. For example, the 66” 
protons, which are at ~ 3.1 Å from the ruthenium atom in [Ru(tpy)Cl3], can have a maximum 
dipolar shift of 23 ppm. Large dipolar contributions to the shift have been reported for low-
spin d5 ruthenium.[19] Exact calculations of the dipolar shift require that the principal g 
directions are available. These can be obtained from single-crystal EPR measurements. The 
principal g directions may also be guessed from the symmetry of the molecule, which has not 
been achieved in this study. 
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The linker protons 1, which are relatively far from the paramagnetic center, show a relatively 
large downfield shift. Contact contributions to the shift through σ bonds are negligible, 
because of the large metal-proton distances. The shift may be due to a large contribution of 
the dipolar shift, or to a spin polarization mechanism, although it has been found for 
nickel(III) complexes that spin density cannot be transmitted through ethereal oxygen 
atoms.[20] Moreover, the chemical shifts of the terpyridine I’ protons of the diamagnetic 
ruthenium(II) moiety differ significantly from those of the corresponding protons of the 
diamagnetic precursor 1 (i.e. 0.64 ppm for the I’3’5’ signal; see experimental section). The 
ruthenium(II) moiety may closely approach the paramagnetic ruthenium(III) center, because 
of the high flexibility of the linker. This approach can result in dipolar interactions between 
the paramagnetic unit and the diamagnetic unit.  However, the shifted and broadened signals 
of the protons of the diamagnetic unit can also originate from intermolecular interactions. 
Concentration-dependent 1H NMR studies have not been performed to study these 
interactions. The fact that the protons of the terminal terpyridine ligand II are less affected by 
the paramagnetic metal center than the terpyridine I’ signals, indicates a distance dependence 
of the influence of the unpaired electron, which supports intramolecular interactions are of 
importance. 
 
2.3.6 Relaxation properties of 2 
 
In Table 2.1, the chemical shifts and relaxation data are summarized for 2. The shifts and T1 
and T2 values of [Ru(tpy)Cl3] are also reported here, as well as metal-proton distances, which 
have been derived from crystal structure data[17] of [Ru(tpy)Cl3]. The I66” protons of 2, which 
are closest to ruthenium, have a very short T1 value (2.80 ms) and a broad line width (T2 = 
1.75 ms), whereas protons further away have longer T1s and narrower line widths. This is 
expected because both T1 and T2 are dependent on r–6 due to dipolar relaxation 
contributions.[8] Thus, protons closer to the ruthenium center experience a stronger 
paramagnetic effect. 
However, for the I3’5’ protons the T1 value is much shorter than that expected. Whereas the 
distance of the considered protons to the metal center is in between that of the I33” and I55” 
protons, T1 is appreciably smaller (10.7 ms versus 17.7 and 28.5 ms, respectively). 
Delocalized π spin density onto the central pyridine clearly affects the relaxation of the I3’5’ 
protons. In fact, the ratios between the T1-1 values of all the different nuclei do not follow the 
ratios of the sixth power of the metal to nucleus distances. This indicates that also for the 




Table 2.1 Chemical shifts and relaxation data for 2 and [Ru(tpy)Cl3] at 320 K, 300 MHz , 
as well as metal-proton distances[17] for [Ru(tpy)Cl3]. 
   2    [Ru(tpy)Cl3]   
protons  δobs (ppm) T1 (ms) T2 (ms)  δobs (ppm) T1 (ms) T2 (ms) rRu-H (Å) 
I66”  –30.19 2.80 1.75  –31.62 4.81 3.41 3.1 
I55”  –9.89 28.6 9.2  –6.63 39.9 15.4 5.2 
I44”  0.94 46.8 18.1  –2.48 54.5 20.3 5.7 
I33”  –8.44 17.5 9.2  –7.87 31.6 15.8 4.9 
I3’5’  4.79 10.7 8.8  5.90 20.3 15.4 5.1 
I4’  – – –  –20.99 13.5 7.6 5.8 
1  14.43 51.0 18.5  – – – – 
2  4.12 100.9 30.5  – – – – 
 
 
2.4 Concluding remarks 
 
The preparations of the water-soluble ruthenium(II) complex [(tpy)Ru(dtdeg)]Cl2 (1) and the 
water-soluble ruthenium(II)-ruthenium(III) complex [(tpy)Ru(dtdeg)RuCl3]Cl2 (2) are 
presented. Characterization of the paramagnetic complex 2 has been achieved in a 
straightforward manner by 1H NMR spectroscopy. The data demonstrate that characterization 
of trichlororuthenium terpyridine complexes is feasible without laborious chemical 
substitution, elaborate examination of T1 and T2 relaxation times, or theoretical studies to 
calculate the different contributions to the chemical shift and nuclear relaxation rates. In fact 
complex 2 represents the first example of a paramagnetic ruthenium(III) complex, which has 
been fully characterized using 1D NOE difference experiments, despite relatively short 
relaxation times. The technique might be widely applicable to other paramagnetic inorganic 
complexes. Analysis of the chemical shift behavior versus temperature for the terpyridine I 
protons of the ruthenium(III) unit indicates Curie behavior. Both dipolar and contact 
interactions are suggested to contribute to the hyperfine shift of the different protons. Spin 
polarization is probably affecting the chemical shift of the I3’5’ protons. Comparison of T1 
and T2 values with the metal-proton distances indicate that relaxation is determined by 
different unpaired-electron proton interactions. The chemical shifts of the protons of the 
diamagnetic ruthenium(II) unit are also influenced by the paramagnetic ruthenium(III) center. 
The shifts possibly originate from intramolecular interactions between the two moieties. 
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Dinuclear ruthenium(II) complexes with long and flexible 
linkers: rotational behavior of coordinated 9-ethylguanine 
and biological properties 
 
 
Abstract – The dinuclear ruthenium(II) complexes [Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2 (1), 
[(tpy)Ru(dtdeg)Ru(bpy)Cl]Cl3 (2), and [(tpy)Ru(dtdeg)Ru(tpy)]Cl4 (3) are described (bpy = 
2,2’-bipyridine, dtdeg = bis[4’-(2,2’:6’,2”-terpyridyl)]-diethyleneglycolether, tpy = 2,2’:6’,2”-
terpyridine). The bifunctional complex 1 has been studied for its hydrolysis and interaction 
with the guanine derivative 9-ethylguanine (9egua). Hydrolysis of a 1 mM solution of 1 in 
D2O at 310 K proceeds fast, but not completely. After approximately 2.5 hours equilibrium is 
accomplished, in which the monoaqua species [(D2O)(bpy)Ru(dtdeg)Ru(bpy)Cl]+ (4) and the 
diaqua species  [(D2O)(bpy)Ru(dtdeg)Ru(bpy)(D2O)]2+ (5) are present in situ in a ratio of 
~ 3:7. At this point the dichloro complex is not present in solution anymore. Upon reaction of 
1 with 9egua, the monoadduct [Cl(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl3 (6) and the bisadduct 
[(9egua)(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl4 (7) are formed, which both have been isolated 
and characterized by variable temperature 1H NMR experiments. The coordinated base is 
hindered for free rotation at RT. At 248 K, 9egua is flipping between two enantiomeric 
rotamers, in which it is positioned in such a way that the keto group is wedged between the 
bpy and tpy ligands. Biological properties (i.e. cytotoxicity, cell uptake and adhesion) of the 
complexes 1, 2, and 3, and the dinuclear complex [(tpy)Ru(dtdeg)RuCl3]Cl2 (labeled as 8 in 










Polynuclear platinum complexes, which are linked by long and flexible α,ω-diaminoalkane 
linkers, have shown great potential as antitumor agents.[1] Their high activity is thought[2] to 
be due to the formation of long-range adducts with DNA, which is generally believed to be 
the ultimate target of anticancer platinum complexes.[3] Structure-activity relationships state 
that polynuclear complexes with monofunctional platinum centers are more active than the 
isomers with bifunctional platinum moieties.[4] It has been demonstrated that the bifunctional 
complexes [{trans-PtCl(NH3)2}2(H2N(CH2)6NH2)]2+ (1,1/t,t) and [{trans-PtCl(NH3)2}2{µ-
trans-Pt(NH3)2(H2N(CH2)6NH2)2}]4+ (1,0,1/t,t,t  or BBR3464) form 1,4-interstrand adducts, 
which consist of two conformers.[5, 6]  For 1,1/t,t these conformers are interconvertible.[5] It 
has been suggested that delocalization of the lesion can represent an extremely efficient block 
to excision repair. 
Ruthenium complexes are also known for their anticancer activity, and polynuclear 
derivatives are under study.[7, 8] A series of dinuclear ruthenium complexes have been 
synthesized inspired by the mononuclear antimetastatic complex NAMI-A (trans-
(H2im)[RuCl4(dmso)(Him)]).[9] It appears that its antimetastatic activity is not related to DNA 
binding,[10] although NAMI-A has been shown to interact with DNA in vitro.[11] Dinuclear 
photoreactive ruthenium complexes have been designed, as it is thought that the greater size, 
higher charge and variation in shape increase DNA-binding affinity and specificity in 
comparison to the mononuclear complexes.[12] These complexes mainly interact with the 
DNA by electrostatic interactions and intercalation. A relation between DNA binding and 
cytotoxicity has not yet been established for this new class of complexes. 
In this Chapter, the dinuclear ruthenium(II) complexes [Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2 (1), 
[(tpy)Ru(dtdeg)Ru(bpy)Cl]Cl3 (2), and [(tpy)Ru(dtdeg)Ru(tpy)]Cl4 (3) are described (Figure 
3.1) (bpy = 2,2’-bipyridine, dtdeg = bis[4’-(2,2’:6’,2”-terpyridyl)]-diethyleneglycolether, tpy 
= 2,2’:6’,2”-terpyridine). The complexes have been synthesized using the long and flexible 
dtdeg linker to allow the formation of long-range DNA adducts. The design and development 
of complex 1 is based on the mononuclear complex [Ru(tpy)(bpy)Cl]Cl, which has been 
reported to monofunctionally coordinate to DNA by substitution of the relatively labile 
chloride ligand.[13] Complex 1 may form bisadducts with DNA by monofunctional 
coordination of both metal units. Complexes 2 and 3 have been synthesized by substitution 
with the inert ligand terpyridine at one or both metal moieties. Substitution-inert ruthenium 
polypyridyl complexes are known to bind to DNA by electrostatic or surface binding, or 
partial intercalation.[14, 15] 
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Since it is thought that hydrolysis occurs before coordination to DNA,[16] the hydrolysis of 1 
into the mono- and di-aqua species [(D2O)(bpy)Ru(dtdeg)Ru(bpy)Cl]+ (4) and 
[(D2O)(bpy)Ru(dtdeg)Ru(bpy)(D2O)]2+ (5) has been studied in situ by 1H NMR. The 
interaction of 1 with the DNA-model base 9-ethylguanine (9egua) is also described. The 
characterization of the monoadduct [Cl(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl3 (6) and the 
bisadduct [(9egua)(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl4 (7) by variable temperature 1H NMR 
experiments is presented. Biological properties (i.e. cytotoxicity, cell uptake and adhesion) of 
the complexes 1, 2, and 3, and of the dinuclear complex [(tpy)Ru(dtdeg)RuCl3]Cl2 (labeled as 








































































3.2 Experimental section 
 
3.2.1 General methods and starting materials 
 
1H NMR spectra were acquired on a Bruker DPX 300 and DMX 600 spectrometer. Spectra 
were recorded in deuterated DMSO, water, or methanol and calibrated on residual solvent 
peaks at δ 2.49, δ 4.78 (298 K) and δ 3.30, respectively. Elemental analyses on C, H and N 
were performed on a Perkin Elmer series II CHNS/O Analyzer 2400. Electrospray mass 
spectra were recorded on a Finnigan TSQ-quantum instrument with an electrospray interface 
(ESI). Hydrated RuCl3·xH2O (x ~ 3) was used as received from Johnson & Matthey. The 
ligands tpy and bpy were obtained from Sigma. The complex [Ru(tpy)Cl3] was synthesized 
following a known procedure.[17] The synthesis of the ligand dtdeg, the 0.1 M ruthenium(III) 
solution, and the complex [(tpy)Ru(dtdeg)RuCl3]Cl2 are described in Chapter 2, section 2.2.3. 
The complexes [Cl3Ru(dtdeg)RuCl3] and [Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2 (1) have 
previously been synthesized,[18] but the procedures will also be reported here for convenience. 
The species [(D2O)(bpy)Ru(dtdeg)Ru(bpy)Cl]+ (4) and 




[Cl3Ru(dtdeg)RuCl3]:[18] A mixture of dtdeg (300 mg; 0.53 mmol), LiCl (300 mg; 
7.08 mmol) and 21.1 mL of 0.1 M ruthenium(III) solution (2.11 mmol) in 40 mL of DMF 
were stirred at 353 K for 2 hours. After filtration, the residue was washed with DMF, EtOH 
and diethyl ether. The product was partly purified by reflux in 200 mL of acetone for 4 hours. 
Yield: 470 mg (91 %). 1H NMR (300 MHz, DMSO, 298 K): δ = –9.96 (s, 4H; I33”), 1.05 (s, 
4H; I44”), –11.48 (s, 4H; I55”), –34.27 (s, 4H; I66”), 4.75 (s, 4H; I3’5’), 16.62 (s, 4H; I1), 
4.08 ppm (s, 4H; I2). 
[Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2 (1):[18] A mixture of [Cl3Ru(dtdeg)RuCl3] (100 mg; 
0.10 mmol), bpy (32 mg; 0.20 mmol), LiCl (43 mg; 1.01 mmol) and triethylamine 37 mg; 
0.37 mmol) in 20 mL of EtOH 98 % were refluxed for 3 hours. The base triethylamine 
assisted in the reduction of ruthenium(III) by EtOH. After filtration and evaporation in vacuo, 
the product was purified by column chromatography on neutral alumina with 
chloroform/EtOH (v:v = 1:1) as the eluens. The purple band was collected in two fractions. 
From the second fraction pure product was obtained. Yield: 99 mg (79 %). 1H NMR (300 
MHz, DMSO, 298 K): δ = 8.70 (d, 4H; I33”), 7.90 (t, 4H; I44”), 7.31 (t, 4H; I55”), 7.58 (d, 
4H; I66”), 8.58 (s, 4H; I3’5’), 4.71 (t, 4H; 1), 4.13 (t, 4H; 2), 8.88 (d, 2H; II3), 8.31 (t, 2H; 
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II4), 8.02 (t, 2H; II5), 10.09 (d, 2H; II6), 8.63 (d, 2H; II3’), 8.75 (t, 2H; II4’), 7.09 (t, 2H; 
II5’), 7.42 ppm (d, 2H; II6’). 
[(tpy)Ru(dtdeg)Ru(bpy)Cl]Cl3, (2): A mixture of a crude batch of [(tpy)Ru(dtdeg)RuCl3]Cl2 
(800 mg; 0.68 mmol), bpy (159 mg; 1.02 mmol), LiCl (143 mg; 3.37 mmol) and triethylamine 
(250 mg; 2.48 mmol) were refluxed for 2.5 hours in 135 mL of absolute EtOH. After filtration 
and evaporation in vacuo, the product was purified by column chromatography on neutral 
alumina with acetone/EtOH (v:v = 6:4) as the eluens. From the brown third band, pure 
product was isolated by precipitation of the particular fraction with diethyl ether. Yield: 
155 mg (18 %). Elemental analysis (%) calculated for C59H47Cl4N11O3Ru2·7H2O: C 49.62, 
N 10.79, H 4.31. Found: C 49.15, N 10.44, H 4.16. 1H NMR (300 MHz, DMSO, 298 K): 
δ = 8.77 (d, 2H; I33”), 7.87 (t, 2H; I44”), 7.31 (t, 2H; I55”), 7.59 (d, 2H; I66”), 8.67 (s, 2H; 
I3’5’), 4.78 (t, 2H; 1), 4.19 (t, 2H; 2), 8.93 (d, 2H; I’33”), 7.95 (t, 2H; I’44”), 7.20 (t, 2H; 
I’55”), 7.36 (d, 2H; I’66”), 8.90 (s, 2H; I’3’5’), 4.78 (t, 2H; 1’), 4.19 (t, 2H; 2’), 8.88 (d, 1H; 
II3), 8.31 (t, 1H; II4), 8.02 (t, 1H; II5), 10.06 (d, 1H; II6), 8.63 (d, 1H; II3’), 8.76 (t, 1H; II4’), 
7.09 (t, 1H; II5’), 7.45 (d, 1H; II6’), 8.84 (d, 2H; III33”), 8.01 (t, 2H; III44”), 7.26 (t, 2H; 
III55”), 7.54 (d, 2H; III66”), 9.08 (d, 2H; III3’5’), 8.48 ppm (t, 1H; III4’). 
[(tpy)Ru(dtdeg)Ru(tpy)]Cl4, (3): An excess of AgBF4 (2.4 g; 12.33 mmol) was dissolved in 
100 mL of acetone and filtered. [Ru(tpy)Cl3] (405 mg; 0.92 mmol) was added to the filtrate 
and the mixture was refluxed for 16 hours to remove the chloride ions from ruthenium. After 
filtration to remove precipitated AgCl, the filtrate was evaporated in vacuo, which resulted in 
a green oil (~ 3 mL). The ligand dtdeg (210 mg; 0.37 mmol) was added and the mixture was 
refluxed for 1 hour in 120 mL DMF, which acted as reducing agent. The reaction mixture was 
filtered and the filtrate evaporated in vacuo until ~ 3 mL of a red oil resulted. The product was 
purified by column chromatography on neutral alumina with a mixture of CH3CN/aqueous 
saturated KNO3 solution/H2O (v:v:v = 35:5:6) as the eluens. The nitrate salt of the product 
was obtained from the fraction containing the first orange red band. The chloride salt of the 
product was synthesized to be able to compare results with complexes 1 and 2, which are 
chloride salts as well. 30 mL of a saturated LiCl solution in MeOH was added to a 
concentrated solution of the complex in MeOH. The product was obtained by precipitation 
with a large amount of acetone (2 L). Column chromatography on neutral alumina and EtOH 
yielded pure complex. Yield: 160 mg (31 %). Elemental analysis (%) calculated for 
C64H50Cl4N12O3Ru2·8H2O: C 50.46, N 11.03, H 4.37. Found: C 49.97, N 10.70, H 4.13. 1H 
NMR (300 MHz, DMSO, 298 K): δ = 9.01 (d, 4H; I33”), 7.93 (t, 4H; I44”), 7.21 (t, 4H; 
I55”), 7.37 (d, 4H; I66”), 8.99 (s, 4H; I3’5’), 4.87 (t, 4H; 1), 4.24 (t, 4H; 2), 8.85 (d, 4H; 
II33”), 8.01 (t, 4H; II44”), 7.29 (t, 4H; II55”), 7.55 (d, 4H; II66”), 9.10 (d, 4H; II3’5’), 
8.49 ppm (t, 2H; II4’). 
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[Cl(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl3, (6): [Cl(bpy)Ru(dtdegRu(bpy)Cl]Cl2  (90 mg; 
0.07 mmol) and an excess of 9egua (53 mg; 0.30 mmol) were stirred in 54 mL of H2O, at 
310 K for 24 hours. The mixture was concentrated in vacuo and filtered to remove free 9egua. 
The mixture was passed to EtOH by coevaporation with EtOH twice. Column 
chromatography on neutral alumina with CHCl3/EtOH (v:v = 1:1) separated 6 from the 
bisadduct 7. From the brown pink third band the monoadduct 6 was isolated by precipitation 
of the fraction with diethyl ether. Yield: 4 mg (4 %). 1H NMR (600 MHz, MeOH, 248 K): 
δ = 8.34 (d, 1H; I3), 7.82 (t, 1H; I4), 7.19 (t, 1H; I5), 8.21 (d, 1H; I6), 8.28 (s, 1H; I3’), 8.52 
(s, 1H; I5’), 8.73 (d, 1H; I3”), 8.02 (t, 1H; I4”), 7.36 (t, 1H; I5”), 7.61 (d, 1H; I6”), 4.70 (t, 
2H; 1), 4.18 (t, 2H; 2), 8.79 (d, 1H; II3), 8.27 (t, 1H; II4), 7.78 (t, 1H; II5), 9.18 (d, 2H; II6), 
8.59 (d, 1H; II3’), 7.81 (t, 1H; II4’), 7.10 (t, 1H; II5’), 7.36 (d, 2H; II6’), 6.86 (s, 1H; 
H8(9egua)), 3.82 (q, 2H; CH2(9egua), 1.07 ppm (t, 3H, CH3(9egua)), 8.58 (d, 1H; I’3), 7.90 
(t, 1H; I’4), 7.29 (t, 1H; I’5), 7.70 (d, 1H; I’6), 8.50 (s, 1H; I’3’), 8.48 (s, 1H; I’5’), 8.57 (d, 
1H; I’3”), 7.84 (t, 1H; I’4”), 7.21 (t, 1H; I’5”), 7.69 (d, 1H; I’6”), 4.66 (t, 2H; 1’), 4.18 (t, 2H; 
2’), 8.78 (d, 1H; II’3), 8.28 (t, 1H; II’4), 7.96 (t, 1H; II’5), 10.10 (d, 1H; II’6), 8.52 (d, 1H; 
II’3’), 7.73 (t, 1H; II’4’), 7.06 (t, 1H; II’5’), 7.52 ppm (d, 1H; II’6’). The monoadduct was not 
analyzed any further, due to the low yield. 
[(9egua)(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl4, (7): After collecting the monoadduct 6 from 
the column, the eluens was changed to a mixture of EtOH and MeOH (v:v = 9:1). From the 
light orange band the bisadduct was isolated by precipitation of the fraction with diethyl ether. 
Yield: 14 mg (12 %). 1H NMR (600 MHz, MeOH, 248 K): δ = 8.41 (d, 2H; I3), 7.84 (t, 2H; 
I4), 7.19 (t, 2H; I5), 8.21 (d, 2H; I6),  8.38 (s, 2H; I3’), 8.64 (s, 2H; I5’), 8.84 (d, 2H; I3”), 
8.06 (t, 2H; I4”), 7.36 (t, 2H; I5”), 7.63 (d, 2H; I6”), 4.71 (t, 4H; 1), 4.19 (t, 4H; 2), 8.79 (d, 
2H; II3), 8.26 (t, 2H; II4), 7.78 (t, 2H; II5), 9.19 (d, 2H; II6), 8.59 (d, 2H; II3’), 7.81 (t, 2H; 
II4’), 7.09 (t, 2H; II5’), 7.38 (d, 2H; II6’), 6.88 (s, 2H; H8(9egua)), 3.84 (q, 4H; CH2(9egua), 
1.07 ppm (t, 6H, CH3(9egua)). The bisadduct was not analyzed any further, due to the low 
yield. 
 
3.2.3 Biological tests. 
 
Cell cultures: KB carcinoma cells were maintained in Minimum Essential Medium 
(EuroClone, Whetherby, UK) containing 1.5 g/L sodium hydrogencarbonate and 
supplemented with 10 % fetal bovine serum (FBS) (Invitrogen Italia, Milano, Italy), 2 mM 
L-glutamine (EuroClone, Whetherby, UK), 100 units/mL penicillin and 100 µg/mL 
streptomycin (EuroClone, Whetherby, UK), 1 mM sodium pyruvate (EuroClone, Wetherby, 
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UK), 1 % non-essential aminoacids (EuroClone, Wetherby, UK), 1 mM Hepes solution, 
EuroClone, Whetherby, UK), in a humidified atmosphere with 5 % CO2 at 310 K. 
HBL-100, non tumorigenic epithelial cells, were maintained in McCoy’s 5A medium 
(SIGMA, St. Louis, MO, USA) supplemented with 10 % fetal bovine serum (FBS), 2 mM L-
glutamine, 100 UI/mL penicillin  and 100 µg/mL streptomycin (EuroClone, Whetherby, UK), 
in a humidified atmosphere with 5 % CO2 at 310 K. 
A2780cis and A2780R cells (cisplatin sensitive and resistant human ovarian carcinoma, 
respectively) were maintained in Dulbecco’s modified Eagle’s Medium (DMEM: Gibco 
BRLTM, Invitrogen Corporation, The Netherlands) supplemented with 10 % fetal calf serum 
(Perbio Science, Belgium), penicillin (100 units/mL: Duchefa Biochemie BV, The 
Netherlands) and streptomycin (100 µg/mL: Duchefa Biochemie BV, The Netherlands) in a 
humidified 6 % CO2, 94 % air atmosphere. L1210/0 and L1210/2 cells (cisplatin sensitive and 
resistant mouse leukemia, respectively) were grown (partly in suspension and partly weakly 
adherent to the flasks) under the above mentioned conditions for maintenance of A2780 cell 
growth. 
Cells from confluent monolayers were removed from flasks by 0.05 % trypsin solution 
(SIGMA, St. Louis, MO, USA); cell viability was determined by the trypan blue exclusion 
test. 
In vitro cytotoxicity evaluation: Cell growth was determined by the MTT assay, a 
colorimetric assay based on the ability of viable cells to reduce the soluble yellow 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide to blue formazan crystals by the 
mitochondria.[19] Cells were seeded between 1000 and 5000 cells/well (depending on the cell 
type) onto 96-well plates (Corning Costar®) in 100 µl of complete medium with 5 to 10 % of 
FBS. KB and HBL-100 cells were treated 24 hours after the sowing by adding 100 µL of 
complete medium containing the test compounds at the appropriate concentrations. A2780 
and L1210 cells were treated 48 hours after sowing. 
Final tested concentrations ranged between 1 µM and 100 µM and have been obtained by 
several dilutions with complete medium from stock solutions (1 mM) in sterile water. After 
24, and 72 hours of incubation, cells were incubated with 1 mg/mL MTT solution for 2 to 4 
hours at 310 K. Subsequently, the medium was discarded and the formed crystals were 
dissolved in 100 µL DMSO per well. Optical density (OD) was measured at 570 nm with a 
spectrophotometer Spectra Count Packard Bell (Meriden, CT, USA), and at 590 nm using a 
Biorad 550 microplate reader. The OD is directly proportional to the number of living cells, 
which are compared to the control (untreated cells). 
Atomic absorption spectroscopy: Cells were sown in 6-well plates and treated with 100 µM 
of the ruthenium compounds in Dulbecco Phosphate Buffer Saline (DPBS) at pH= 7.4 for 1 
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hour at 310 K. At the end of treatment the cells were extensively washed and harvested with a 
solution of Trypsin-EDTA. Cell specimens, counted by trypan blue exclusion test were dried 
overnight at 353 K and then at 378 K in Nalgene® cryovials. Cell decomposition was 
facilitated by addition of an aliquot of tetramethylammonium hydroxide (25 % in water) 
(Aldrich Chimica, Gallarate, Milano, Italy) and of milliQ water at a ratio 1:1 directly to each 
vial, at room temperature and under shaking (modified from Tamura and Arai). Final volumes 
were adjusted to 1 mL with milliQ water. The ruthenium concentration was measured using a 
Graphite Furnace Atomic Absorption Spectrometer (GFAAS), model SpectrAA-220Z, 
supplied with the GTA 110Z power and with a specific ruthenium emission lamp (Hollow 
cathode lamp P/N 56-101447-00) (Varian, Mulgrave, Victoria, Australia). The quantification 
of ruthenium was carried out in 10 µL samples at 349.9 nm with an atomizing temperature of 
2773 K, using argon as carrier gas at a flow rate of 3.0 L min-1. Before each daily analysis 
session, a five-point calibration curve was obtained using Ruthenium Custom-Grade Standard 
998 µg mL-1 (Inorganic Ventures Inc., Saint Louis, MO, USA).  
Adhesion assay: To evaluate pro-adhesive effects of the ruthenium compounds, cells were 
sown in 96-well plates (Corning Costar, Milano, Italy) in complete medium. Two days later 
cells were treated with each ruthenium compound for 1 hour in complete medium at the 
concentrations of 1, 10, 100 µM at 310 K. The pro-adhesive effect was determined as the 
resistance of cells to the action of a trypsin solution (0.05 % w:v for 30 min at 310 K). After 
this time cells were washed twice with PBS (Phosphate Buffer Saline pH = 7.4). Cells, which 
remained attached, were fixed and stained with 50 µl of sulforhodamine B (Sigma Chemical 
Co.) for 1 hour at room temperature (Skehan et al, 1990). After removal of the unreacted dye, 
cells were washed twice with a solution of 1 % (v:v) acetic acid and left to air dry. 
Sulforhodamine B bound to cells was dissolved with a 10 mM solution of Tris base (Sigma 
Chemical Co.) at pH = 10.5, and the absorbance was measured at 570 nm using a 
spectrophotometer Spectra Count Packard Bell (Meridien, CT,USA). In each experiment 
controls, which were not subjected to incubation with the compounds and trypsinization, were 
added. 
Morphological analysis: To evaluate a possible modification of cell structure, KB and 
HBL-100 cells were treated for 1 hour with 100 µM of the compounds in complete medium. 
At the end of treatment cells were fixed with 4 % paraformaldehyde for 10 min, and were 
washed twice with DPBS. Cell structure was evaluated with a phase contrast microscope, 
with a magnification of 200X. 
Statistical analysis: Data were submitted to computer-assisted statistical analysis using 
ANOVA analysis of variance and Dunnett post-test or Student t-test. 
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3.3 Results and discussion 
 
3.3.1 Characterization of complexes 1, 2 and 3 by 1H NMR spectroscopy 
 
1H NMR characterization of 1 has been performed previously.[18] For convenience, its 1H 
NMR spectrum in DMSO-d6 is shown in Figure 3.2 (top). The appearance of two individual 
resonances in the region between 4 and 5 ppm for the linker protons of 1 clearly indicates the 
presence of a symmetric species consisting of two identical moieties. Symmetry is also 
displayed within each unit due to the occurrence of a second C2 symmetry axis. The eight 
signals of the bipyridine ligand II are easily recognized, because of the relative intensity of 2 
caused by the fact that the ligand is located in the plane of symmetry. For comparison, the 
terpyridine I signals have a relative intensity of 4. The II6 bipyridine signal is shifted 
relatively downfield, due to the deshielding effect of the nearby chloride ligand. In contrast, 
the II6’ resonance is shifted relatively upfield as these protons are shielded by terpyridine 
ligand I. 
The 1H NMR spectrum of 2 in DMSO-d6 is also depicted in Figure 3.2 (middle). The 
assignment of the 1H NMR data has been done by 2D COSY and NOESY experiments (data 
not shown). In the upfield region of the spectrum, four different resonances are not clearly 
observed for the linker protons. However, four sets of signals are identified in the aromatic 
region for the four nonequivalent polypyridine ligands I, I’, II and III, which indicates the 
presence of two different metal moieties. The signals for the pyridine 6 protons have been 
identified by the small J value, as compared to that of the pyridine 3 protons (~ 5 Hz versus 
~ 9 Hz, respectively). The eight resonances of the bipyridine ligand II protons are recognized 
through their relative intensity of 1. The II6 and II6’signal have been distinguished by the 
relative downfield shift of the former. From the relative double intensity of the terpyridine 
protons of 2, the presence of a C2 symmetry axis within each unit can be inferred. The 
terpyridine ligand III has been distinguished from the terpyridine ligands I and I’ by the signal 
for the III4’ proton, since it is the only terpyridine signal with a relative intensity of 1. The 
terpyridine ligands I and I’ have been differentiated by the II6-I66” interligand NOE 
crosspeak. 
Characterization of 3 by 1H NMR has been performed similarly to that of 1 and 2. Therefore, 
it will not be discussed in detail. The 1D spectrum is displayed in Figure 3.2 (bottom). 
Characteristic features are the presence of only two resonances in the upfield region between 
4 and 5 ppm, and the relative intensity of 4 for the two sets of terpyridine signals observed in 
the aromatic region. These indicate the C2 symmetry of the species. The signals of the 






























Figure 3.2 1D 1H NMR spectra of 1 (top), 2 (middle), and 3 (bottom) in DMSO-d6 at 298 
K with some assignments, and schematic representations of the cations of 1, 2, and 3. The 

















































































3.3.2 Hydrolysis of the dinuclear compounds in D2O 
 
It is generally believed that hydrolysis of the chloride ligands of cisplatin occurs before it 
coordinates to DNA.[16] Since a similar reaction pathway is suggested for ruthenium 
anticancer complexes,[7, 20] the hydrolysis of 1 mM solutions of the dinuclear complexes has 
been studied at 310 K. The hydrolysis of 1 can easily be followed by monitoring the 
resonances of the II6 bipyridine protons in the 1D 1H NMR spectra at 310 K (Figure 3.3), as 
these protons are shifted relatively downfield and are well isolated from other resonances. 
 
Figure 3.3 Downfield region of the 1H NMR spectra (600 MHz) of 1 in D2O (1 mM) at 
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The bipyridine 6 resonance of 1 is found relatively downfield in D2O at t = 0, because of the 
deshielding effect of the coordinated chloride ions. Upon hydrolysis of the first chloride ion, 
an asymmetric species results, i.e. [Cl(bpy)Ru(dtdeg)Ru(bpy)(D2O)]3+ (4). The species is 
observed in 1H NMR by the appearance of two signals of identical intensity for the two 
different bipyridine protons 6 and 6*. The resonance of the bipyridine proton close to the 
coordinated D2O molecule (6*), experiences an upfield shift of 0.44 ppm in comparison with 
that of the corresponding resonance of the intact ruthenium moiety. Already after 15 minutes, 
the relative occurrence of the mono-aqua species amounts to 45 %. The diaqua species is 
present then as well for approximately 10 %, which is inferred from the relative intensity of 
the new signal at 9.5 ppm. This resonance arises from the two identical bipyridine 6* protons 
of the fully hydrolyzed symmetric species, [(D2O)(bpy)Ru(dtdeg)Ru(bpy)(D2O)]4+ (5), and 
increases with time. The chemical shift of the bipyridine 6* signal of 5 is shifted upfield with 
respect to the bipyridine 6 signal of 1, but remains in the downfield region of the spectrum. 
The shift may indicate coordination of a hydroxide anion in stead of water. However, the pH 
of the solution has not been measured during the hydrolysis experiment to examine this 
possibility. 
The relative intensity of the different species present in solution has been plotted against time 
in Figure 3.4. The abundance of the dichloro species decreases rapidly. Within 12 minutes, 
half of the original complex is hydrolyzed, and both the mono-aqua species and the fully 
hydrolyzed complex are observed. For the first 20 minutes, the monoaqua species is formed 
relatively fast in comparison to the diaqua complex. After half an hour the presence of the 
monoaqua species starts to decrease, but it does not disappear completely in time. After about 
2.5 hours equilibrium is accomplished, in which the mono-aqua and di-aqua species are 
present in a ratio of ~ 3:7 and the dichloro complex is absent. 
Hydrolysis of 2 only occurs at one metal moiety. Similarly to 1, the hydrolysis has been 
followed by monitoring the chemical shift of the II6 resonance (data not shown). Hydrolysis 
of 2 proceeds almost completely, i.e. 95 % of the aqua species is formed from a 1 mM 
solution of 2 in D2O after 2.5 hours at 310 K. These results indicate that for 1 hydrolysis of 
the first chloride ion decreases the rate and thermodynamic equilibrium of hydrolysis of the 
second chloride ion. Since 3 does not have labile leaving groups coordinated to ruthenium, 
hydrolysis does not occur and its 1H NMR spectrum is stable with time. 
Hydrolysis of the complexes also seems to be dependent on the concentration of the 
complexes, i.e. hydrolysis of a higher concentrated solution is relatively slow. Furthermore, 
complexes 1 and 2 are poorly soluble in physiological solutions containing 0.9 % of NaCl. 
The chloride counter ions probably affect hydrolysis and solubility. Hydrolysis of the 
complexes has not been studied at different ionic strengths or in buffer solution. 
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Figure 3.4 Plots of the normalized integral of the bipyridine 6 and 6* resonances versus 
time in minutes for the dichloro (1), mono-aqua (4) and di-aqua species (5). 
 
 
3.3.3 Characterization of the bisadduct 7 
 
The reaction of 1 with 9egua has been performed in water with a twofold excess of 9egua, and 
resulted in a mixture of monoadduct (6) and bisadduct (7), and hydrolyzed species. The fact 
that 1 not fully hydrolyzes probably influences the reactivity towards 9egua. Moreover, 9egua 
was found to dissociate from ruthenium at RT upon removal of the excess of 9egua. 
Dissociation of 9egua was particularly fast in water, as hydrolyzed species were formed. As a 
result, complexes 6 and 7 were obtained in low yield and not completely pure. However, it 
has been possible to characterize the 9egua adducts by 1D and 2D 1H NMR spectroscopy. 
Since the bisadduct displays a relatively simple 1H NMR spectrum with respect to that of the 
monoadduct, it will be discussed first. 1H NMR experiments were performed in MeOH-d4 to 
prevent the dissociation of the base from ruthenium. 
Parts of the 1H NMR spectra of [(9egua)(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl4 (7) in MeOH-d4 
at 298 K (top) and 248 K (bottom) are shown in Figure 3.5. At both temperatures, only two 
resonances of intensity four are observed for the linker protons between 4 and 5 ppm, 
indicating that the two metal moieties are identical. At 248 K, a double intensity for each 




the H8, CH2 and CH3 protons, respectively, have shifted from the corresponding values for 
free 9egua (7.71, 4.08 and 1.43 ppm), which prove coordination of the DNA-model base to 
ruthenium. The relative intensity of the H8 signal confirms the formation of the bisadduct. 
The large upfield chemical shift of the H8 in comparison with that of free 9egua clearly 
indicates N7 coordination to ruthenium. In the aromatic region of the spectrum at RT, sharp 
signals are observed for the bipyridine protons, whereas broad resonances are seen for the 
terpyridine protons. The broad resonances suggest hindered rotational behavior of coordinated 
9egua, which affects the terpyridine resonances exclusively. Variable temperature 1H NMR 
experiments have been performed to study this behavior. 
Figure 3.5 Parts of the 1H NMR spectra of 7 at 298 K (top) and 248 K (bottom) in 
MeOH-d4, and schematic representation of the bisadduct 7. A numbering scheme is only 
given for the terpyridine ligand I, the bipyridine ligand II and the linker protons 1 and 2, 
because the two metal moieties are identical. The H8 proton of 9egua is indicated with an 
asterisk in the schematic representation of the adduct. In the spectrum at 298 K, the bipyridine 
resonances are indicated. In the spectrum at 248 K, assignments of the terpyridine protons are 
given. At 248 K, the D2O signal has shifted beyond the shown region. 
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At low temperatures, 9egua is not expected to rotate, which would result in sharp resonances 
for all protons. At high temperatures 9egua is expected to rotate fast at the NMR time scale. 
Then, all protons sense an average of the rotating 9egua, which would result in sharp 
resonances as well. Upon decreasing the temperature in 1H NMR measurements of 7, all 
resonances sharpen rather fast, i.e. at 278 K the individual terpyridine signals are already 
recognized. Thus, the 9egua base may be in a fixed position at relatively high temperatures. 
The terpyridine signals have a maximum intensity at 248 K. At this temperature, a total of 
eighteen sharp signals of double intensity are observed in the aromatic region (Figure 3.5). 
Using 2D COSY and NOESY experiments all signals have been assigned at 248 K. The 
particular J couplings for the 6 and 3 protons (vide supra) have been taken into account. The 
II6’ resonance is shifted relatively upfield in comparison to the II6 signal, because the II6’ 
protons are shielded by the terpyridine ligand. One set of eight signals with relative intensities 
of 2 has been assigned to the bipyridine ligand, and one set of ten signals with similar 
intensities has been attributed to the terpyridine protons. Thus, a signal is observed for every 
single terpyridine proton, indicating that no C2 symmetry is present within the metal moieties. 
The model base 9egua is apparently not positioned in a plane of symmetry. The orientation of 
9egua has been determined from H8–I5’ and H8–I3” NOE crosspeaks (Figure 3.6). 
In Figure 3.6 clear NOEs are observed from the H8 signal to the II6, I5’ and I6” resonances. 
The H8-I3” NOE is relatively weak. The H8–I5’ and H8–I3” NOEs indicate that the 
orientation of 9egua is such that the keto group is located at a position between the bipyridine 
ligand and the I6 proton of the terpyridine ligand, as is indicated in the schematic 












Figure 3.6 Part of the 2D 1H NOESY spectrum of 7 in MeOH-d4 at 248 K showing the 
H8–I3” and H8–I5’ crosspeaks, as well as the H8–II6 and H8–I6” NOEs. 
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The keto group is likely to be the least sterically hindered in this particular position, which 
agrees with the crystal structure[21] of the known 9egua monoadduct [Ru(bpy)2(9egua)Cl]+. 
The relatively intense I6”–II6 NOE and the absence of a I6–II6 NOE confirm the orientation 
(Figure 3.7). The difference in intensity between the H8–I5’ and H8–I3” NOEs may be 
explained by the fact that the H8 proton is located more close to the I5’ proton. The H8–I6” 
and H8–II6 NOEs may result from flipping of the 9egua from one position to another, 
whereby the H8 proton passes rather closely along the II6 and I6” protons. Only one species is 
observed in the 1H NMR spectra, and therefore it is thought that the two rotamers are 
enantiomers. In the second rotamer the keto group of 9egua is wedged in between the 
bipyridine ligand and the I6” proton of the terpyridine ligand. The observed I3–I3”, I4–I4”, 
I5–I5”, I6–I6”, and I3’–I5’ exchange peaks confirm this assumption (Figure 3.7). The 
terpyridine signals are interchanged by the flipping of 9egua (Figure 3.8). 
 
Figure 3.7 Part of the 2D 1H NOESY spectrum of 7 in MeOH-d4 at 248 K with the II6-I6” 
NOE and the I3–I3”, I4–I4”, I5–I5”, I6–I6”, and I3’–I5’ exchange peaks indicated. H8 NOEs 

















Two similar rotamers have also been found for the bis(methylbenzimidazole) adduct of 1, 
albeit at 183 K.[18] Clearly, 9egua is more sterically demanding than methylbenzimidazole, 
and stops rotating at relatively high temperatures. A space-filling model of the cation 
[Ru(bpy)2(9egua)Cl]+, which is structurally rather similar to a single metal moiety of 7, has 
indicated a potential energy barrier for rotation around the ruthenium N7 bond.[21] The keto 
group of 9egua appears to be sterically hampered for rotation by the bipyridine ligand, to 
which the base is coordinated in a trans position. From studies with the mononuclear complex 
[Ru(tpy)(bpy)(9egua)]2+ it is also known that steric interactions of the bipyridine ligand 
hinder rotation of 9egua.[22] Therefore, flipping most likely occurs in such a way that the keto 
group passes under the terpyridine ligand (Figure 3.8). The fact that H8–I6” and H8–II6 
NOEs are observed confirm such passage. 
 
Figure 3.8 Schematic representation of the metal moieties of the two enantiomeric 
rotamers of 7. The structures are viewed from above along the bpy-ruthenium-9egua axis. 
Thus, the bpy ligand is pointing towards the reader, with its plane parallel to the mirror plane. 
The tpy ligand is positioned in the plane of the paper. The 9egua base coordinates to 
ruthenium from below, and is located under the tpy plane. The base is represented by the bar 
with its H8 and keto group indicated. The tpy signals are interchanged by the flipping of 
9egua, because the two rotamers are mirror images. 
 
Since the bpy protons are in the plane of symmetry, they experience either an average of the 
presence of the rotating 9egua or see the presence of 9egua in a single position, which is 
actually degenerate. Both possibilities yield sharp resonances for all bpy protons. 2D NOESY 
experiments have not been performed at temperatures below 248 K. Therefore, it cannot be 
inferred whether 9egua is still flipping at these temperatures or is fixed in one of the positions. 
Upon slightly increasing the temperature to 308 K, the terpyridine signals broaden beyond 
recognition (Figure 3.9). Sharp terpyridine signals are not observed within the measured 
temperature range, which has been limited to a maximum of 328 K due to the low boiling 























Figure 3.9 Parts of the 1H NMR spectrum of 7 in MeOH-d4 at 308 K with some 
assignments. The tpy signals are broadened beyond recognition. 
 
 
3.3.4 Characterization of the monoadduct 6 
 
The monoadduct [Cl(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl3 (6) has also been identified and 
characterized by 1D and 2D COSY and NOESY 1H NMR in MeOH-d4 at 248 K. The 1H 
NMR spectra at RT (top) and 248 K (bottom) are shown in Figure 3.10. A similar temperature 
dependence of the motion of 9egua as in 7 has been observed for 6. Therefore, the 
characterization will not be discussed in detail. 
Characteristic features are the four different signals for the linker protons (data not shown), as 
well as two resonances for the two different bipyridine II6 and II’6 protons in the downfield 
region. Both indicate the presence of two inequivalent metal moieties. The II’6 resonance is 
shifted downfield in comparison to the II6 signal, due to the nearby deshielding chloride ion  
An interesting feature to note is the fact that only the terpyridine resonances of the moiety to 
which 9egua is coordinated are broadened at RT. The chloride moiety displays sharp signals 
for all protons at this temperature. At 248 K sharp signals of intensity one are observed in the 
aromatic region for all protons, including those of the chloride moiety. Thus, C2 symmetry is 
not present within both metal moieties. The terpyridine protons of the chloride unit also 
display exchange signals in a 2D NOESY experiment, like the terpyridine signals of the 
9egua moiety. 
The exchange rate can be calculated for both metal units from the line widths of the 
resonances, which are in exchange, at the different temperatures. A similar exchange rate for 
both metal units may indicate that the chloride moiety is affected by the rotational behavior of 
the 9egua ligand, which is coordinated to the other ruthenium moiety. The flexible linker can 
allow close approach of the two different metal units, thereby facilitating the interaction. The 











Figure 3.10 Schematic representation of 6 with its numbering scheme, and the aromatic 
region of the 1H NMR spectra of 6 at RT (upper) and 248 K (lower) with some assignments. 
Only the tpy resonances of the metal moiety to which 9egua is coordinated are broadened. 
 
 
3.3.4 Biological properties of the dinuclear complexes 
 
Cytotoxicity has been evaluated on human KB carcinoma cells and HBL-100 epithelial non-
tumor cells for 24 and 72 hours. Cytotoxicity has also been evaluated on cisplatin-sensitive 
and cisplatin-resistant mouse leukemia L1210 cells and human ovarian carcinoma A2780 
cells for 72 hours. Complexes 1 and [(tpy)Ru(dtdeg)RuCl3]Cl2 (8) reach approximately 40 % 
of cell growth inhibition of KB cells at the highest concentration used (100 µM) after 24 
hours. Complexes 2 and 3 are slightly less potent as only 30 % of inhibition is reached at 
100 µM. Prolonging cell exposure from 24 to 72 hours results in a slight increase (up to 50-60 






















































HBL-100 cell line, about 50 % of growth inhibition is displayed by complexes 1, 2, and 8 
after 24 hours at 100 µM. After 72 hours, anti-proliferative activity up to 60 % is shown. 
Complex 3 is devoid of any activity against HBL-100 cells. 
Complex 1 shows an inhibition of cell growth of 50 % at a concentration of 33 µM against 
L1210/0 and L1210/R cells, but anti-proliferative activity does not increase with higher 
concentrations. Complexes 2 and 3 are less active, 50 % of inhibition is reached at 
concentrations of 100 µM. The complexes are less active against A2780 cells. Complex 8 is 
not active against the A2780 and the L1210 cell lines. 
Thus, in general none of the complexes displays significant cytotoxicity. The IC50 values 
given in Table 3.1 are only an indication of cytotoxicity, since only one concentration shows 
an effect slightly higher than 50 % of cell growth inhibition. IC50 values are only shown for 
cell exposure of 72 hours. Only 8 inhibits cell growth of KB and HBL-100 cells for more than 
50 % already after 24 hours at a concentration of 100 µM (IC50 ~ 74 µM). 
 
Table 3.1 Indication of IC50 values for the series of dinuclear ruthenium complexes 
calculated after 72 hours of treatment. 
    IC50  
complex KB HBL-100 L1210cis L1210R A2780cis A2780R 
1 68 34 33 33 > 100 > 100 
2 57 87 ~ 100 ~ 100 > 100 > 100 
3 93 > 100 ~ 100 ~ 100 >100 > 100 
8 > 100 74 > 100 > 100 > 100 > 100 
 
Ruthenium cell uptake has been studied using KB and HBL-100 cells, which were treated 
with 100 µM of the dinuclear complexes in DPBS for 1 hour at 310 K. Complexes 1 and 8 are 
taken up by KB and HBL-100 cells to the same extent, reaching intracellular concentrations 
much higher than the concentrations used to treat the cells (3 mM and 7 mM, respectively). 
Compared to 1 and 8, complexes 2 and 3 are not significantly taken up by both type of cells. 
Intracellular concentrations approximately similar to the treated concentrations are attained. 
For comparison, under the same experimental conditions NAMI-A is taken up by cells 
reaching concentrations 4 to 5 times that used to treat the cells. The results indicate that 
uptake of the complexes is not per se hindered by the dinuclear nature of the complexes. 
However, uptake of the different complexes is unrelated to the anti-proliferative effects. 
Pro-adhesive effects have been studied as well. The pro-adhesive effect is the percentage of 
increase in adhesion strength of treated cells versus control cells. The adhesion assay has been 
developed to study the anti-metastatic activity[23] of the mononuclear ruthenium complex 
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NAMI-A. Increased adhesion may indicate a decrease in the cell’s capability to dissociate 
from the solid tumor to invade other tissues. The pro-adhesive effect was studied using KB 
and HBL-100 cells, since particularly complex 2 showed a change of the cells shape in the 
tests with human ovarian A2780 cisplatin-sensitive cells. The A2780cis cells were spread on 
the wells bottom after treatment with 2, indicating increased adherence to the well.  
In general, all complexes show dose-dependent pro-adhesive effects, which are strongest on 
KB cells. However, effects are not dose dependent for 1 on both cell lines and not for 3 on 
HBL-100 cells. Increase in adhesion is strongest for 2 on KB cells, i.e. at 100 µM an increase 
of about 300 % is observed, which is comparable to that observed for NAMI-A. A significant 
increase is also displayed by 8. At 10 µM an increase of 200 % is displayed, but adhesion 
does not increase much further at higher dose. 
Morphological analysis of the KB and HBL-100 cell line did not show a significant 
modification of the cell shape upon incubation with the complexes. 
 
3.4 Concluding remarks 
 
The dinuclear ruthenium(II) complexes [Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2 (1), 
[(tpy)Ru(dtdeg)Ru(bpy)Cl]Cl3 (2), and [(tpy)Ru(dtdeg)Ru(tpy)]Cl4 (3) are described. The 
hydrolysis of 1 has been studied, as well as its binding to the DNA-model base 
9-ethylguanine. At 310 K and 1 mM hydrolysis of 1 proceeds fast, but not completely. After 
about 2.5 hours, equilibrium is accomplished, in which the monoaqua and diaqua species are 
present in a ratio of ~ 3:7. The partial hydrolysis of 1 is likely to have an effect on the 
reactivity towards 9egua. Although 9egua easily dissociates from ruthenium at RT in the 
absence of excess 9egua, both the monoadduct [Cl(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl3 (6) and 
the bisadduct [(9egua)(bpy)Ru(dtdeg)Ru(bpy)(9egua)]Cl4 (7) have been isolated and 
characterized by variable temperature 1H NMR experiments. The base is hindered for free 
rotation at RT. At 248 K, flipping of 9egua between two enantiomeric rotamers is seen. 
Unfortunately, the dinuclear complexes 1, 2, 3, and [(tpy)Ru(dtdeg)RuCl3]Cl2 (8) do not 
display cytotoxicity against a variety of cancer cells. High cellular uptake of 1 and 8 has been 
found, but is not related to cytotoxicity. Complexes 2 and 8 significantly increase adhesion of 
KB tumor cells, but morphological changes of the cell’s shape are small. 
Concluding, the dinuclear ruthenium complexes represent the first of a new class of 
polynuclear ruthenium polypyridyl compounds as potential anticancer agents. Variation of the 
metal, terminal ligands or the linker can provide a wealth of polypyridyl polynuclear 
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Heterodinuclear ruthenium-platinum complexes with long 
and flexible linkers: crystal structure and cytotoxicity 
 
 
Abstract – The complexes [Cl3Ru(dtdeg)] (1) and [Cl(bpy)Ru(dtdeg)]Cl (2) have been 
produced for the synthesis of the heterodinuclear ruthenium-platinum complexes 
[Cl3Ru(dtdeg)PtCl]Cl (3), and [Cl(bpy)Ru(dtdeg)PtCl]Cl2 (4) (bpy = 2,2’-bipyridine, dtdeg = 
bis[4’-(2,2’:6’,2”-terpyridyl)]-diethyleneglycolether). The complex [(tpy)Ru(dtdeg)PtCl]Cl3 
(5) has been synthesized from [(tpy)Ru(dtdeg)]Cl2, which has been presented in Chapter 2 
(tpy = 2,2’:6’,2”-terpyridine). The paramagnetic complexes 1 and 3 have been characterized 
by 1H NMR spectroscopy, including 1D NOE difference experiments. The crystal structure of 
the cation of 5 has been elucidated, and shows self-stacking interactions of the platinum units. 
The distance between the ruthenium and platinum metals in the crystal structure is 
approximately 14.5 Å. Complex 5 has been reacted with the DNA-model base 9-ethylguanine 
(9egua). The adduct [(tpy)Ru(dtdeg)Pt(9egua)](PF6)4 (6) has been isolated and characterized 
by 1H NMR experiments. The results suggest that the platinum moiety is able to both 
intercalate and coordinate to the DNA, without being hindered by the dangling ruthenium 
moiety. The length and flexibility of the linker may allow the formation of long-range DNA 













Polynuclear platinum complexes constitute a class of compounds, which has been developed 
to circumvent resistance to the antitumor drug cisplatin.[1, 2] It is believed these complexes can 
achieve a unique spectrum of anticancer activity, because they form radically different 
adducts to DNA, the known ultimate target of anticancer platinum complexes.[3] Whereas 
cisplatin forms mainly 1,2-intrastrand adducts,[4] the high cytotoxicity displayed by 
polynuclear α,ω-diaminoalkane-linked platinum complexes is thought to be due to the 
formation of long-range DNA-adducts.[2] Mononuclear and polynuclear ruthenium complexes 
are also studied for their anticancer activities.[5] One example is the series of dinuclear 
complexes based upon the mononuclear antimetastatic compound NAMI-A.[6] The extension 
of the polynuclear concept to heteropolynuclear ruthenium-platinum complexes represents an 
interesting challenge. Mononuclear ruthenium and platinum anticancer complexes are known 
to display different mechanisms of action, which are intrinsic to their geometry, reactivity and 
biological pharmacology.[4, 5, 7] Selective reactivity at each metal center may be achieved by 
the use of ruthenium and platinum for the different metal moieties of polynuclear anticancer 
complexes. 
Only a few examples of heteropolynuclear ruthenium-platinum anticancer complexes have 
been reported so far. One example of a dinuclear ruthenium-platinum complex with a long 
and flexible linker has been reported, i.e. [{cis-RuCl2(dmso)3}H2N(CH2)4NH2{cis-
PtCl2(NH3)}].[8] This complex has, however, been found to be too reactive to be used as a 
DNA-binding agent. A small class of dinuclear ruthenium-platinum complexes comprises 
polyazine bridged compounds. For these heterodinuclear complexes it is thought that light 
absorption of the ruthenium unit, and subsequent energy transfer, activates the platinum 
moiety for reaction with DNA.[9] Biological data have not yet been reported.  
In this Chapter, the synthesis of the complexes [Cl3Ru(dtdeg)] (1) and 
[Cl(bpy)Ru(dtdeg)]Cl (2) is described (bpy = 2,2’-bipyridine, dtdeg = bis[4’-(2,2’:6’,2”-
terpyridyl)]-diethyleneglycolether). They have been produced for the assembly of the 
heterodinuclear ruthenium-platinum complexes [Cl3Ru(dtdeg)PtCl]Cl (3), and 
[Cl(bpy)Ru(dtdeg)PtCl]Cl2 (4). The ruthenium-platinum complex [(tpy)Ru(dtdeg)PtCl]Cl3 (5) 
is presented as well (tpy = 2,2’:6’,2”-terpyridine). The complexes have been synthesized 
using the long and flexible dtdeg linker to allow the formation of long-range DNA adducts. 
The design and subsequent development of the complexes have been inspired by the cytotoxic 
mononuclear complex [Pt(tpy)Cl]Cl·2H2O, which can intercalate[10] and coordinate[11] to 
DNA. The ruthenium unit of the complexes has been varied in the number of relatively labile 








































[Ru(tpy)(bpy)Cl]+ and [Ru(tpy)2]2+. The complex [Ru(tpy)Cl3] has been reported to display 
antitumor activity, which is believed to be due to the coordination to two guanines of opposite 
DNA strands.[12, 13] The complex [Ru(tpy)(bpy)Cl]Cl has been shown to bind 
monofunctionally to DNA.[12] Substitution-inert ruthenium polypyridyl complexes are known 
to be able to bind to DNA by electrostatic or surface binding, or partial intercalation.[14] 
The complexes, including the paramagnetic compounds 1 and 3, have been characterized by 
different 1H NMR experiments. A crystal structure of complex 5 is presented. This complex 
has also been studied for its interaction with the DNA-model base 9-ethylguanine (9egua). 
The characterization of the adduct [(tpy)Ru(dtdeg)Pt(9egua)](PF6)4 (6) by 1H NMR is 
described. The complexes have been tested for their cytotoxicity against cisplatin-sensitive 



























4.2 Experimental section 
 
4.2.1 General methods and starting materials 
 
Elemental analyses on C, H and N were performed on a Perkin Elmer series II CHNS/O 
Analyzer 2400. Electrospray mass spectra were recorded on a Finnigan TSQ-quantum 
instrument with an electrospray interface (ESI). Hydrated RuCl3·xH2O (x ~ 3) and K2PtCl4 
were used as received from Johnson & Matthey. The ligands bipyridine and terpyridine were 
obtained from Sigma. The complexes [Ru(tpy)Cl3] and [Pt(cod)Cl2] were produced according 
to literature procedures.[15] The 0.1 M ruthenium(III) solution and the ligand dtdeg have 
previously been synthesized,[16] the procedures are described in Chapter 2 for convenience. 
The complex [Cl3Ru(dtdeg)] (1) has earlier been synthesized as well, but was not obtained 
pure.[16] Therefore, its synthesis is described here. The synthesis of [(tpy)Ru(dtdeg)]Cl2 is 
described in Chapter 2. The ruthenium-platinum complexes 3, 4, and 5 have been prepared by 
modification of a procedure known[17] for the synthesis of [Pt(tpy)Cl]Cl·2H2O. 
 
4.2.2 1H NMR measurements 
 
NMR spectra were acquired on a Bruker DPX 300, a DMX 600, and an AV 400 MHz 
spectrometer. Spectra were recorded in deuterated DMSO, acetone and MeOH, and were 
calibrated on residual solvent peaks at δ 2.49, 2.06 and 3.30 ppm, respectively. The 1D 1H 
NMR spectra of the paramagnetic complexes 1 and 3 were obtained using a 100 ppm spectral 
width. Longitudinal relaxation times were measured by the standard inversion-recovery 
method, with 7 s relaxation delay and a spectral width of 100 ppm. Variable delays ranged 
from 50 µs to 500 ms to define the T1 values for the proton signals of the paramagnetic 
ruthenium(III) moiety, and from 100 ms to 5000 ms to define the T1 values for the proton 
signals of the diamagnetic ruthenium(II) moiety. Magnetization recovery was exponential 
within experimental error. T2 values were estimated from the peak half-widths. The COSY 
spectra were obtained by collecting 1024 F2 x 1024 F1 data points with a relaxation delay of 
20 ms. 1D NOE difference experiments were carried out according to published 
procedures.[18] These procedures include a WEFT pulse sequence, which was not applied 








[Cl3Ru(dtdeg)], (1): 0.1 M ruthenium solution (1.77 mL; 0.18 mmol) was added to a hot 
solution of the ligand dtdeg (200 mg; 0.35 mmol) in 200 mL of EtOH 98 %. After 2 hours of 
reflux, the hot reaction mixture was filtered to remove unwanted [Cl3Ru(dtdeg)RuCl3]. The 
filtrate was cooled to RT for 24 hours. The formed precipitate was collected by filtration and 
was washed three times with ~ 10 mL of chloroform to remove excess dtdeg. The residue was 
subsequently washed with EtOH 98 %, acetone and diethyl ether. Yield 62 mg (45 %). 
Elemental analysis (%) calculated for C34H28Cl3N6O3Ru·1CHCl3: C 46.95, N 9.39, H 3.26. 
Found: C 46.42, N 9.70, H 3.20. 1H NMR (300 MHz, DMSO, 340 K): δ = –7.38 (2H; I33”), 
1.35 (2H; I44”), –8.28 (2H I55”), –27.24 (2H; I66”), 5.07 (2H; I3’5’), 14.28 (t, 2H; 1), 3.74 
(2H; 2), 8.85 (2H; I’33”), 7.62 (2H; I’44”), 8.13 (2H; I’55”), 8.91 (2H; I’66”), 8.18 (2H; 
I’3’5’), 4.65 (2H; 1’), 4.13 ppm (2H; 2’). 
[Cl(bpy)Ru(dtdeg)]Cl (2): [Cl3Ru(dtdeg)] (95 mg; 0.12 mmol), 2.2’-bipyridine (19 mg; 0.12 
mmol), triethylamine (22 mg; 0.22 mmol) and LiCl (11 mg; 0.26 mmol) were dissolved in 
19 mL of EtOH 98 % and refluxed for 5 hours. After filtration at RT,  the mixture was 
evaporated in vacuo and purified by column chromatography on neutral alumina using a 
mixture of EtOH 98 % and acetone (v:v = 1:1). The first fraction eluting, yielded pure product 
after precipitation with diethyl ether and filtration. Yield: 47 mg (43 %). Elemental analysis 
(%) calculated for C44H36Cl2N8O3Ru·3H2O: C 55.58, N 11.78, H 4.45. Found: C 55.22, N 
11.78, H 3.91. 1H NMR (300 MHz, DMSO, 298 K): δ = 8.68 (d, 2H; I33”), 7.93 (t, 2H; I44”), 
7.32 (t, 2H; I55”), 7.58 (d, 2H; I66”), 8.59 (s, 2H; I3’5’), 4.65 (t, 2H; 1), 4.03 (t, 2H; 2), 8.68 
(d, 2H; I’33”), 7.47 (t, 2H; I’44”), 7.98 (t, 2H I’55”), 8.62 (d, 2H; I’66”), 8.03 (s, 2H; I’3’5’), 
4.49 (t, 2H; 1’), 4.03 (t, 2H; 2’), 8.86 (d, 1H; II3), 8.29 (t, 1H; II4), 8.00 (t, 1H; II5), 10,07 (d, 
1H; II6), 8.59 (d, 1H; II3’), 7.72 (t, 1H; II4’), 7.05 (t, 1H; II5’), 7,39 ppm (d, 1H; II6’). 
[Cl3Ru(dtdeg)PtCl]Cl, (3): [Pt(cod)Cl2] (88 mg; 0.23 mmol) was added to a hot solution of 
[Cl3Ru(dtdeg)] (134 mg; 0.17 mmol) in 320 mL of a mixture of EtOH 98 % and MeOH (v:v = 
1:1). After 6 hours of reflux, the mixture was cooled to RT. The formed precipitate was 
filtered and washed with acetone to remove unreacted [Pt(cod)Cl2]. The residue was 
subsequently washed with diethyl ether. Yield: 106 mg (61 %). Elemental analysis (%) 
calculated for C34H28Cl5N6O3RuPt·3H2O: C 37.26, N 7.67, H 3.13. Found: C 36.70, N 8.13, H 
2.79. 1H NMR (300 MHz, DMSO, 310 K): δ = –9.13 (2H; I33”), 0.75 (2H; I44”), –10.58 (2H 
I55”), –31.79 (2H; I66”), 4.63 (2H; I3’5’), 15.06 (t, 2H; 1), 3.89 (2H; 2), 8.83 (2H; I’33”), 
8.19 (2H; I’44”), 8.91 (2H; I’55”), 9.08 (2H; I’66”), 8.91 (2H; I’3’5’), 5.03 (2H; 1’), 4.30 
ppm (2H; 2’). 195Pt NMR (300 MHz, MeOH, 298 K): δ = –2705 ppm. 
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[Cl(bpy)Ru(dtdeg)PtCl]Cl2 (4): [Cl(bpy)Ru(dtdeg)]Cl (22 mg, 0.025 mmol) and 
[Pt(cod)Cl2] (11 mg, 0.030 mmol) were refluxed for 6 hours in 18 mL of MeOH. The reaction 
mixture was cooled to RT and filtered. The filtrate was slowly precipitated with diethyl ether. 
Yield: 16 mg (55 %). Elemental analysis (%) calculated for C44H36Cl4N8O3RuPt·3H2O: 
C 43.43, N 9.21, H 3.48. Found: C 42.90, N 9.22, H 3.21. 1H NMR (300 MHz, DMSO, 
298 K): δ = 8.70 (d, 2H; I33”), 7.92 (t, 2H; I44”), 7.30 (t, 2H; I55”), 7.55 (d, 2H; I66”), 8.59 
(s, 2H; I3’5’), 4.68 (t, 2H; 1), 4.07 (t, 2H; 2), 8.70 (d, 2H; I’33”), 8.46 (t, 2H; I’44”), 7.91 (t, 
2H I’55”), 8.89 (d, 2H; I’66”), 8.43 (s, 2H; I’3’5’), 4.63 (t, 2H; 1’), 4.06 (t, 2H; 2’), 8.87 (d, 
1H; II3), 8.30 (t, 1H; II4), 8.01 (t, 1H; II5), 10,06 (d, 1H; II6), 8.60 (d, 1H; II3’), 7.74 (t, 1H; 
II4’), 7.07 (t, 1H; II5’), 7,40 (d, 1H; II6’). 195Pt NMR (300 MHz, MeOH, 298 K): δ = –2702 
ppm. 
[(tpy)Ru(dtdeg)PtCl]Cl3 (5): [(tpy)Ru(dtdeg)]Cl2 (100 mg; 0.10 mmol) and [Pt(cod)Cl2] 
(50 mg; 0.15 mmol) were refluxed in 20 mL of MeOH for 6 hours. The reaction mixture was 
cooled to RT and filtered. Red plate-shaped crystals were obtained by slow precipitation of 
the filtrate with diethyl ether. Yield: 107 mg (88 %). Elemental analysis (%) calculated for 
C49H39Cl4N9O3PtRu·7H2O (A different batch then the obtained crystals was used. The 
presence of predominantly methanol molecules in the solvent region of the crystal structure of 
5, has clearly been indicated by the electron density of first models of the crystal structure. 
Importantly, the solvent region might – instead – also contain some water molecules but due 
to disorder the refinement of the solvent molecules has not been succeeded. Because the 
solvent region in the packing of the crystal structure of 5 is rather large and disordered, it is 
reasonable that in a different batch of crystals a different arrangement of solvent molecules is 
present in the solvent region. Water, which is present in methanol, was used instead of 
methanol to fit the elemental analysis as the C/N ratio of the analysis corresponds to the 
structural formula of the complex. The water molecules might also have been taken from the 
air after drying of the product in vacuo on P2O5, which has been done before elemental 
analysis.): C 43.09, N 9.23, H 3.91. Found: C 43.26, N 9.42, H 3.90. ESI-MS: m/z: 378 [M3+]. 
1H NMR (600 MHz, DMSO, 298 K): δ = 8.95 (d, 2H; I33”), 7.99 (t, 2H; I44”), 7.22 (t, 2H; 
I55”), 7.36 (d, 2H; I66”), 8.89 (s, 2H; I3’5’), 4.77 (t, 2H; 1), 4.14 (t, 2H; 2), 8.83 (d, 2H; 
I’33”), 8.46 (t, 2H; I’44”), 7.93 (t, 2H I’55”), 8.92 (d, 2H; I’66”), 8.55 (s, 2H; I’3’5’), 4.72 (t, 
2H; 1’), 4.11 (t, 2H; 2’), 8.84 (d, 2H; II33”), 8.01 (t, 2H; II44”), 7.28 (t, 2H; II55”), 7,52 (d, 
2H; II66”), 9.09 (d, 2H; II3’5’), 8.49 ppm (t, 1H; II4’). 195Pt NMR (300 MHz, MeOH, 298 K): 
δ = –2701 ppm. 
Crystal structure data for 5·8CH3OH: C57H63Cl4N9O11PtRu, Mr = 1496.20, red plate-shaped 
crystal (0.03 x 0.13 x 0.30 mm), triclinic, space group P 1   with a = 8.8396(12) Å, b = 
15.961(2) Å, c = 23.548(4) Å, α = 75.031(13)º, β = 88.528(13)º, γ = 78.975(17)º, V = 
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3149.4(8) Å3, Z = 2, Dx = 1.578 g cm-3, µ(Mo Kα) = 2.804 mm-1. A total of 53838 reflections 
were measured (11287 independent, Rint = 0.1061, θmax = 25.35º, T = 150 K, Mo Kα 
radiation, graphite monochromator, λ = 0.71073) on a Nonius Kappa CCD diffractometer on 
a rotating anode; data were corrected for absorption using PLATON/MULABS, T-range 
0.741-0.929. The structure was solved by automated direct methods (SHELXS86). Full-
matrix least-squares refinement of 577 parameters on F2 (SHELXL-97) resulted in a final R1 
value of 0.0470, wR2 = 0.0927, S = 0.898. H-atoms were introduced on calculated positions. 
A volume of 1257 Å3 per unit cell is filled with disordered methanol solvent molecules in 
which the chloride counter ions are positioned as well. Disorder models of solvent and 
counter ions suggest the presence of three chloride ions per ruthenium-platinum complex, one 
of which is disordered over two positions. However, these models proved to be unstable upon 
refinement. Using the PLATON/SQUEEZE method, a total of 379 e- was found in the 
disordered region which corresponds to circa 8 methanol molecules per ruthenium-platinum 
complex. CCDC-230794 contains the supplementary crystallographic data for this paper. 
These data can be obtained online free of charge (or from the Cambridge Crystallographic 
Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or 
deposit@ccdc.cam.ac.uk). 
[(tpy)Ru(dtdeg)Pt(9egua)](PF6)4 (6): 5 (55 mg; 0.044 mmol) and 9egua (12 mg; 0.066 
mmol) were stirred in 20 mL of H2O for 2 days at 310 K. An excess of an aqueous solution of 
NH4PF6 was added and the resulting precipitate was filtered off. The residue was 
recrystallized from acetone and diethyl ether. Yield: 37 mg (45 %). ESI-MS: m/z: 319 [M4+]. 
1H NMR (600 MHz, acetone, 293 K): δ = 8.81 (d, 2H; I33”), 8.04 (t, 2H; I44”), 7.28 (t, 2H; 
I55”), 7.65 (d, 2H; I66”), 8.71 (s, 2H; I3’5’), 4.84 (t, 2H; 1), 4.24 (t, 2H; 2), 8.72 (d, 2H; 
I’33”), 8.51 (t, 2H; I’44”), 7.83 (t, 2H I’55”), 8.37 (d, 2H; I’66”), 8.40 (s, 2H; I’3’5’), 4.84 (t, 
2H; 1’), 4.24 (t, 2H; 2’), 8.80 (d, 2H; II33”), 8.07 (t, 2H; II44”), 7.35 (t, 2H; II55”), 7,80 (d, 
2H; II66”), 9.05 (d, 2H; II3’5’), 8.54 ppm (t, 1H; II4’). 195Pt NMR (300 MHz, acetone, 298 
K): δ = –2690 ppm. 
 
4.2.4 Cytotoxicity tests 
 
Cell cultures: A2780cis and A2780R cells (cisplatin sensitive and resistant human ovarian 
carcinoma, respectively) were maintained in Dulbecco’s modified Eagle’s Medium (DMEM: 
Gibco BRLTM, Invitrogen Corporation, The Netherlands) supplemented with 10 % fetal calf 
serum (Perbio Science, Belgium), penicillin (100 units/mL: Duchefa Biochemie BV, The 
Netherlands) and streptomycin (100 µg/mL: Duchefa Biochemie BV, The Netherlands) in a 
humidified 6 % CO2, 94 % air atmosphere at 310 K. Cisplatin sensitive and resistant mouse 
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leukemia L1210/0 and L1210/2 cells were grown (partly in suspension and partly adherent to 
the flasks) under the above mentioned conditions. 
Cells were removed from the flasks by a 0.05 % trypsin solution. Cell viability was 
determined by the trypan blue exclusion test. 
In vitro cytotoxicity evaluation: Between 1000 and 5000 cells were seeded per well 
(depending on the cell type) onto 96-well plates (Corning Costar®) in 100 µL of complete 
medium with 5 to 10 % of FCS. Cells were treated 24 hours after sowing by addition of 100 
µL of the complex in complete medium at the appropriate concentration. Cell growth was 
determined after 72 hours of incubation by the MTT assay, a colorimetric assay based on the 
ability of viable cells to reduce the soluble yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide to blue formazan crystals by the mitochondria.[19] 
Final tested concentrations ranged between 4 µM and 100 µM and have been obtained by 
several dilutions with complete medium from stock solutions (2 mM) in sterile water. Stock 
solutions of complexes 3 and [Ru(tpy)Cl3] were prepared in DMSO due to poor water 
solubility. The highest tested concentration of 3 was only 10 µM, which contained 3.3 % of 
DMSO. [Ru(tpy)Cl3] was tested with 4 % of DMSO in the highest concentration (100 µM). 
Control experiments with DMSO have been carried out and will be considered while 
discussing the cytotoxic activity of these complexes. After 72 hours of incubation at 310 K, 
cells were incubated with 1 mg/mL MTT solution for 2 to 4 hours at 310 K. Subsequently, the 
medium was discarded and the formed crystals were dissolved in 100 µL DMSO per well. 
Optical density (OD) was measured at 590 nm with a Biorad 550 microplate reader. The OD 
is directly proportional to the number of living cells, which are compared to the control 
(untreated cells). 
 
4.3 Results and discussion 
 
4.3.1 Characterization of the paramagnetic complexes 1 and 3 by 1H NMR 
spectroscopy 
 
The paramagnetic complex [Cl3Ru(dtdeg)] (1) contains both a paramagnetic ruthenium(III)-
terpyridyl unit and a metal-free terpyridyl moiety. The resonances of the former are 
significantly broadened and shifted, due to the presence of the unpaired electron in the t2g 
orbital of the ruthenium(III) ion (Figure 4.2). The signals of the latter are observed within the 
normal diamagnetic envelope, but are somewhat broadened. In Chapter 2 of this thesis, a 
strategy for the characterization of paramagnetic trichlororuthenium(III)-terpyridine 


























[(tpy)Ru(dtdeg)RuCl3]2+ as a model compound. A similar strategy will be used for the 
characterization of 1 (and 3). 
The 1H NMR spectrum of 1 has been acquired at 340 K. At this temperature the 
“paramagnetic” signals, i.e. the resonances of the paramagnetic ruthenium(III) moiety, do not 
overlap. The signal at 5.07 ppm has also been established as a “paramagnetic” signal, since it 
exhibits short longitudinal (T1) and transverse (T2) relaxation times. Five resonances of 
similar intensity are observed in the aromatic region of the 1H NMR spectrum for the 
terpyridine I’ signals of the diamagnetic ruthenium(II) unit of 1, which indicates the presence 
of a C2 symmetry axis within the molecule. The resonances have been assigned by 2D COSY 
1H NMR experiments at 340 K using a mixing time of 20 ms (Figure 4.3). The signal at 8.91 
ppm has been assigned to the I’66’ protons, since it is observed as a doublet. The resonance 
displays a J value (~ 7 Hz), which is too small for that of 33” pyridyl protons. For the latter, a 
J value of ~ 9 Hz is usually observed in diamagnetic species. The signal at 8.18 ppm does not 
show a crosspeak in the COSY spectrum. Therefore, it has been assigned to the I’3’5’ 
protons. 
 
Figure 4.2 Schematic representation of the structure of 1, and its 1D 1H NMR spectrum at 
340 K in DMSO-d6 with the paramagnetic signals indicated. The numbering scheme given for 
the terpyridine protons I, can also be applied to the I’ protons. 
 
In agreement with the double C2 symmetry of the complex, five resonances have also been 
found for the I protons of the paramagnetic ruthenium(III) unit. They have partly been 
assigned by 2D COSY 1H NMR (Figure 4.3). The signal at –27.24 ppm appears to be too 
broad to show crosspeaks. In analogy with the complexes [(tpy)Ru(dtdeg)RuCl3]2+ (Chapter 






closest to the paramagnetic ruthenium(III) center, and can therefore be expected to shift the 
most. The paramagnetic resonance at 1.35 ppm displays crosspeaks to the signals at –7.38 and 
–8.28 ppm. Hence, it has been attributed to the I44” protons. The I33” and I55” protons can 
not be assigned, yet. A two-spins system is shown by the resonances at 14.28 and 3.74 ppm, 
which assigns these signals to the diethylene protons 1 and 2. The resonance at 14.28 ppm has 
been ascribed to the linker protons 1, since they are closest to the paramagnetic center. 
 
Figure 4.3 2D 1H COSY NMR spectrum of 1 in DMSO-d6 at 340 K with some crosspeaks 
indicated, and assignments given. 
 
1D NOE difference experiments (Figure 4.4) complete the assignment of 1. Upon irradiation 
of the paramagnetic signal at 5.07 ppm, signal enhancements are displayed by the diethylene 
protons 1 at 14.28 ppm, and by the resonance at –7.38 ppm. As a result, the signal at 5.07 
ppm has been assigned to the I3’5’ protons. Thereby, the signal at –7.38 ppm can be ascribed 
to the I33” protons. Irradiation of the largely shifted and broadened I66” resonance at –27.24 







I66” I55” I33” 
assignment of the I66” and I55” protons. The 1’ and 2’ resonances have been assigned by a 
I’3’5’-1’ crosspeak (data not shown). 
 
Figure 4.4 1D 1H NOE difference NMR spectra (top and middle) and 1D 1H NMR 
spectrum (bottom) of 1 in DMSO-d6 at 340 K. Irradiated signals are indicated with an arrow. 
NOEs are indicated by an asterisk. 
 
The 1D 1H NMR spectrum of the paramagnetic complex [Cl3Ru(dtdeg)PtCl]Cl (3) in 
DMSO-d6 is depicted in Figure 4.5. The complex displays a similar spectrum to that of its 
precursor 1. The paramagnetic signals of the ruthenium(III) moiety are observed outside the 
diamagnetic region, whereas the signals of the diamagnetic platinum(II) moiety are found 
within this region. For both metal moieties five signals are observed for the aromatic protons, 
which indicates that C2 symmetry is displayed within each unit. The chemical shifts of the 
platinum-terpyridine protons have shifted in comparison to the corresponding signals of 1 
(δ = 8.83, 8.19, 8.91, 9.08, and 8.91 versus 8.89, 7.70, 8.25, 8.89, and 8.25 for the I’33”, 
I’44”, I’55”, I’66”, and I’3’5’ protons of 3 and 1, respectively. The differences in shifts 
indicate coordination of platinum to the free terpyridyl unit of 1. The 195Pt NMR shift of 3 































Figure 4.5 1D 1H NMR spectrum of 3 at 310 K in DMSO-d6 with the paramagnetic 
signals indicated, and schematic representation of the structure of the cation of 3. The 
numbering scheme given for the terpyridine protons I, can also be applied to the I’ protons. 
 
The 1H NMR spectrum of 3 has been acquired at 310 K. At this temperature the 
“paramagnetic” signals, i.e. the resonances of the paramagnetic ruthenium(III) moiety, do not 
overlap. The paramagnetic signals of 3 show crosspeaks comparable to those of 1 in the 2D 
COSY NMR spectrum. Therefore, these data are not shown. 1D NOE difference experiments 
are depicted in Figure 4.6. Similar to 1, signal enhancements of the diethylene protons 1 and 
I33” are seen upon irradiation of the paramagnetic signal at 4.63 ppm. Thereby, the latter can 
be attributed to the I3’5’ protons. A NOE of the I55” signal upon saturation of the I66” signal 
has not been observed. In contrast to 1, the I3’5’-1 and I3’5’-I33” NOEs are identical in sign 
as the saturated signal. This difference shows that the NOE values are a function of the 
rotational correlation time. The latter is dependent on the molecular size of the species. The 
observed NOEs are rather small in comparison to those observed for 1, which may be caused 
by concentration differences of the samples. However, the values of  the NOEs may be close 
to zero, because the function of the NOE value first decreases to zero upon decreasing 
rotational correlation times (which decreases upon an increase of molecular weight), and 
subsequently becomes negative. The sign of the NOEs for 3 is similar to that observed for the 













Figure 4.6 1D NOE difference 1H NMR spectrum (top) and 1D 1H NMR spectrum 
(bottom) of 3 in DMSO-d6 at 310 K. Irradiated signals are indicated with an arrow. NOEs are 
indicated by an asterisk. 
 
 
4.3.2 Characterization of the diamagnetic complexes 2, 4, and 5 by 1H NMR 
spectroscopy 
 
The 1D 1H NMR spectra of [Cl(bpy)Ru(dtdeg)]Cl (2) and [Cl(bpy)Ru(dtdeg)PtCl]Cl2 (4) in 
DMSO-d6 are shown in Figure 4.7. The assignment of the 1H NMR data has been performed 
by 2D COSY and NOESY 1H NMR experiments (see experimental section). The appearance 
of four individual resonances in the region between 4 and 5 ppm for the linker protons of 2 
and 4, indicates the presence of two different moieties for both complexes. This is confirmed 
by the fact that three sets of signals are identified in the aromatic region for the three 
nonequivalent polypyridine ligands of both 2 and 4. Symmetry is displayed within each unit, 
due to the occurrence of a C2 symmetry axis. The bipyridine ligand is located in the plane of 
symmetry, and therefore individual resonances of intensity 1 are observed for all its protons. 
The terpyridine signals have a relative intensity of 2. The II6 bipyridine signal has been 
recognized by its significant downfield shift, due to the deshielding effect of the nearby 
chloride ligand. The signals for the pyridine 6 protons and pyridine 3 protons have been 
identified by their J values  of ~ 5 Hz and ~ 9 Hz, respectively. The two terpyridine ligands I 














































Figure 4.7 1D 1H NMR spectra of 2 (top) and 4 (bottom) at 298 K in DMSO-d6 with some 
assignments, and schematic representations of the cations of 2 and 4. The numbering scheme 
given for the terpyridine protons I, can also be applied to the I’ protons, and to those of 4. 
 
The downfield shift of the I’66” signal of 4 in comparison to the analogues signal of 2, 
indicates coordination of platinum to the free terpyridyl moiety. Coordination of platinum has 
been confirmed by the signal at -2700 in 195Pt NMR. 
The characterization of [(tpy)Ru(dtdeg)PtCl]Cl3 (5) is very similar to that of complexes 2 and 
4. The 1H NMR spectrum of 5, measured at 600 MHz, is shown in Figure 4.8. The appearance 
of four distinct signals between 4 and 5 ppm for the linker protons indicates the presence of 
two different metal moieties. In the aromatic region, three sets of signals are observed for the 
three inequivalent terpyridine ligands I, I’ and II. C2 symmetry is displayed within each unit. 
All signals exhibit an intensity of two except for the triplet appearing at 8.49 ppm. This signal 



























Figure 4.8 1D 1H NMR spectrum of 5 at 298 K in DMSO-d6 (600 MHz) with some 
assignments, and schematic representation of the cation of 5. The numbering scheme given 
for the terpyridine protons I, can also be applied to the I’ and II protons. 
 
With the identification of the II4’ signal, the signals of the terpyridyl ligand II have been 
assigned next by 2D 1H COSY and NOESY NMR. A characteristic downfield shift of the 
I’66” signal is seen, because of coordination of platinum to terpyridine ligand I. The 
recognition of the I’66” signal has been used to assign the two remaining sets of signals for 
the protons of terpyridyl ligands I and I’ taking into account the specific J values of the 33” 
and 66” pyridine protons as well. A typical shift of approximately -2700 ppm in 195Pt NMR 
has also been observed. 
 
4.3.3 Crystal structure of 5 
 
Red plated-shaped crystals of 5 have been obtained by slow precipitation from the reaction 
mixture with diethyl ether. The crystal structure has been elucidated (Figure 4.9) confirming 
unambiguously the molecular structure of the cation of 5. Due to disorder, the coordinates of 
the chloride counter ions could not be refined (see experimental section). No crystal structures 
of heterodinuclear ruthenium-platinum complexes, in which the two metal moieties are linked 
through a long and flexible linker, have been reported to date. Bond lengths and angles are in 
agreement with literature data for parental cationic mononuclear complexes.[20, 21] The 
intramolecular Ru····Pt distance is 14.547(3) Å. For comparison, the intramolecular Ru····Pt 
distance in the crystal structure of [Ru(bpy)2(µ-2,3-dpp)PtCl2](PF6)2, in which dpp is the short 
and rigid bridging ligand 2,3-bis(2-pyridyl)pyrazine, is 6.7 Å.[22] Given that the 
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diethyleneglycolether linker of 5 is somewhat folded in the crystal structure, the length over 
which both metal moieties can interact with DNA might even be larger. Long-range binding 
from the minor to the major groove of the DNA has been shown[23] for the trinuclear platinum 
compound [{trans-PtCl(NH3)2}2µ-{H2N(CH2)6NH2}2Pt(NH3)2](NO3)4, BBR3464, bound to a 
self-complementary DNA octamer 5’-d(ATG*TACAT)2-3’. The two trans-PtCl(NH3)2 units 
coordinate in the major groove at the N7 positions of guanines on opposite DNA strands, 
whereas the central tetraamine linker is located in, or close to, the minor groove. Considering 
the length of the linker of 5, either intercalative binding or coordination of the platinum 
moiety of 5 might occur in the major groove of the DNA after pre-association, which is 




Figure 4.9 Displacement ellipsoid (50 % probability) plot of the structure of the cation of 
5. Counter ions and solvent molecules are not shown. Hydrogen atoms are omitted for clarity. 
 
The crystal structure of 5 shows intermolecular stackings between the platinum moieties 
despite the linked, rather bulky ruthenium units (Figure 4.10). The platinum units stack in a 
head-to-tail fashion (Figure 4.11) with alternating short and long Pt····Pt distances of 
3.4935(7) and 6.7337(12) Å, respectively. The short Pt····Pt distances are indicated with 
dashed lines in Figure 4.10. The packing of the crystal structure of 5 is such that chains of 
alternating platinum units related by inversion symmetry are situated in between the 
ruthenium units. Along the platinum-terpyridine chain, a continuous π–π stacking is 
displayed. The perpendicular distances of the center of geometry of one ring to the least-
squares plane of the other ring are approximately 3.38 and 3.45 Å for the short and long pair, 
respectively. The short Pt····Pt distance of 3.49 Å might even allow d 2z – d 2z  interactions.[24] 
Aggregation via weak bonding interactions into metal-bound d8–d8 pairs in an infinite π–π 
 103
stack has indeed been reported for the perchlorate salt of the parental mononuclear 
[Pt(tpy)Cl]+ cation.[21] Studies to examine the Pt-Pt interactions of 5 have not been 
undertaken. 
The self-stacking interactions suggest that the platinum unit of 5 is able to intercalate in the 
DNA, like its mononuclear counterpart. Intercalation into DNA has been shown to occur for 
substitution-inert platinum(II) terpyridine analogues of the parental mononuclear complex 
[Pt(tpy)Cl]+, such as 2-hydroxyethanethiolate and 4-picoline terpyridine-platinum 
complexes.[10, 25] A crystal structure[26] of a double helical fragment with the 2-
hydroxyethanethiolate derivative, has revealed stacking of the metallo-intercalator between 
two Watson-Crick GC base pairs with the DNA unwinding angle being 23°. 
Chloroterpyridineplatinum(II) has been illustrated to have two adenosine-5’-monophosphate 
molecules, which base pair in a rarely observed hybrid Watson-Crick-Hoogsteen variety, 
intercalated between two platinum complexes.[27] Intercalation may subsequently result in 
coordination to DNA, since DNA coordination has been reported to be the thermodynamically 
more favorable mode of binding for mononuclear platinum terpyridine complexes containing 
a fourth relatively labile ligand like chloride or hydroxide.[11, 28] 
 
 
Figure 4.10 View of the packing of the crystal structure of the cation of 5 in which 
alternating short and long Pt····Pt distances are displayed by the platinum units. A short 
intermolecular Pt·····Pt [2-x,-y,-z] distance (dashed lines) of 3.4935(7) Å is observed between 
two platinum terpyridine units that are exactly orientated in a head-to-tail fashion. The long 
intermolecular Pt·····Pt [1-x,-y,-z] distance is caused by a lateral shift of one Pt-tpy unit with 




Figure 4.11 View in the direction of the short Pt·····Pt [2-x,-y,-z] vector showing the π-π 
stacking interactions along the Pt-tpy chain: A, Pt·····Pt = 3.4935(7) Å; B, Pt·····Pt = 
6.7337(12) Å. The planes through the rings are nearly parallel for both dimers, the dihedral 
angle between the planes being 1.1º and 2.4º for A and B, respectively. The perpendicular 
distances of the geometrical center of one ring to the least-squares plane through the other 
ring system are nearly identical for interaction A (approximately 3.38 Å) and interaction B 
(approximately 3.45 Å). 
 
 
4.3.4 Binding of 5 to the DNA-model base 9-ethylguanine 
 
Mononuclear platinum terpyridine complexes are known to bind preferentially to the DNA 
base guanine.[29] To study whether the platinum unit of 5 is capable of coordination to DNA, 
the reaction with the DNA-model base 9-ethylguanine has been performed in water at 310 K 
for 2 days. 
The monoadduct [(tpy)Ru(dtdeg)Pt(9egua)](PF6)4 (6) has been isolated as the 
hexafluorophosphate salt. The hexafluorophosphate salt of the adduct is not soluble in water. 
Therefore, the 1D 1H NMR spectrum of 6 has been acquired in acetone-d6, and is shown in 
Figure 4.12. Assignments of the terpyridyl signals have been done in analogy to those of 5. 







































DNA-model base (δ = 1.61, 4.36, 6.68 and 8.90 versus 1.40, 4.06, 5.98 and 7.60 ppm for CH2, 
CH3, NH2 and H8, respectively) indicate binding of 9egua to the complex. Binding of 9egua 
is in agreement with the large upfield shift of the platinum terpyridine I’66” protons of 6 
compared to that of the chloride complex 5 (δ = 8.37 versus 8.92 ppm), which is due to 
substitution of the relatively labile, deshielding chloride ligand. The relative intensity of 1 for 
the H8 signal demonstrates binding occurs in a ratio of 1:1 of 9egua to 5. N7 coordination is 
proven by the large shift of the H8 signal in particular, and the observed I66”-H8 NOE 
crosspeak in 2D 1H NOESY experiments (Figure 4.13). No significant shift of 6 compared to 
5 is displayed in 195Pt NMR. 
The resonance of the H8 proton and its NOE to the I’66” signal are in agreement with data 
reported for the N7 coordinated guanosine adduct of [Pt(tpy)(4-picoline)]2+, in which the 
picoline ligand has been substituted by the DNA base.[29, 30] Recently, a crystal structure of the 
guanosine-5’-monophosphate platinum terpyridine adduct has proven N7 coordination of the 




Figure 4.12 1D 1H NMR spectrum of the adduct 6 in acetone-d6 at 293 K (600 MHz) with 





























Figure 4.13 Part of the 2D 1H NOESY NMR spectrum of 6 (600 MHz) in acetone-d6 at 
293 K with some assignments. 
 
 
4.3.5 Biological activity 
 
The complexes 3, 4 and 5 do not display significant cytotoxicity against the cisplatin-sensitive 
and cisplatin-resistant human ovarian carcinoma cells A2780cis and A2780R, and the mouse 
leukemia cells L1210/0 and L1210/2. In terms of cell growth inhibition, only 
[Cl(bpy)Ru(dtdeg)PtCl]Cl2 (4) shows moderate reduction of A2780R cell growth (55 %), but 
at a relatively high concentration of 100 µM. The complex [Cl3Ru(dtdeg)PtCl]Cl (3) shows 
no inhibition of cell growth at concentrations (3 µM) at which the DMSO (necessary to 
dissolve 3) percentage is negligible (1.5 %). Thus, whereas the mononuclear complex 
[Pt(tpy)Cl]Cl has IC50 values of approximately 1 µM, complexes 3, 4 and 5 can be regarded 
as noncytotoxic. The inactivity of 3 is particularly surprising, since both its metal moieties are 
derived from promising anticancer agents. 
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It has been reported that dinuclear platinum terpyridine complexes, in which a long and 
flexible linker is attached to either the 4’ position of the terpyridine ligand or to the 4’ site of a 
coordinating fourth pyridine ligand, are not cytotoxic either.[32, 33] In contrast, cytotoxicity is 
displayed by platinum-terpyridine complexes, which are linked through more short and rigid 
dipyridyl linkers. An exception is a trinuclear compound in which two platinum-terpyridine 
moieties are linked through a trans-diammine bis(4,4’-dipyridyl)platinum(II) unit by 
coordination to the dipyridyl ligands. The charge of this linker has been suggested to be of 
importance for the activity of the complex.[33] 
 
4.4 Concluding remarks 
 
The synthesis and characterization of the heterodinuclear ruthenium-platinum complexes 
[Cl3Ru(dtdeg)PtCl]Cl (3), [Cl(bpy)Ru(dtdeg)PtCl]Cl2 (4), and [(tpy)Ru(dtdeg)PtCl]Cl3 (5) is 
presented. The paramagnetic dinuclear ruthenium(III)-platinum(II) complex 3 represents the 
first heterodinuclear ruthenium-platinum complex, which has been characterized by 1D NOE 
difference experiments. The crystal structure of the cation of 5 has been elucidated, and shows 
self-stacking interactions of the platinum moieties. The length of the linker is 14.5 Å, which 
may allow the formation of long-range DNA adducts. The adduct of 5 with the DNA-model 
base 9-ethylguanine has been isolated and characterized by 1H NMR. The results suggest that 
the platinum moiety of the complexes is able to both intercalate and coordinate to the DNA, 
without being hindered by the dangling ruthenium unit. However, none of the complexes 
shows significant activity against A2780 and L1210 cisplatin sensitive and resistant cells. The 
lack of anticancer activity may have its origin in the nature and length of the linker. In 
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Trinuclear and tetranuclear ruthenium and platinum 
complexes with long and flexible linkers: syntheses, 
characterization and biological properties  
 
 
Abstract – The complexes [(dtdeg)Ru(dtdeg)]Cl2 (1) and [(dtdeg)Ru(dtdeg)Ru(dtdeg)]Cl4 (2) 
(dtdeg = bis[4’-(2,2’:6’,2”-terpyridyl)]-diethyleneglycolether) have been used for the 
synthesis of the trinuclear and tetranuclear ruthenium(II)-ruthenium(III) complexes 
[Cl3Ru(dtdeg)Ru(dtdeg)RuCl3]Cl2 (3) and [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4 (4), 
and the ruthenium(II)-platinum(II) mixed-metal compounds [ClPt(dtdeg)Ru(dtdeg)PtCl]Cl4 
(5) and [ClPt(dtdeg)Ru(dtdeg)Ru(dtdeg)PtCl]Cl6 (6). The paramagnetic complexes 3 and 4 
have been characterized by 1H NMR spectroscopy, including 1D 1H NOE difference 
experiments. The hyperfine shifts of the paramagnetic signals of 3 and 4 display Curie 
behavior, and are suggested to be mainly dipolar of origin. The characterization of complexes 
5 and 6 is also presented. 
In general, the complexes do not show significant cytotoxicity against different cancer cell 
lines. However, inhibition of cell growth is observed, and is highest for the tetranuclear 
complexes. Complex 4 exhibits an IC50 value of 8 µM against A2780cis cells, and displays 
moderate activity against the A2780R cell line. Complex 6 displays moderate activity against 
A2780 and L1210 cells. Interestingly, A2780cis cells adhere together and form clots upon 
incubation with 4. This effect appears to be characteristic for the molecular structure of 4 and 










The development of polynuclear platinum complexes as anticancer agents is a productive 
field of research.[1] The α,ω-diaminoalkane-linked polynuclear platinum complexes 
developed by Farrell et al. have extensively been examined.[2] It appears that chain length and 
flexibility, and charge and hydrogen-bonding capabilities are of importance for their activity. 
The long and flexible linker has been found to allow the formation of long-range adducts on 
DNA,[2] which is the target of platinum anticancer complexes.[3] The positive charge of these 
promising class of polynuclear complexes has been shown to assist in DNA binding by 
preassociation to the duplex through electrostatic interactions.[4] The trinuclear complex 
BBR3464, [{trans-PtCl(NH3)2}2{µ-trans-Pt(NH3)2(H2N(CH2)6NH2)2}]4+ (1,0,1/t,t,t), is the 
most active complex within the series, and has entered clinical trials.[5] Compared to the 
dinuclear derivatives, BBR3464 contains a positively charged tetraamine-platinum linker. 
This linker supports an extraordinary way of DNA binding, i.e. it preassociates in the minor 
groove, whereas the outer platinum units of the trinuclear complex subsequently coordinate in 
the major groove.[6] 
Results from studies with polynuclear terpyridine platinum complexes have also indicated the 
importance of a charged linker.[7] These dinuclear complexes display less activity against 
different cell lines upon increasing the length of their dipyridyl linker, which has ethynyl 
bonds of variable lengths, with or without phenyl groups in between. However, a trinuclear 
complex, in which a positively charged diaminedi(4,4’-bipyridine)platinum unit links the two 
platinum terpyridine units, does show high activity. 
A small variety of polynuclear ruthenium[8, 9] and heteropolynuclear ruthenium-platinum 
complexes have also been designed and studied as anticancer agents.[10, 11] The relatively long 
and flexible linker dtdeg (dtdeg = bis[4’-(2,2’:6’,2”-terpyridyl)]-diethyleneglycolether) has 
been used for the syntheses of dinuclear polypyridyl ruthenium complexes, as presented in 
Chapters 2 and 3. The complexes consist of at least one substitution-inert ruthenium moiety, 
or of two units which are capable of monofunctional coordination after dissociation of the 
labile chloride ligand. It has been demonstrated that the complexes do not display significant 
cytotoxicity against different cell lines. In Chapter 4, heterodinuclear ruthenium-platinum 
derivatives have been described, which were developed based upon the cytotoxic[7] complex 
[Pt(tpy)Cl]Cl (tpy = 2,2’:6’,2”-terpyridine). These complexes do not show activity either. The 
data presented suggest that the platinum moiety is capable of both intercalation and 
coordination to the DNA.[11] However, even when the platinum moiety is linked to the 
trichlororuthenium moiety, which is derived from the antitumor active[12] complex 





















































































In this Chapter, the complexes [(dtdeg)Ru(dtdeg)]Cl2 (1) and [(dtdeg)Ru(dtdeg)Ru(dtdeg)]Cl4 
(2) are presented. They have been produced for the assembly of flexible and particularly long 
polynuclear ruthenium and platinum terpyridine complexes. The linker-complexes 1 and 2 
contain one or two positively charged bis(terpyridyl)-ruthenium(II) moieties, respectively, to 
enhance water solubility and DNA affinity by electrostatic interactions. They have been used 
to join two ruthenium(III) or two platinum(II) units, which resemble the mononuclear 
complexes [Ru(tpy)Cl3] and [Pt(tpy)Cl]Cl, respectively. The antitumor activity of 
[Ru(tpy)Cl3] has been suggested to be due to DNA coordination by interstrand binding to two 
guanines.[12, 13] DNA intercalation and coordination have been reported[7, 14] to account for the 
cytotoxicity of [Pt(tpy)Cl]Cl. The synthesis and characterization of the trinuclear and 
tetranuclear ruthenium(II)-ruthenium(III) complexes [Cl3Ru(dtdeg)Ru(dtdeg)RuCl3]Cl2 (3) 
and [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4 (4) (Figure 5.1), and of the 
ruthenium(II)-platinum(II) mixed-metal compounds [ClPt(dtdeg)Ru(dtdeg)PtCl]Cl4 (5) and 
[ClPt(dtdeg)Ru(dtdeg)Ru(dtdeg)PtCl]Cl6 (6) (Figure 5.1), are presented in this Chapter. The 



















Figure 5.1 The polynuclear cationic ruthenium(II)-ruthenium(III) complexes 3 and 4, and  
the polynuclear cationic ruthenium(II)-platinum(II) complexes 5 and 6. 
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 5.2 Experimental section 
 
5.2.1 General methods and starting materials 
 
Elemental analyses on C, H and N were performed on a Perkin Elmer series II CHNS/O 
Analyzer 2400. Electrospray mass spectra were recorded on a Finnigan TSQ-quantum 
instrument with an electrospray interface (ESI). Hydrated RuCl3·xH2O (x ~ 3) and K2PtCl4 
were used as received from Johnson & Matthey. The ligand dtdeg, the complex 
[Cl3Ru(dtdeg)RuCl3], and the 0.1 M ruthenium(III) solution have previously been 
synthesized,[15] their synthesis is described in Chapter 2 for convenience. 
 
5.2.2 1H NMR measurements 
 
1H NMR and 195Pt NMR spectra were acquired on a Bruker DPX 300 and DMX 600 
spectrometer. 1H NOE difference spectra were measured on a Bruker DMX 600 spectrometer. 
Spectra were recorded in deuterated DMSO, and calibrated on residual solvent peak at δ 2.49 
ppm. 1D 1H spectra of the paramagnetic complexes were obtained using a 100 ppm spectral 
width. Longitudinal relaxation times were measured by the standard inversion-recovery 
method, with 7 s relaxation delay and a spectral width of 100 ppm. Variable delays ranged 
from 50 µs to 500 ms to define the T1 values for the proton signals of the paramagnetic 
ruthenium(III) moiety, and from 100 ms to 5000 ms to define the T1 values for the proton 
signals of the diamagnetic ruthenium(II) moiety. Magnetization recovery was exponential 
within experimental error. T2 values were estimated from the peak half-widths. The COSY 
spectra were obtained by collecting 1024 F2 x 1024 F1 data points with a relaxation delay of 
20 ms. 1D NOE experiments were carried out according to published procedures.[16] These 
procedures include a WEFT pulse sequence, which was not applied here. The irradiation time 




[(dtdeg)Ru(dtdeg)]Cl2, (1): The ligand dtdeg (600 mg; 1.06 mmol), triethylamine (0.15 mL; 
1.16 mmol), and 3 mL of the 0.1 M ruthenium(III) solution (0.30 mmol) were stirred under 
nitrogen for 20 minutes in 100 mL of a EtOH/H2O mixture (v:v = 3:1). Subsequently, the 
mixture was refluxed for 18 hours under nitrogen. The mixture was evaporated in vacuo with 
EtOH for three times. The resulting precipitate (mainly unreacted dtdeg) was filtered off, and 
the filtrate was concentrated in vacuo. The product was purified by column chromatography 
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on neutral alumina with EtOH/CH3CN (v:v = 1:1) as the eluens. From the first part of the red 
band, pure product was isolated by precipitation of the particular fraction with diethyl ether. 
Yield: 89 mg (23 %). Elemental analysis (%) calculated for C68H56Cl2N12O6Ru·5H2O (water, 
originating from the used solvents, was used to fit the elemental analysis as the C/N ratio of 
the analysis corresponds to the structural formula of the complex): C 58.37, N 12.01, H 4.75. 
Found: C 58.05, N 12.03, H 5.09. ESI-MS: m/z: 619 [M2+], 413 [M2++H+]. 1H NMR (600 
MHz, DMSO, 310 K): δ = 8.60 (d, 4H; I33”), 7.97 (t, 4H; I44”), 7.47 (t, 4H; I55”), 8.66 (d, 
4H; I66”), 8.02 (s, 4H; I3’5’), 4.51 (t, 4H; 1), 4.06 (t, 4H; 2), 8.80 (d, 4H; I’33”), 7.94 (t, 4H; 
I’44”), 7.19 (t, 4H; I’55”), 7.43 (d, 4H; I’66”), 8.78 (s, 4H; I’3’5’), 4.74 (t, 4H; 1’), 4.14 ppm 
(t, 4H; 2’). 
[(dtdeg)Ru(dtdeg)Ru(dtdeg)]Cl4, (2): An excess of AgBF4 (580 mg) was dissolved in 45 
mL of acetone and filtered. [Cl3Ru(dtdeg)RuCl3] (150 mg; 0.15 mmol) was added to the 
filtrate and the mixture was refluxed in the dark for 16 hours to remove the chloride ions from 
ruthenium. After filtration to remove precipitated AgCl, the filtrate was evaporated in vacuo, 
which resulted in a green oil (~ 1.5 mL). The ligand dtdeg (340 mg; 0.60 mmol) was added 
and the mixture was refluxed for 1 hour in 35 mL of DMF, which acted as the reducing agent. 
The red reaction mixture was filtered, and the filtrate was evaporated in vacuo until a red oil 
resulted (~ 1.5 mL). To synthesize the chloride salt of the product, 12 mL of a saturated LiCl 
solution in EtOH was added to the oil. The desired product was obtained by precipitation with 
350 mL of acetone. Column chromatography on neutral alumina with acetone/MeOH/EtOH 
(v:v:v = 7:1:2) yielded pure product from the first fraction by precipitation with diethyl ether. 
Yield: 51 mg (16 %). Elemental analysis (%) calculated for C102H84Cl4N18O9Ru2·8H2O 
(water, originating from the used solvents, was used to fit the elemental analysis as the C/N 
ratio of the analysis corresponds to the structural formula of the complex): C 55.84, N 11.49, 
H 4.59. Found: C 54.12, N 11.15, H 4.00. ESI-MS: m/z: 477 [M4+], 382 [M4++H+]. 1H NMR 
(600 MHz, DMSO, 293 K): δ = 8.62 (d, 4H; I33”), 8.02 (t, 4H; I44”), 7.49 (t, 4H; I55”), 8.68 
(d, 4H; I66”), 8.04 (s, 4H; I3’5’), 4.49 (t, 4H; 1), 4.04 (t, 4H; 2), 8.88 (d, 4H; I’33”), 7.98 (t, 
4H; I’44”), 7.24 (t, 4H; I’55”), 7.50 (d, 4H; I’66”), 8.86 (s, 4H; I’3’5’), 4.72 (t, 4H; 1’), 4.11 
ppm (t, 4H; 2’), 8.97 (d, 4H; II33”), 7.91 (t, 4H; II44”), 7.21 (t, 4H; II55”), 7.47 (d, 4H; 
II66”), 8.95 (s, 4H; II3’5’), 4.81 (t, 4H; 1”), 4.20 ppm (t, 4H; 2”). 
[Cl3Ru(dtdeg)Ru(dtdeg)RuCl3]Cl2, (3): 1 (70 mg; 0.054 mmol) was dissolved in 27 mL of 
MeOH. At reflux temperature, 2 mL of 0.1 M ruthenium(III) solution was added to the 
solution. The mixture was refluxed for 3 hours and the resulting precipitate was filtered at RT. 
To remove any insoluble species (probably ruthenium-oxo species), the crude product was 
dissolved in 400 mL of hot MeOH, and filtered. The filtrate was concentrated in vacuo and 
the product was precipitated with diethyl ether. After filtration of the mixture, the residue was 
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extensively washed with diethyl ether resulting in pure product. Yield: 53 mg (57 %). 
Elemental analysis (%) calculated for C68H56Cl8N12O6Ru3·6H2O·HCl (Besides water (vide 
supra), HCl was used to fit the elemental analysis, as the product precipitates from an acidic 
solution and an aqueous solution of the product is slightly acidic): C 43.71, N 8.99, H 3.72. 
Found: C 43.43, N 8.89, H 3.67. ESI-MS: m/z: 826 [M2+]. 1H NMR (600 MHz, DMSO, 327 
K): δ = –8.52 (s, 4H; I33”), 0.96 (s, 4H; I44”), –9.91 (s, 4H; I55”), –30.25 (s, 4H; I66”), 4.80 
(s, 4H; I3’5’), 14.20 (s, 4H; 1), 4.15 (s, 4H; 2), 9.26 (s, 4H; I’33”), 8.14 (s, 4H; I’44”), 7.21 (s, 
4H; I’55”), 7.92 (s, 4H; I’66”), 9.48 (s, 4H; I’3’5’), 5.28 (s, 4H; 1’), 4.40 ppm (s, 4H; 2’). 
[Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4, (4): 2 (70 mg; 0.034 mmol) was dissolved in 
30 mL of MeOH. At reflux temperature, 1.4 mL of the 0.1 M ruthenium(III) solution was 
added to the solution. The mixture was refluxed for 3 hours and the resulting precipitate was 
filtered at RT. To remove any insoluble species (probably ruthenium oxo species), the crude 
product was dissolved in 300 mL of hot MeOH, and filtered. The filtrate was concentrated in 
vacuo and the product was precipitated with diethyl ether. After filtration of the mixture, the 
residue was extensively washed with diethyl ether resulting in pure product. Yield: 60 mg 
(71 %). Elemental analysis (%) calculated for C102H84Cl10N18O9Ru4·12H2O·1.5HCl (Besides 
water (vide supra), HCl was used to fit the elemental analysis, as the product precipitates from 
an acidic solution and an aqueous solution of the product is slightly acidic): C 44.78, N 9.22, 
H 4.03. Found: C 44.35, N 9.12, H 3.77. 1H NMR (600 MHz, DMSO, 315 K): δ = –8.41 (s, 
4H; I33”), 1.08 (s, 4H; I44”), –9.99 (s, 4H; I55”), –30.88 (s, 4H; I66”), 4.93 (s, 4H; I3’5’), 
15.04 (s, 4H; 1), 4.35 (s, 4H; 2), 9.59 (s, 4H; I’33”), 8.37 (s, 4H; I’44”), 7.60 (s, 4H; I’55”), 
7.98 (s, 4H; I’66”), 9.76 (s, 4H; I’3’5’), 5.52 (s, 4H; 1’), 4.66 ppm (s, 4H; 2’), 9.38 (s, 4H; 
II33”), 8.29 (s, 4H; II44”), 7.50 (s, 4H; II55”), 8.09 (s, 4H; II66”), 9.36 (s, 4H; II3’5’), 5.23 
(s, 4H; 1”), 4.57 ppm (s, 4H; 2”). 
[ClPt(dtdeg)Ru(dtdeg)PtCl]Cl4, (5): 1 (39 mg; 0.031 mmol) and [Pt(cod)Cl2] (32 mg; 0.087 
mmol) were refluxed in 37 mL MeOH for 6 hours. The reaction mixture was cooled to RT 
and filtered. The product was obtained by slow precipitation of the filtrate with diethyl ether. 
Yield: 43 mg (76 %). Elemental analysis (%) calculated for C68H56Cl6N12O6Pt2Ru·11H2O 
(water, originating from the used solvents, was used to fit the elemental analysis as the C/N 
ratio of the analysis corresponds to the structural formula of the complex): C 40.05, N 8.24, H 
3.85. Found: C 40.39, N 8.41, H 3.90. 1H NMR (600 MHz, DMSO, 312 K): δ = 8.85 (d, 4H; 
I33”), 8.46 (t, 4H; I44”), 7.93 (t, 4H; I55”), 8.90 (d, 4H; I66”), 8.55 (s, 4H; I3’5’), 4.74 (t, 4H; 
1), 4.12 (t, 4H; 2), 8.95 (d, 4H; I’33”), 7.97 (t, 4H; I’44”), 7.23 (t, 4H; I’55”), 7.45 (d, 4H; 
I’66”), 8.87 (s, 4H; I’3’5’), 4.78 (t, 4H; 1’), 4.15 ppm (t, 4H; 2’). 195Pt NMR (300 MHz, 
MeOH, 298 K): δ = –2702 ppm. 
 115
[ClPt(dtdeg)Ru(dtdeg)Ru(dtdeg)PtCl]Cl6, (6): 2 (45 mg; 0.022 mmol) and [Pt(cod)Cl2] (25 
mg; 0.068 mmol) were refluxed in 40 mL MeOH for 6 hours. The reaction mixture was 
cooled to RT and filtered. 6 was obtained by slow precipitation of the filtrate with diethyl 
ether. Yield: 37 mg (62 %). Elemental analysis (%) calculated for 
C102H84Cl8N18O9Pt2Ru2·12H2O (water, originating from the used solvents, was used to fit the 
elemental analysis as the C/N ratio of the analysis corresponds to the structural formula of the 
complex): C 43.79, N 9.01, H 3.89. Found: C 43.95, N 9.30, H 4.15. 1H NMR (600 MHz, 
DMSO, 298 K): δ = 8.86 (d, 4H; I33”), 8.44 (t, 4H; I44”), 7.90 (t, 4H; I55”), 8.74 (d, 4H; 
I66”), 8.52 (s, 4H; I3’5’), 4.71 (t, 4H; 1), 4.10 (t, 4H; 2), 9.01 (d, 4H; I’33”), 7.95 (t, 4H; 
I’44”), 7.23 (t, 4H; I’55”), 7.50 (d, 4H; I’66”), 8.94 (s, 4H; I’3’5’), 4.79 (t, 4H; 1’), 4.14 (t, 
4H; 2’), 8.98 (d, 4H; II33”), 7.82 (t, 4H; II44”), 7.19 (t, 4H; II55”), 7.46 (d, 4H; II66”), 8.99 
(s, 4H; II3’5’), 4.86 (t, 4H; 1”), 4.22 ppm (t, 4H; 2”). 195Pt NMR (300 MHz, MeOH, 298 K): 
δ = –2699 ppm. 
 
5.2.4 Cytotoxicity tests 
 
Cell cultures: A2780cis and A2780R cells (cisplatin sensitive and resistant human ovarian 
carcinoma, respectively) were maintained in Dulbecco’s modified Eagle’s Medium (DMEM: 
Gibco BRLTM, Invitrogen Corporation, The Netherlands) supplemented with 10 % fetal calf 
serum (Perbio Science, Belgium), penicillin (100 units/mL: Duchefa Biochemie BV, The 
Netherlands) and streptomycin (100 µg/mL: Duchefa Biochemie BV, The Netherlands) in a 
humidified 6 % CO2, 94 % air atmosphere. L1210/0 and L1210/2 cells (cisplatin sensitive and 
resistant mouse leukemia, respectively) were grown (partly in suspension and partly weakly 
adherent to the flasks) under the same conditions as mentioned above. 
Hs683 and U-373MG glioblastoma cells, HCT-15 and LoVo colorectal cancer cells, A549 
lung cancer and MCF-7 breast cancer cells were cultured at 310 K in sealed (airtight) Falcon 
plastic dishes (Nunc, Gibco, Belgium) containing Eagle’s minimal essential medium (MEM, 
Gibco) supplemented with 5 % fetal calf serum (FCS). All the media were supplemented with 
a mixture of 0.6 mg/mL glutamine (Gibco), 200 IU/mL penicillin (Gibco), 200 IU/mL 
streptomycin (Gibco) and 0.1 mg/mL gentamycin (Gibco). The FCS was heat-inactivated for 
1 hour at 329 K. 
Cells from confluent monolayers were removed from the flasks by a 0.05 % trypsin solution. 
Cell viability was determined by the trypan blue exclusion test. 
In vitro cytotoxicity evaluation: Cell growth was determined by the MTT assay, a 
colorimetric assay based on the ability of viable cells to reduce the soluble yellow 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide to blue formazan crystals by the 
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mitochondria.[17] Cells were seeded between 1000 and 5000 cells/well (depending on the cell 
type) onto 96-well plates (Corning Costar®) in 100 µl of complete medium with 5 to 10 % of 
FCS. Cells were treated 24 hours after the sowing by adding 100 µL of complete medium 
containing the test compounds at the appropriate concentrations.  
Final tested concentrations ranged between 1 µM and 50 µM and have been obtained by 
several dilutions from stock solutions in sterile water. Stock solutions of 0.2 mM or 0.67 mM 
were prepared for the trinuclear and tetranuclear complexes, respectively. A 4 mM stock 
solution of [Ru(tpy)Cl3] was prepared in DMSO, because of poor water solubility. A 40 µM 
solution contained 1 % of DMSO, which was on average not of influence on cell growth. 
After 72 hours of incubation at 310 K, cells were incubated with 1 mg/mL MTT solution for 2 
to 4 hours at 310 K. Subsequently, the medium was discarded and the formed crystals were 
dissolved in 100 µL DMSO per well. Optical density (OD) was measured at 590 nm using a 
Biorad 550 microplate reader. The OD is directly proportional to the number of living cells, 
which are compared to the control (untreated cells). 
 
5.3 Results and discussion 
 
5.3.1 Characterization of the linker-complexes 1 and 2 
 
The linker-complex [(dtdeg)Ru(dtdeg)]Cl2 (1) has been characterized by 1H NMR 
experiments in analogy with the characterization of [(dtdeg)Ru(dtdeg)Ru(dtdeg)]Cl4 (2), 
which will be illustrated here. The 1D 1H NMR spectrum of 2 in DMSO-d6 is given in Figure 
5.2. Assignments have been made by 2D 1H NMR experiments. The six signals for the 
ethylene protons of the linker indicate the presence of a C2 symmetry axis between the two 
ruthenium moieties. In the aromatic region, three sets of signals have been identified for the 
three inequivalent terpyridine ligands I, I’ and II, which indicate a second C2 symmetry axis. 
The 33” signals and 66” signals have been assigned by their specific J coupling constants of 
~ 9 Hz and ~ 6 Hz, respectively. The aromatic signals of the terpyridine ligand I have been 
selected by the relatively downfield shift of the I66” signal in comparison to that of I’66” and 
II66”. The I’66” protons are shielded by the aromatic terpyridine ligand II, and the II66” 
protons are shielded by the terpyridine ligand I’. Therefore, both the I’66” and II66” 
resonances are shifted relatively upfield. 
A I3’5’–I33” NOE is not observed, probably because of fast rotation of the outer pyridine 
rings of the terpyridine ligand I. These pyridines are not in a fixed position, as they are not 
coordinated to the ruthenium ion. Fast rotation of the outer pyridine rings of I is clearly 
observed for 1. The sign of a NOE cross peak in a NOESY spectrum depends on the 
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reciprocal of the rotational correlation time. Due to a difference in the rate of rotation between 
the outer pyridines of terpyridine ligand I and those of I’, the I33”–I44”, I44”–I55”, I55”–I66” 
and I3’5’–1 NOEs are of opposite sign (opposite to the diagonal) in comparison to the 
corresponding NOEs of terpyridine ligand I’, which is coordinated to ruthenium. At 600 
MHz, all NOEs displayed by 1 are of similar sign. This observation agrees with the fact that 
the strength of the magnetic field is also of influence on the sign of a NOE. The 1H 2D 
NOESY NMR experiment of 2 has only been performed at 600 MHz, where a similar sign for 
all NOEs has been identified. 
The I’3’5’–I’33” and II3’5’–II33” NOEs are not observed, presumably due to overlap with 
the diagonal. Therefore, the 33” doublet at 8.88 ppm and the singlet at 8.86 ppm have been 
attributed to the similar terpyridine ligand (either I’ or II), as well as the 33” doublet and the 
singlet at 8.97 and 8.95 ppm, respectively. The singlet at 8.04 ppm has been assigned to the 
I3’5’ protons. The terpyridine ligands I’ and II have been distinguished using the 2-2’ cross 
peak of the ethylene-linker protons, which is displayed in the NOESY spectrum of 2. The I’ 
resonances have subsequently been assigned via the 2’–1’ COSY cross peak and the I’3’5’–1’ 






Figure 5.2 1D 1H NMR spectrum of 2 in DMSO-d6 at 293 K with some assignments, and 
a schematic representation of the cation of 2. The numbering scheme given for terpyridine 









































































5.3.2 Characterization of the paramagnetic trinuclear ruthenium complex 3 
 
The complex [Cl3Ru(dtdeg)Ru(dtdeg)RuCl3]Cl2 (3) is a paramagnetic species, due to the 
presence of an unpaired electron in the t2g orbital of the low-spin ruthenium(III) ions. 
Therefore, 1H NMR resonances of the ruthenium(III) moieties are significantly broadened and 
shifted (Figure 5.3). Signals from the central diamagnetic ruthenium(II) moiety are broadened 
to some extent, but are observed in the normal diamagnetic envelop. In Chapter 2 of this 
thesis, a strategy for the characterization of paramagnetic trichlororuthenium(III)-terpyridine 
complexes by 1H NMR spectroscopy has been presented using the complex 
[(tpy)Ru(dtdeg)RuCl3]2+ as a model compound. A similar strategy will be used for the 
characterization of 3 (and 4). 
The 1H NMR spectrum of 3 has been acquired at 327 K. At this temperature the 
“paramagnetic” signals, i.e. the resonances of the paramagnetic ruthenium(III) moiety, do not 
overlap. The signal at 4.80 ppm has also been established as a “paramagnetic” signal, since it 
exhibits short longitudinal (T1) and transverse (T2) relaxation times (11 and 8 ms, 
respectively). Five resonances of similar intensity are observed in the aromatic region of the 
1H NMR spectrum for the terpyridine I’ signals of the ruthenium(II) unit of 3, which indicate 
the presence of two C2 symmetry axes within the molecule. The resonances have been 
assigned by 2D COSY 1H NMR experiments, using a relaxation delay of 20 ms (Figure 5.4). 
 
 
Figure 5.3 1D 1H NMR spectrum of 3 in DMSO-d6 at 327 K with the “paramagnetic” 
signals indicated, and molecular structure of the cation of 3. The numbering scheme of I is 







Figure 5.4 2D 1H COSY NMR spectrum of 3 in DMSO-d6 at 327 K with some cross 
peaks indicated, and some assignments given. 
 
The I’33” and I’66”signal have been assigned by the characteristic upfield shift of the latter. 
The shift is due to deshielding of the aromatic rings. In analogy to 1, the two resonances at 
5.28 and 4.40 ppm have been ascribed to the diethylene protons 1’ and 2’, respectively. 
In agreement with the double C2 symmetry of the complex, five resonances have also been 
found for the protons of the paramagnetic ruthenium(III) units. They have partly been 
assigned by 2D COSY 1H NMR spectroscopy (Figure 5.4). The signal at –30.25 ppm appears 
to be too broad to show cross peaks. In analogy with the complexes [(tpy)Ru(dtdeg)RuCl3]2+ 
(Chapter 2) and [Ru(tpy)Cl3],[15] the signal has been assigned to the I66” protons. These are 
the protons closest to the paramagnetic ruthenium(III) moiety, and can therefore be expected 
to shift the most. The “paramagnetic” resonance at 0.96 ppm displays cross peaks to the 
signals at –8.52 and –9.91 ppm; hence, it has been attributed to the I44” protons. The I33” and 










and 4.15 ppm, which assigns these signals to the diethylene protons 1 and 2. The resonance at 
14.20 ppm has been ascribed to the linker protons 1, since they are closest to the paramagnetic 
center. 1D NOE difference experiments (Figure 5.5) complete the assignment of 3. 
Upon irradiation of the paramagnetic signal at 4.80 ppm, signal enhancements are displayed 
by the diethylene protons 1 at 14.20 ppm, and by the resonance at –8.52 ppm. As a result, the 
signal at 4.80 ppm has been assigned to the I3’5’ protons. Consequently, the signal at –8.52 
ppm can be ascribed to the I33” protons. Irradiation of the largely shifted and broadened I66” 
resonance at –30.25 ppm only results in a small NOE of the signal at –9.91 ppm. 
The chemical shifts of all paramagnetic resonances have been monitored in the temperature 
range from 300 to 360 K. All signals appear to shift gradually to the diamagnetic region upon 
increasing the temperature. The observed chemical shifts have been plotted against reciprocal 
temperatures T-1 (Figure 5.6). For all resonances a linear decrease in the hyperfine shift is 
observed upon a stepwise decrease of 1/T, which indicates Curie behavior. The intercepts, 
which are extrapolated at infinite temperature, differ only slightly from the diamagnetic 
values for most signals. 
Figure 5.5 1D 1H NOE difference NMR spectra (top and middle) and 1D 1H NMR 
spectrum (bottom) of 3 in DMSO-d6 at 327 K. Irradiated signals are indicated with an arrow. 




Figure 5.6 Plots of the chemical shifts versus 1/T for the “paramagnetic” signals of 3. 
 
Both dipolar and contact hyperfine interactions are likely to contribute to the hyperfine shift 
of complex 3, as has been suggested for the analogues trichlororuthenium complex 
[(tpy)Ru(dtdeg)RuCl3]Cl2 (see Chapter 2 for more details). 
  
5.3.3 Characterization of the paramagnetic tetranuclear ruthenium complex 4 
 
The complex [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4 (4) displays a spectrum similar to 
that of 3. The “paramagnetic signals” of the ruthenium(III) moieties are observed outside the 
diamagnetic region, whereas the signals of the diamagnetic ruthenium(II) moieties are found 
within this region. The 1H NMR spectrum of 4 in dmso-d6 at 315 K (overlap of 
“paramagnetic” signals is not observed at this temperature) is depicted in Figure 5.7. 
Assignments have been done by 2D COSY NMR (data not shown), and 1D NOE difference 
experiments (Figure 5.8) in analogy to the characterization of 3. The tetranuclear complex 4 
contains two diamagnetic ruthenium(II) moieties, which are identical because of the presence 
of two C2 symmetry axes. However, the two terpyridine ligands I’ and II are inequivalent. 
Therefore, two sets of terpyridine signals are identified in the aromatic region of the COSY 
spectrum. Moreover, two two-spin systems are shown by the diethylene protons 1’ and 2’, 
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Figure 5.7 1D 1H NMR spectra of 4 in DMSO-d6 at 315 K with assignments, and 
molecular structure of the cation of 4. The spectrum at the bottom is an enlargement of the 
diamagnetic region. The numbering scheme given for I is also applicable to I’ and II. The 
terpyridine I’ signals have not been distinguished from terpyridine II resonances. 
 
The resonances at 5.52 and 4.66 have been assigned to the 1’ and 2’ protons, since these 
signals exhibit short T1 values (77 and 115 ms, respectively) in comparison to the 1” and 2” 
resonances (137 and 158 ms, respectively). In 1D NOE difference experiments, I’3’5’–1’ and 
II3’5’–1” NOEs are observed (data not shown). However, I’3’5’–I’33” and II3’5’–II33” 









Figure 5.8 1D 1H NOE difference NMR spectra (top and middle) and 1D 1H NMR 
spectrum (bottom) of 4 in DMSO-d6 at 315 K. Irradiated signals are indicated with an arrow. 
NOEs are indicated by an asterisk. 
 
As a consequence, the two different terpyridine ligands I’ and II cannot be distinguished. 
They can also not be distinguished by their T1 values, since these are not clearly different for 
the two sets of terpyridine signals. The distance to the ruthenium(III) ion may vary due to 
internal movements of the flexible linker, thereby affecting the protons of the diamagnetic 
unit. 
The “paramagnetic” signals of 4 show cross peaks comparable to those of 3 in the 2D COSY 
NMR spectrum. Therefore, these data are not shown. 1D NOE difference experiments are 
depicted in Figure 5.8. Similar to 3, signal enhancements of the diethylene proton 1 and I33” 
are seen upon irradiation of the “paramagnetic” signal at 4.93 ppm. Thereby, the latter can be 
attributed to the I3’5’ protons. The I55” resonance exhibits a NOE upon irradiation of the 
significantly broadened and shifted I66” signal at –30.88 ppm. This confirms the assignment 
of the terpyridine I protons. Interestingly, the NOEs displayed by the different “paramagnetic” 
resonances are of considerable intensity. The large enhancement is, besides a high 
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intensity for paramagnetic complexes is proportional to the rotational correlation time, which 
is significantly affected by a high molecular weight.[18] 
Hyperfine shifts have been observed over a temperature range from 300 to 360 K, and have 
been plotted against the reciprocal temperature T-1 (Figure 5.9). It can be concluded that all 
signals display Curie behavior, i.e. upon decreasing T-1, a linear decrease in the hyperfine 
shift is observed for all resonances. The intercepts extrapolated at infinite temperature are 
















Figure 5.9 Plots of the chemical shifts versus 1/T for the “paramagnetic” signals of 4. 
 
 
5.3.4 Characterization of the polynuclear ruthenium platinum complexes 5 and 6 
 
The ruthenium(II)-platinum(II) complexes [ClPt(dtdeg)Ru(dtdeg)PtCl]Cl4 (5) and 
[ClPt(dtdeg)Ru(dtdeg)Ru(dtdeg)PtCl]Cl6 (6)  have been characterized by 1D and 2D 1H NMR 
experiments, as well as with 195Pt NMR spectroscopy (see experimental section). Their 
characterization is very similar to that of their precursors 1 and 2, respectively. Both 
complexes are of C2 symmetry, causing the appearance of four ethylene signals and two sets 
of terpyridine resonances in the 1H NMR spectrum of 5 (Figure 5.10, top), and six ethylene 





































































The 33” and 66” signals have been assigned according to their specific J coupling constants of 
9 and 5 Hz, respectively. The set of signals for terpyridine ligand I has been identified by the 
relatively downfield shift of the I66” protons in comparison to the shift of the I’66” and II66” 
protons. The downfield shift of the I66” protons is due to deshielding by the chloride ligand, 
which is coordinated to platinum. All expected cross peaks are observed in the 2D NOESY 
spectra of the complexes. The two terpyridine ligands I’ and II of 6 have been distinguished 
by the 2-2’ NOE, which indirectly indicates the I’ signals via the 2’-1’ COSY and I3’5’-1’ 
NOE cross peaks. 
 
 
Figure 5.10 1D 1H NMR spectra of 5 (top) and 6 (bottom) in DMSO-d6 at 312 K and 298 
K, respectively, with some assignments. The structures of the cations of 5 and 6 are also 
given. The numbering scheme of I is also applicable to I’ and II. 
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5.3.5 Cytotoxicity tests 
 
Cytotoxic activity of the tetranuclear complexes against A2780cis and A2780R cisplatin 
sensitive and resistant cell lines, respectively, is reported in Table 5.1. The IC50 values have 
also been determined under the same conditions for the mononuclear derivatives [Ru(tpy)Cl3] 
and [Pt(tpy)Cl]Cl, and cisplatin for comparison. 
The complex [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4 (4) displays activity against 
A2780cis cells with an IC50 value of 8 µM. Moderate activity is displayed against A2780R 
cells. It shows higher activity than the mononuclear complex [Ru(tpy)Cl3], which displays 
IC50 values of 14 µM and 45 µM against A2780cis and A2780R cells, respectively. The 
complex [ClPt(dtdeg)Ru(dtdeg)Ru(dtdeg)PtCl]Cl6 (6) shows moderate cytotoxicity against 
both cell lines. The trinuclear derivatives 3 and 5 inhibit cell growth of A2780cis cells for 
50 % at a concentration of 20 µM. An IC50 value could not be determined, since only one 
concentration showed an effect of 50 % of cell growth inhibition. Higher concentrations of 3 
and 5 have not been tested, because of poor solubility in the used medium. The trinuclear 
complexes inhibit cell growth of A2780R cells for only 30 % at 20 µM. 
 
Table 5.1 IC50 values for the polynuclear complexes 3, 4, 5 and 6 calculated after 72 
hours of treatment. IC50 values given for 3 and 5 are only indicative.  
    IC50 (µM)   
Complex 3 4 5 6 [Ru(tpy)Cl3] [Pt(tpy)Cl]Cl Cisplatin 
A2780cis ~ 20 8 ~ 20 15 14 1 1 
A2780R >> 20 20 >> 20 22 45  2  6 
 
The complex [Ru(tpy)Cl3] has been reported to display an IC50 value of 7 µM against 
L1210cis cells.[12] However, this result has not been reproduced by tests reported here. In fact, 
none of the ruthenium complexes described in this Chapter, including [Ru(tpy)Cl3], 
considerably inhibits cell growth of L1210 cells. Of the ruthenium-platinum derivatives, only 
6 shows moderate activity against the leukemia cell lines. It displays IC50 values of 30 µM 
and 24 µM against L1210cis and L1210/2 cells, respectively. 
In general, the trinuclear complexes also show no cytotoxic effect against Hs683 and U-
373MG glioblastoma cells, HCT-15 and LoVo colorectal cancer cells, A549 lung cancer and 
MCF-7 breast cancer cells at the highest concentration tested (20 µM). At 50 µM, the 
tetranuclear complexes 4 and 6 show an average inhibition of cell growth of 55 % and 47 %, 
respectively. Complex 6 inhibits cell growth of Hs683, HCT-15 and MCF-7 cells for more 
than 50 %, but only at the highest concentration used, i.e. at 50 µM. Complex 4 inhibits 50 % 
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of cell growth of LoVo, HCT-15 and MCF-7 cells at concentrations between 10 and 30 µM, 
but the average inhibition of cell growth is approximately 40 % only. Therefore, IC50 values 
have not been determined. At negligible DMSO concentrations, [Ru(tpy)Cl3] shows an 
average inhibition of cell growth of 25 % at 50 µM against these cell lines. [Pt(tpy)Cl]Cl 
shows even higher activity than cisplatin against all cell lines tested. It displays IC50 values 
that range between 1 and 5 µM. 
The dinuclear derivatives [(tpy)Ru(dtdeg)RuCl3]Cl2 and [(tpy)Ru(dtdeg)PtCl]Cl3, which have 
been presented in the previous Chapters, only show an average inhibition of cell growth of 
55 % and 71 %, respectively, at 100 µM against Hs683, U-373MG, HCT-15, LoVo, A549 
and MCF-7 cancer cells. Thus, of the polynuclear trichlororuthenium and platinum terpyridyl 
complexes the tetranuclear complexes show the highest inhibition of cell growth at similar 
concentrations. 
The length of the linker may in part be of influence on the cytotoxicity of the polynuclear 
complexes. It has been reported that intercalation of platinum terpyridine complexes possibly 
requires a precise orientation of the preferred binding site.[19] However, bisintercalation of 
dinuclear platinum terpyridine complexes has been implied to disrupt the DNA binding 
site.[20] It has been suggested that the use of long linkers may allow both units to 
independently interact with the DNA. However, the cytotoxicity of 6, which has been 
synthesized using an extremely long linker, is not as high as that of the mononuclear 
derivative [Pt(tpy)Cl]Cl. The tetranuclear complex 4 exhibits appreciable cytotoxicity, but 
only against A2780cis cells. Thereby, 4 is more active than its mononuclear counterpart 
[Ru(tpy)Cl3]. However, it is not more active than cisplatin, which displays an IC50 value of 
1 µM against A2780cis cells. 
 
5.3.6 Clotting of A2780cis cells. 
 
Interestingly, clotting of A2780cis cells has been observed upon incubation with 4 (Figure 
5.11). The cells seem to assemble on top of each other to form a kind of bundles, which 
remain attached to the bottom of the well during the tests. The effect is noticed after one day 
of incubation, and seems to be concentration dependent. It is already clearly seen at a 
concentration of 20 µM. At this particular concentration, almost no normally growing cells 
are observed (Figure 5.11). Within the clots some cells are still alive, as proven by the MTT 
assay, i.e. 35 % of cell growth is observed at 20 µM. An increase in concentration does not 
result in a significant increase in inhibition of cell growth. At 50 µM, 30 % of the cells are 













Figure 5.11 Analysis of cell growth of untreated A2780cis cells after 72 hours at 310 K 
(A), and of A2780cis cells after treatment with 4 for 72 hours at 310 K (B and C). Picture C 
represents an enlargement of one clot. 
 
The cells return to their normal growth after plating treated cells into drug-free medium, 
which implies that 4 is not significantly taken up by the cells. Cell uptake experiments have 
not been performed to confirm this hypothesis, but the high positive charge (4+) of the 
complex is likely to affect internalization. The complex may remain on the negatively charged 
cell surface. A possible straightforward explanation for the clotting of the A2780cis cells is 
that electrostatic interactions between 4 and cell membranes join cells together. The trinuclear 
analogue 3, which has a 2+ charge, shows the effect as well, albeit less significant. However, 
cells do not adhere together by incubation with the dinuclear complex 
[(tpy)Ru(dtdeg)RuCl3]Cl2, which is also 2+ charged. Moreover, the trinuclear and tetranuclear 
platinum analogues 5 and 6, which display charges of 4+ and 6+, respectively, do not show 
the effect either. Therefore, the positive charge of the complexes cannot be the only factor 
causing this effect. The trichlororuthenium(III) moieties and the length of the linker seem to 
be of importance. 
DNA is believed to be the ultimate target of many anticancer drugs,[3] but the results imply 
that the activity of 4 may not be related to DNA binding. A target different from DNA has 
also been implied for the mononuclear complex NAMI-A.[21] Its high activity in vivo against 
lung metastasis[22] has been associated with inhibition of angiogenesis.[8, 23] Further 
experiments have to be performed to elucidate the mechanism of action of complex 4. 
Nevertheless, it is clear that the effect is only displayed by the tetranuclear complex 4, and by 
its trinuclear derivative 3, although to a lesser extent. The other complexes tested, including 
cisplatin, [Ru(tpy)Cl3] and [Pt(tpy)Cl]Cl, do not show the effect. Furthermore, the A2780R 
and the leukemia cells do not adhere together upon incubation with 4. The Hs683, U-373MG, 
A B C
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HCT-15, LoVo, A549 and MCF-7 cancer cells have not specifically been observed for the 
appearance of the effect, but the low inhibition of cell growth suggests the absence of clotting 
cells. Thus, the effect appears to be specific for the particular structure of 4, and is 
characteristic for the A2780cis cell line. The clotting of A2780cis cells may hamper migration 
and metastasis of these cancer cells, since the cells remain adhered to each other and do not 
dissociate from the clot. 
 
5.4 Concluding remarks 
 
The positively charged complexes [(dtdeg)Ru(dtdeg)]Cl2 (1) and 
[(dtdeg)Ru(dtdeg)Ru(dtdeg)]Cl4 (2) have been synthesized and characterized. They have 
proven to be highly valuable for the simple construction of homo and heteropolynuclear 
complexes. They have been used for the syntheses of the new linear trinuclear and 
tetranuclear ruthenium(II)-ruthenium(III) complexes 3 and 4, and that of the ruthenium(II)-
platinum(II) analogues 5 and 6, which have been presented in this Chapter. The paramagnetic 
complexes 3 and 4 have been characterized by 1H NMR spectroscopy, including the use of 1D 
1H NOE difference experiments. Especially complex 4 displays strong NOE’s even upon 
irradiation of signals which exhibit short T1 values. The high molecular weight of 4 is 
probably of appreciable influence for the observed high intensity of the NOE’s. The hyperfine 
shifts of the paramagnetic signals of 3 and 4 show Curie behavior. The shifts are 
approximately identical to those of the mononuclear and dinuclear derivatives [Ru(tpy)Cl3] 
and [(tpy)Ru(dtdeg)RuCl3]Cl2. The ruthenium-platinum complexes have also been 
characterized by 1H NMR spectroscopy. 
Cytotoxicity tests reveal that the complexes do not show significant activity against a variety 
of cancer cell lines. Complex 6 exhibits moderate cytotoxicity against A2780 and L1210 cells. 
Complex 4 displays an IC50 value of 8 µM against A2780cis cells, and is moderately active 
against the cisplatin resistant cell line A2780R. An interesting effect has been observed upon 
analysis of cell growth of A2780cis cells. The cells adhere together and form clots upon 
incubation with 4. The effect appears to be characteristic for the A2780cis cells and is specific 
for the particular structure of 4. 
Concluding, in additition to the dinuclear derivatives of NAMI-A[8] and the trinuclear 
ruthenium complex  ruthenium red[24], this Chapter presents the first tetranuclear ruthenium 
complex, which shows biological activity against cancer cells. Considering the urgent need 
for targeted drugs, complex 4 may represent a true novelty. The clotting suggests that 4 may 
inhibit cell migration and metastasis. The relation between clotting and invasion inhibition 
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Heteropolynuclear ruthenium(II)-platinum(II) complexes 
with short and semi-rigid linkers: synthesis, 
characterization and DNA-model base studies 
 
 
Abstract – The paramagnetic ruthenium(III) complex [Ru(qpy)Cl3] (1) (qpy = 4’-pyridyl-
2,2’:6’,2”-terpyridine) has been characterized by 1H NMR spectroscopy. The chemical shifts 
of the pendant pyridine protons demonstrate that spin delocalization partly occurs by a spin 
polarization mechanism. The water-soluble ruthenium(II) complexes [(tpy)Ru(qpy)]Cl2 (2) 
and [Ru(qpy)2]Cl2 (3) have been produced for the synthesis of the dinuclear and trinuclear 
ruthenium(II)-platinum(II) complexes [(tpy)Ru(qpy)Pt(en)Cl](NO3)3 (4) and 
[Cl(en)Pt(qpy)Ru(qpy)Pt(en)Cl](NO3)4 (5), respectively (en = 1,2-ethylenediamine). The 
complexes have been characterized by different techniques. Electronic spectra show that 
coordination of platinum to the pendant pyridine of the qpy ligand lowers the energy level of 
the MLCT band of the ruthenium metal. It has been demonstrated that the polynuclear 
complexes do not hydrolyze in D2O. In stead coordination to the DNA-model base 
9-ethylguanine (9egua) occurs, as has been demonstrated for 4. 1H NMR data prove that the 
base coordinates to platinum via the N7, with its keto group directed towards the amine 
protons of the ethylene diamine ligand. The complexes do not show cytotoxicity against 












Polynuclear platinum complexes have been developed as new anticancer drugs.[1] The 
α,ω-diaminoalkane-linked polynuclear platinum complexes developed by Farrell et al. 
represent a very promising class of anticancer compounds.[2] The long and flexible linker 
allows the formation of long-range adducts to the DNA, which is generally believed to be the 
target of platinum anticancer complexes.[3] The formation of these specific adducts appears to 
be of importance for the high antitumor activity, which is displayed by the complexes.[4] In 
contrast, dinuclear platinum complexes with short and rigid linkers, in which the platinum 
moieties are joined by pyrazole and a hydroxo group, have also been shown to exhibit high 
activity against different cancer cell lines.[5] The two platinum centers have been found to be 
sufficiently close to mimic DNA binding of the antitumor drug cisplatin.[6] However, they 
form the 1,2-intrastrand DNA adduct without major distortions of the DNA, which may avoid 
recognition and repair of the adduct.[7] 
Ruthenium compounds are also known for their antitumor activity,[8] and some polynuclear 
complexes have been designed and studied as anticancer agents.[9] Different heterocyclic 
bridging ligands have been used to link two ruthenium units, which resemble the 
antimetastatic complex NAMI-A.[9] The complexes have been demonstrated to display 
antimetastatic activity in vivo, but not as profound as the mononuclear counterpart.[10] A small 
variety of heterodinuclear ruthenium-platinum complexes have mainly been synthesized by 
the use of short bridging heterocyclic ligands.[11] These compounds have been devised to 
photoreact with DNA. Light absorption of the ruthenium moiety, and subsequent energy 
transfer is thought to impart reactivity at the platinum unit, which can coordinate to DNA. 
In this Chapter heteropolynuclear ruthenium-platinum complexes, for which the short and 
semi-rigid linking ligand[12] 4’-pyridyl-2,2’:6’,2”-terpyridine (quaterpyridine or qpy) has been 
used, are described. The ligand qpy presents a tridentate coordination site, and can coordinate 
to a second metal via the fourth pyridine, which is appended at the 4’ position of the 
terpyridine part. The syntheses of the mononuclear ruthenium complexes [Ru(qpy)Cl3], 
[Ru(qpy)(tpy)](PF6)2, and [Ru(qpy)2](PF6)2 (tpy = 2,2’:6’,2”-terpyridine), in which qpy 
coordinates to ruthenium as a tridentate ligand, have already been reported elsewhere.[13, 14] 
The non-coordinated pyridyl groups of the bis(quaterpyridine) ruthenium complex have been 
shown to react with a range of electrophiles.[13] In this Chapter, the characterization of the 
paramagnetic ruthenium(III) complex [Ru(qpy)Cl3] (1) is presented, as well as the syntheses 
of the water soluble ruthenium(II) complexes [Ru(qpy)(tpy)]Cl2 (2), and [Ru(qpy)2]Cl2 (3). 
The characterization of 2 and 3 will be discussed briefly. 
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The chloride salts 2 and 3 have been produced for the syntheses of the polynuclear complexes 
[(tpy)Ru(qpy)Pt(en)Cl](NO3)3 and [Cl(en)Pt(qpy)Ru(qpy)Pt(en)Cl](NO3)4 (en = 1,2-
ethylenediamine) (4 and 5, respectively, Figure 6.1). These complexes consist of a 
bis(terpyridyl)-ruthenium(II) moiety, and one or two platinum-ethylenediamine centers, 
which coordinate to the fourth pyridine ligand of qpy. The ruthenium moiety can provide 
water solubility and electrostatic interactions with the DNA by its 2+ charge, as is known[15] 
for the parental mononuclear complex [Ru(tpy)2]2+. The ligand qpy may affect DNA binding 
affinity, due to its extended aromaticity. The platinum moieties can monofunctionally 
coordinate to the DNA by substitution of the relatively labile chloride ligand. 
The dinuclear complex 4 has been reacted with the DNA-model base 9-ethylguanine (9egua) 
to study the DNA binding behavior of the platinum unit. The adduct 
[(tpy)Ru(qpy)Pt(en)(9egua)](PF6)4 (6) has been isolated, its characterization by 1H NMR 
experiments is presented here as well. The complexes have been tested for cytotoxicity 














Figure 6.1 The polynuclear cationic ruthenium(II)-platinum(II) complexes 4 and 5. 
 
 
6.2 Experimental section 
 
6.2.1 General methods and starting materials 
 
Elemental analyses on C, H and N were performed on a Perkin Elmer series II CHNS/O 





























instrument with an electrospray interface (ESI). UV-VIS spectra were measured on a Cary 50 
UV-VIS spectrometer version 3.00, from 200 to 800 nm. Hydrated RuCl3·xH2O (x ~ 3) was 
used as received from Johnson & Matthey. The ligand tpy was obtained from Sigma, and 
[Pt(en)Cl2] from Kreatech. The ligand qpy[12] and the complex[16] [Ru(tpy)Cl3] were 
synthesized following known procedures. The preparation of the 0.1 M ruthenium(III) 
solution has been described elsewhere,[17] and is reported in Chapter 2. 
  
6.2.2 1H NMR measurements 
 
NMR spectra were performed on a Bruker DPX 300, a DMX 600, and an AV 400 MHz 
spectrometer. Spectra were recorded in deuterated DMSO, acetone and water, and were 
calibrated on residual solvent peaks at δ 2.49, 2.06 and 4.75 ppm (T = 298 K), respectively. 
The 1D 1H spectrum of the paramagnetic complex [Ru(qpy)Cl3] (1) was obtained using a 100 
ppm spectral width. Longitudinal relaxation times were measured by the standard inversion-
recovery method, with 7 s relaxation delay and a spectral width of 100 ppm. Variable delays 
ranged from 50 µs to 3 s. Magnetization recovery was found to be exponential within 
experimental error. T2 values were estimated from the peak half-widths. The COSY spectrum 





[Ru(qpy)Cl3], (1): The ligand qpy (200 mg; 0.645 mmol) was dissolved in 50 mL of MeOH 
by reflux. 0.1 M ruthenium(III) solution (6.5 mL; 0.65 mmol) was added drop wise to the 
solution. The mixture was refluxed for 1.5 hours, which resulted in precipitation of crude 
product. The mixture was filtered hot. Relatively pure complex precipitated from the filtrate at 
253 K, and was obtained by filtration. Yield: 215 mg (65 %). 1H NMR (300 MHz, DMSO, 
298 K): δ = –8.61 (s, 2H; 33”), –3.38 (s, 2H; 44”), –7.41 (s, 2H; 55”), –34.76 (s, 2H; 66”), 
6.47 (s, 4H; 3’5’), 10.04 (s, 2H; 2”’6”’), 0.13 ppm (s, 2H; 3”’5”’). 
[Ru(qpy)(tpy)]Cl2, (2): An excess of AgBF4 (120 mg; 0.616 mmol) was dissolved in 5 mL of 
acetone and filtered. [Ru(tpy)Cl3] (20 mg; 0.045 mmol) was added to the filtrate and the 
mixture was refluxed in the dark for 16 hours. After filtration to remove precipitated AgCl, 
the filtrate was evaporated in vacuo, which resulted in a green oil (~ 0.5 mL). The ligand qpy 
(23 mg; 0.074 mmol) was added and the mixture was refluxed for 1.5 hours in 10 mL of 
DMF, which acted as the reducing agent. The red reaction mixture was filtered, and the 
filtrate was evaporated in vacuo until ~ 0.5 mL of a red oil resulted. To synthesize the 
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chloride salt of the product, 2 mL of a saturated LiCl solution in EtOH was added to the oil. 
The desired product was obtained by precipitation with a large amount of acetone (~ 100 mL). 
The product was partly purified by column chromatography on neutral alumina with 
CH3CN/EtOH (v:v = 1:1). The orange fraction was precipitated with diethyl ether. The 
product was recrystallized from MeOH and diethyl ether. Yield: 24 mg (75 %). Elemental 
analysis (%) calculated for C35H25Cl2N7Ru: C 58.75, N 13.70, H 3.52. Found: C 58.13, N 
13.46, H 3.87. ESI-MS: m/z: 322 [M2+]. 1H NMR (300 MHz, DMSO, 298 K) (the qpy and tpy 
protons are denoted by I and II, respectively): δ = 9.14 (d, 2H; I33”), 8.08 (t, 2H; I44”), 7.29 
(t, 2H; I55”), 7.45 (d, 2H; I66”), 9.60 (s, 2H; I3’5’), 8.98 (d, 2H; I2”’6”’), 8.45 (d, 2H; 
I3”’5”’), 8.85 (d, 2H; II33”), 8.02 (t, 2H; II44”), 7.25 (t, 2H; II55”), 7.52 (d, 2H; II66”), 9.11 
(s, 2H; II3’5’), 8.55 ppm (t, 2H; II4’). UVVIS (H2O): λmax 484 (ε = 1.9 · 104), 308 (ε = 5.1 · 
104), 272 nm (ε = 4.6 · 104 M-1 cm-1). 
[Ru(qpy)2]Cl2, (3): An excess of AgBF4 (330 mg; 1.695 mmol) was dissolved in 20 mL of 
acetone and filtered. 1 (65 mg; 0.125 mmol) was added to the filtrate and the mixture was 
refluxed in the dark for 16 hours. After filtration and evaporation of the filtrate in vacuo, a 
green oil (~ 1 mL) resulted to which qpy (43 mg; 0.139 mmol) was added. The mixture was 
refluxed for 1.5 hours in 20 mL of DMF. The red reaction mixture was filtered, and the 
filtrate was evaporated in vacuo until an oil (~ 1 mL) resulted. 6 mL of a saturated LiCl 
solution in EtOH was added to the oil. The desired product was obtained by precipitation with 
a large amount of acetone (~ 350 mL). The product was purified by column chromatography 
on neutral alumina with acetone/EtOH/MeOH (v:v:v = 3:6:1). Red fractions were collected. 
Pure product was obtained by slow precipitation with diethyl ether. Yield: 43 mg (43 %). 
Elemental analysis (%) calculated for C40H28Cl2N8Ru: C 60.61, N 14.14, H 3.56. Found: C 
59.91, N 13.84, H 3.82. ESI-MS: m/z: 361 [M2+]. 1H NMR (300 MHz, DMSO, 298 K): δ = 
8.99 (d, 4H; 33”), 8.09 (t, 4H; 44”), 7.28 (t, 4H; 55”), 7.56 (d, 4H; 66”), 9.61 (s, 4H; 3’5’), 
9.13 (d, 4H; 2”’6”’), 8.44 ppm (d, 4H; 3”’5”’). UVVIS (H2O): λmax 490 (ε = 3.3 · 104), 313 (ε 
= 5.8 · 104), 274 (ε = 7.7 · 104), 240 nm (ε = 4.5 · 104 M-1 cm-1). 
[(tpy)Ru(qpy)Pt(en)Cl](NO3)3, (4): An aqueous solution of AgNO3 (14 mg in 0.55 mL) was 
added in five portions over 1 hour to a suspension of [Pt(en)Cl2] (28 mg; 0.084 mmol) in 3 
mL of H2O at 310 K. Subsequently, the mixture was stirred for 2 hours at 310 K. After 
filtration, an aqueous solution of 2 (30 mg; 0.042 mmmol) was added to the filtrate. The 
mixture was stirred at 363 K for 18 hours. The reaction mixture was concentrated in vacuo 
and coevaporated three times with EtOH/MeOH (v:v = 6:1) to remove the water. The residue 
was dissolved in MeOH. The product was precipitated by slow addition of diethyl ether. 
Yield: 28 mg (67 %). ESI-MS: m/z: 312 [M3+]. 1H NMR (300 MHz, D2O, 298 K): δ = 8.62 (d, 
2H; I33”), 7.93 (t, 2H; I44”), 7.18 (t, 2H; I55”), 7.37 (d, 2H; I66”), 9.13 (s, 2H; I3’5’), 9.01 
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(d, 2H; I2”’6”’), 8.26 (d, 2H; I3”’5”’), 8.50 (d, 2H; II33”), 7.89 (t, 2H; II44”), 7.11 (t, 2H; 
II55”), 7.46 (d, 2H; II66”), 8.79 (s, 2H; II3’5’), 8.43 (t, 2H; II4’), 2.70 (s, 2H; b), 2.66 ppm (s, 
2H; c). 195Pt NMR (300 MHz, D2O, 298 K): δ = -2517 ppm. UVVIS (H2O): λmax 489 (ε = 
2.0 · 104), 306 (ε = 4.7 · 104), 272 nm (ε = 4.2 · 104 M-1 cm-1). 
[Cl(en)Pt(qpy)Ru(qpy)Pt(en)Cl](NO3)4, (5): An aqueous solution of AgNO3 (14 mg in 0.55 
mL) was added in five portions over 1 hour to a suspension of [Pt(en)Cl2] (28 mg; 0.084 
mmol) in 3 mL of H2O at 310 K. Subsequently, the mixture was stirred for 2 hours at 310 K. 
After filtration, an aqueous solution of 3 (18.2 mg; 0.023 mmmol) was added to the filtrate. 
The mixture was stirred at 363 K for 18 hours. The reaction mixture was concentrated in 
vacuo and co-evaporated three times with EtOH/MeOH (v:v = 6:1) to remove the water. The 
residue was dissolved in MeOH. The product was precipitated by slow evaporation of the 
solution. Yield: 21 mg (63 %). Elemental analysis (%) calculated for 
C44H44Cl2N16O12Pt2Ru·2.5H2O: C 33.11, N 14.04, H 3.09. Found: C 32.69, N 13.98, H 2.69. 
1H NMR (300 MHz, D2O, 298 K): δ = 8.63 (d, 4H; 33”), 7.94 (t, 4H; 44”), 7.17 (t, 4H; 55”), 
7.42 (d, 4H; 66”), 9.14 (s, 4H; 3’5’), 9.02 (d, 4H; 2”’6”’), 8.26 ppm (d, 4H; 3”’5”’), 2.82 (s, 
4H; b), 2.75 ppm (s, 4H; c). 195Pt NMR (300 MHz, D2O, 298 K): δ = -2518 ppm. UVVIS 
(H2O): λmax 497 (ε = 2.7 · 104), 312 (ε = 3.6 · 104), 275 nm (ε = 4.7 · 104 M-1 cm-1). 
[(tpy)Ru(qpy)Pt(en)(9egua)](PF6)4, (6): A mixture of 4 (6 mg; 0.006 mmol) and 9egua (2 
mg; 0.012 mmol) was stirred in 1.5 mL H2O for 2 days at 310 K. A saturated NH4PF6 solution 
in H2O was added until a precipitate was formed. The product was filtered off, and washed 
with a small amount of H2O. Yield: 2 mg (20 %). ESI-MS (A mass spectrum was taken from 
a solution of an 1H NMR experiment, in which [(tpy)Ru(qpy)Pt(en)(9egua)]4+ was formed in 
situ from 4 and 9egua. Hence, the hydrochloric salt of the 9egua adduct has been found in the 
mass spectrum): m/z: 279 [M4+ + H+ + Cl–]. 1H NMR (400 MHz, acetone, 294 K): δ = 8.93 
(d, 2H; I33”), 8.07 (t, 2H; I44”), 7.35 (t, 2H; I55”), 7.71 (d, 2H; I66”), 9.49 (s, 2H; I3’5’), 
9.16 (d, 2H; I2”’6”’), 8.48 (d, 2H; I3”’5”’), 8.79 (d, 2H; II33”), 8.06 (t, 2H; II44”), 7.27 
(t, 2H; II55”), 7.68 (d, 2H; II66”), 9.07 (s, 2H; II3’5’), 8.59 (t, 2H; II4’), 6.10 (s, 2H; a), 3.16 
(s, 2H; b), 3.11 (s, 2H; c), 5.91 (s, 2H; d), 8.33 (s, 1H; H8), 6.62 (s, 1H; NH2), 4.16 (q, 2H; 
CH2), 1.41 ppm (t, 3H; CH3). 
 
6.2.4 Cytotoxicity tests 
 
Cell cultures: A2780cis and A2780R cells (cisplatin sensitive and resistant human ovarian 
carcinoma, respectively) were maintained in Dulbecco’s modified Eagle’s Medium (DMEM: 
Gibco BRLTM, Invitrogen Corporation, The Netherlands) supplemented with 10 % fetal calf 
serum (Perbio Science, Belgium), penicillin (100 units/mL: Duchefa Biochemie BV, The 
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Netherlands) and streptomycin (100 µg/mL: Duchefa Biochemie BV, The Netherlands) in a 
humidified 6 % CO2, 94 % air atmosphere at 310 K. Cisplatin sensitive and resistant mouse 
leukemia L1210/0 and L1210/2 cells were grown (partly in suspension and partly adherent to 
the flasks) under the above mentioned conditions. 
Cells were removed from the flasks by a 0.05 % trypsin solution. Cell viability was 
determined by the trypan blue exclusion test. 
In vitro cytotoxicity evaluation: Between 1000 and 5000 cells were seeded per well 
(depending on the cell type) onto 96-well plates (Corning Costar®) in 100 µl of complete 
medium with 5 to 10 % of FBS. Cells were treated 24 hours after sowing by addition of 100 
µL of the complex in complete medium at the appropriate concentration. Cell growth was 
determined after 72 hours of incubation by the MTT assay, a colorimetric assay based on the 
ability of viable cells to reduce the soluble yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide to blue formazan crystals by the mitochondria.[18] 
Final tested concentrations ranged between 10 µM and 100 µM and have been obtained by 
several dilutions with complete medium from stock solutions (2 mM) in sterile water. After 
72 hours of incubation at 310 K, cells were incubated with 1 mg/mL MTT solution for 2 to 4 
hour at 310 K. Subsequently, the medium was discarded and the formed crystals were 
dissolved in 100 µL DMSO per well. Optical density (OD) was measured at 590 nm with a 
Biorad 550 microplate reader. The OD is directly proportional to the number of living cells, 
which are compared to the control (untreated cells). 
 
6.3 Results and discussion 
 
6.3.1 Characterization of the mononuclear complexes 1, 2 and 3 
 
The complex [Ru(qpy)Cl3] (1) has been synthesized previously, but the complex was not 
characterized.[13] Characterization of [Ru(Xtpy)Cl3] complexes is often not performed, due to 
their insolubility in a wide variety of solvents.[19] Complex 1 is indeed poorly soluble even in 
DMSO. Moreover, the paramagnetic ruthenium(III) ion of 1 hampers characterization of the 
complex by standard 1H NMR techniques. Complex 1 has been characterized by 1H NMR 
spectroscopy using a strategy similar to that described in Chapter 2 for the characterization of 
paramagnetic trichlororuthenium(III) terpyridine complexes. The 1D 1H NMR spectrum of 1 
in DMSO-d6 is depicted in Figure 6.2. Signals have considerably shifted from the diamagnetic 
envelope from 0 to 12 ppm, because of the unpaired electron in the t2g orbital of the low-spin 













Figure 6.2 Schematic representation and 1H NMR spectrum of 1 in DMSO-d6 at 298 K 
with assignments. 
 
Signals are also significantly broadened. In total, seven signals of identical intensity are 
observed in the region from 50 to -50 ppm, which agrees with C2 symmetry of the complex. 
The 1D 1H NMR spectrum of 1 shows minor amounts of impurities. In contrast, in the 1D 1H 
NMR spectrum of its crude product (see experimental section) impurities are clearly observed 
in the diamagnetic region (data not shown). Complexes of the type [Ru(Xtpy)Cl3] are often 
not purified, due to their poor solubility.[19] However, for the synthesis of 2 the starting 
material, [Ru(qpy)Cl3], should be as pure as possible. Therefore, characterization of 1 by 1H 
NMR has been of significant use. Attempts to characterize 1 by different techniques have not 
been successful. The complex is most probably contaminated with ruthenium-oxo species, 
which are not observed in 1H NMR. 
The 1H NMR resonances displayed by 1 have partly been assigned by a 2D COSY NMR 
experiment (Figure 6.3) using a relaxation delay of 20 ms. The signal at –34.76 ppm shows no 
crosspeaks, which is most probably due to its short longitudinal and transversal relaxation 
times T1 (4.1 ms) and T2, respectively. Since the protons closest to the paramagnetic center 
are influenced the most, this signal has been assigned to the 66” protons. The three-spin 
connectivity pattern in the upfield region of the spectrum assigns these signals to the 33”, 44” 
and 55” protons. The resonance at –3.38 ppm can be attributed to the 44” protons, because it 
displays crosspeaks to both other signals. The signals at 10.04 and 0.13 ppm have been 
ascribed to the 2”’6”’ and 3”’5”’ protons, because of the COSY coupling. The resonance at 
6.47 ppm has been assigned to the 3’5’ protons, since it shows no crosspeaks. 
1D NOE difference experiments, as described in the foregoing chapters, have been 
unsuccessful for 1, due to its low solubility. However, the signals for the 2”’6”’ and 3”’5”’ 


























longitudinal relaxation time of 378 ms, which is significantly larger than that displayed by the 
resonance at 0.13 ppm (T1 = 86.2 ms). Therefore, the former has been ascribed to the protons 
furthest away from the paramagnetic center, i.e. the 2”’6”’ protons. The assignment is in 
agreement with that reported for the analogues complex [Ru(Phtpy)Cl3], in which a phenyl 
group has been substituted at the 4’ position of the terpyridine ligand.[17] The T1 values of the 
33” and 55” signals do not differ greatly, which is probably due to the fact that the metal-
proton distance for the 33” protons (4.9 Å) is approximately similar to that for the 55” protons 
(5.2 Å).[20] However, from 1H NMR studies of the complex[17] [Ru(tpy)Cl3] and its 
polynuclear derivatives (Chapters 2, 4 and 5), it has been found that the 33” resonance 
displays a smaller T1 value than the 55” signal. The resonances at –7.41 and –8.61 ppm 
exhibit T1 values of 33.5 and 25.2 ms, respectively. Consequently, the latter has been assigned 
to the 33” protons. For [Ru(tpy)Cl3], the most upfield shifted signal of the 33” and 55” 





















Figure 6.3 2D 1H COSY NMR spectrum of 1 in DMSO-d6 at 298 K with some 
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The observed chemical shifts have been plotted against 1/T (Figure 6.4). For all resonances a 
linear decrease in the hyperfine shift is observed upon a stepwise decrease of 1/T, which 
indicates Curie behavior. The Curie law predicts zero magnetism at infinite temperatures. 
Thus, the observed shifts should approach the diamagnetic values. The intercepts extrapolated 
at 1/T = 0 are close to the aromatic region, except for the 66” signal. Deviation from Curie 
behavior will not be discussed, as it is not important for the discussion here. The decrease in 
shift is higher for the 33” than for the 55” protons. It confirms their assignment, as a similar 
behavior has also been observed for the analogues protons of [Ru(tpy)Cl3] and its polynuclear 
















Figure 6.4 Plots of the chemical shifts versus 1/T for the signals of 1. 
 
The protons of the terpyridine part of 1 display a pattern of chemical shifts, which is similar to 
that of the corresponding protons of the mononuclear complex[17] [Ru(tpy)Cl3], and of the 
paramagnetic polynuclear derivatives (Chapters 2, 4 and 5). In addition, the chemical shifts of 
the protons of the 4’-pyridine are comparable to those of the phenyl ring protons of 
[Ru(phtpy)Cl3] (phtpy = 4’-phenyl-2,2’:6’,2”-terpyridine).[17] Therefore, it is likely that for 
the protons of 1 both contact (through bonds) and dipolar (through space) mechanisms 
contribute similarly to the hyperfine shift, i.e. the shift resulting from the interaction between 
the unpaired electron and the proton nucleus. 
For [Ru(tpy)Cl3], and the polynuclear ruthenium(III) terpyridine analogues, both contact 
(through chemical bonds) and dipolar (through space) interactions have been suggested to 
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contribute to the hyperfine shift (Chapter 2). A direct contact contribution to the chemical 
shift decreases rapidly as the number of chemical bonds between the metal and the resonating 
proton increases. Dipolar interactions decrease upon increasing metal-proton distances. The 
33”, 44”, 55” and 66” protons of the trichlororuthenium(III) terpyridine complexes (including 
1) display hyperfine shifts, which agree with their metal-proton distances, as well as with the 
number of chemical bonds to the metal center. The protons closest to the unpaired electron 
(i.e. the 66” protons) display the largest hyperfine shift, whereas the protons furthest away 
from the metal center (the 44” protons) show a relatively small hyperfine shift. 
A reversed pattern has been observed[17] for the resonances of the central pyridine ring of 
[Ru(tpy)Cl3]. The 3’5’ protons, for which the metal proton distance is approximately similar 
to that of the 33” and 55” protons, displays a small upfield shift to 5.5 ppm. In contrast, the 4’ 
proton, which is further away from the ruthenium(III) ion, exhibits a significant upfield shift 
(–23 ppm). It has been suggested that a spin polarization mechanism affects the chemical 
shifts of these protons in particular (Chapter 2). Spin polarization causes alternating upfield 
and downfield shifts in an aromatic system.[21] Since the 3’5’ resonance is not shifted 
downfield from the aromatic region, it is believed that spin polarization adds to a different 
mechanism. The sum does result in a positive shift of the 3’5’ signal relative to the 33” and 
55” resonances. 
A small upfield shift is also observed for the 3’5’ protons of 1 (Figure 6.2). Moreover, 
considering the metal-proton distance, a relatively large upfield shift is displayed by the 
3”’5”’ resonance (0.13 ppm). The 2”’6”’ signal is shifted downfield with respect to its 
diamagnetic value (10.04 ppm). These shifts underline that the central pyridine ring of 
paramagnetic trichlororuthenium(III) terpyridine complexes is affected by a spin polarization 
mechanism. The conjugated π system of the quaterpyridine ligand clearly transfers unpaired 
spin density to the fourth pyridine through this mechanism. A different hyperfine interaction 
is probably also present in the pendant pyridine, since the absolute hyperfine shifts of the 
3”’5”’ and 2”’6”’ protons are sensitive to the metal-proton distance. 
The characterization of [Ru(qpy)(tpy)]Cl2 (2), and [Ru(qpy)2]Cl2 (3) by 1H NMR 
spectroscopy will not be discussed in detail, since the characterization of the 
hexafluorophosphate salts of the complex cations by 1D and 2D COSY 1H NMR experiments 
has already been described.[13, 14] However, the characterization by 2D NOESY experiments 
has not been reported earlier. The incomplete characterization is surprising. Whereas the 33” 
and 66’ signals can be distinguished by the difference in J values (5 and 9 Hz, respectively), 
the 2”’6”’ and 3”’5”’ resonances cannot. The most upfield shifted signal of the two doublets 
under consideration has been assigned to the 2”’6”’ protons, to which the authors refer to as 
the ortho protons.[13] However, here a NOE of the 3’5’ qpy protons to the relatively upfield 
shifted doublet at 8.45 ppm is clearly observed in the 2D NOESY spectra of 2 and 3 (data not 
shown). Hence, this doublet has been attributed to the 3”’5”’ protons, whereas the doublet at 
approximately 9 ppm has been assigned to the 2”’6”’ protons (i.e. the meta protons). 
 
6.3.2 Characterization of the polynuclear complexes 4 and 5 
 
 (4) and [Cl(en)Pt(qThe complexes [(tpy)Ru(qpy)Pt(en)Cl](NO )3 3 py)Ru(qpy)Pt(en)Cl](NO3)4 
) have been fully characterized by 1D (Figure 6.5) and 2D COSY and NOESY 1H NMR, as 
ottom) in D2O at 298 K, with some assignments. The numbering scheme for the qpy ligand 
 
(5
well as 195Pt NMR experiments (see experimental section). Complex 4 displays one set of 
signals in the aromatic region for the terpyridine ligand II, and one set of signals for the 





















Figure 6.5 Schematic representation and 1D 1H NMR spectra (300 MHz) of 4 (top) and 5 
(b
I, tpy ligand II and the en protons of 4 are indicated. The numbering scheme for 5 is only 
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The terpyridine signals have been identified by the signal for the 4’ proton, which displays a 
relative intensity of one. The relative intensities of all other aromatic signals of 4 are two, 
which implies the presence of a C2 symmetry axis. Complex 5 displays one set of signals in 
the aromatic region for the quaterpyridine signals, which agrees with C2 symmetry. For both 
complexes the 66” resonances have been distinguished from the 33” resonances by the 
difference in J values, which are 5 and 9 Hz, respectively. A characteristic feature is the 
relative upfield shift of the 66” protons of 4 and 5, because of shielding by the other aromatic 
ligand. The chemical shifts of the 2”’6”’ and 3”’5”’ resonances of 4 have shifted downfield 
from the corresponding signals of the mononuclear derivative (0.24 and 0.28 ppm, 
respectively, in DMSO-d6), which implies coordination of platinum to the quaterpyridine 
ligand. For 5 only the 3”’5”’ resonance has shifted appreciably (0.16 ppm). 
The complexes also display resonances for the protons a, b, c, and d of the ethylenediamine 
ligand coordinated to platinum. The resonances for the amine protons are not observed in 
D2O, due to exchange with deuterated solvent. In DMSO-d6, the amine signals a and d of 4 
are seen at 6.66 and 5.89 ppm, respectively, at 298 K (data not shown). The corresponding 
resonances of 5 are observed at 6.25 and 5.90 ppm, respectively (data not shown). The 
resonances for the ethylene protons b and c overlap with residual solvent signal in DMSO-d6. 
These signals are clearly observed between 2 and 3 ppm in D2O (Figure 6.5). Their relative 
intensity indicates the formation of the polynuclear complexes 4 and 5. The 195Pt NMR shift 
for both 4 and 5 (~ -2517 ppm) in comparison to that of the starting complexes [Pt(en)Cl2] 
and [Pt(en)(H2O)Cl]+ (–2394 ppm and –2118, respectively, at 298 K in D2O) proves 
coordination of the platinum center to the quaterpyridine ligand. 
Electronic spectra were recorded in the range from 200 to 800 nm for aqueous solutions of 4 
and 5. Intense metal-to-ligand charge-transfer (MLCT) transitions are observed in the visible 
region (λmax 489 (ε = 2.0 · 104 M-1 cm-1) and λmax 497 nm (ε = 2.7 · 104 M-1 cm-1) for 4 and 5, 
respectively). These MLCT transitions originate from charge-transfer from the ruthenium 
metal to the π* orbitals of the quaterpyridine ligand. The MLCT bands have shifted to lower 
energy in comparison with those of the mononuclear derivatives (λmax 484 (ε = 1.9 · 104 M-1 
cm-1) and λmax 490 (ε = 3.3 · 104 M-1 cm-1) for 2 and 3, respectively). These observations are 
consistent with coordination of the electron-withdrawing platinum unit to the free 4’-pyridine, 
which lowers the energy level of the empty π* orbitals of the quaterpyridine ligand. 
 
6.3.3 Hydrolytic behavior 
 
Hydrolysis of 0.1 mM solutions of 4 and 5 in D2O at 310 K has been studied by 1H NMR 
experiments. No changes in the 1D spectra were observed after several days, which implies 
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that the complexes do not hydrolyze. Even at 363 K, no significant hydrolysis was observed 
after a couple of days. Incubation with AgBF4 for 2 days to remove the chloride ligand 
resulted in a slight downfield shift (~ 0.08 ppm) of the 3”’5”’ signal for both 4 and 5. A more 
significant shift was observed in 195Pt NMR, i.e. from –2518 to –2327 ppm, which clearly 
proves substitution of the chloride ligand by D2O. 
The minimal change in chemical shift of the 3”’5”’ 1H NMR signal upon hydrolysis is 
surprising. A large difference in chemical shift (0.6 ppm) for the 3”’5”’ signal has been 
observed (by others) upon protonation or methylation of the free pyridine of the [Ru(qpy)2]2+ 
cation.[13] For 4 and 5, considerable changes in chemical shifts were also expected upon 
hydrolysis, because of the strong electron-withdrawing effect of the chloride ligand and the 
change of the total charge of the complex. The chloride ligand is possibly not substituted by a 
water molecule but by a hydroxide ion, which is electron withdrawing as well. Coordination 
of a hydroxide ion instead of water would result in a slightly acidic pH of the solution. 
Unfortunately, the pH has not been measured after hydrolysis. Electronic effects within the 
quaterpyridine ligand may be the reason why a change in chemical shift is observed for the 
3”’5”’ protons instead of a shift for the 2”’6”’ protons, which are closer to the site where 
hydrolysis occurs. 
For cisplatin, it is believed that hydrolysis occurs before coordination to DNA.[22] It is not 
clear why 4 and 5 do not hydrolyze. Electronic effects within the extended aromatic system 
may also be of influence on the strength of the platinum-chloride coordination bond. 
 
6.3.4 Coordination of the DNA-model base 9-ethylguanine to platinum 
 
From the reaction of the dinuclear complex 4 with 9egua, the monoadduct 
[(tpy)Ru(qpy)Pt(en)(9egua)](PF6)4 (6) has been isolated as the hexafluorophosphate salt. The 
hexafluorophosphate salt of the adduct is not soluble in water. Therefore, the 1D 1H NMR 
spectrum of 6 has been acquired in acetone-d6, and is shown in Figure 6.6. 
The adduct 6 displays similar symmetry as 4, and the terpyridyl and quaterpyridyl 1H NMR 
resonances have analogously been assigned (vide supra). The chemical shifts of the 9egua 
protons of 6 in acetone-d6 compared to those of the free DNA-model base indicate binding of 
9egua to the complex (δ =  1.41, 4.16, 6.62 and 8.33 ppm versus 1.40, 4.06, 5.98 and 7.60 
ppm for CH3, CH2, NH2 and H8 of 4 and 6, respectively). The relative intensity of the 9egua 
resonances indicates coordination of one base. The NH1 proton of 9egua is not observed 
probably due to fast exchange with deuterated solvent. The large shift for the H8 resonance 
and the I2”’6”’–H8 NOE crosspeak present in the 2D NOESY spectrum of 6 (Figure 6.7) 













Figure 6.6 Schematic representation of 6 and its 1D 1H NMR spectrum in acetone-d6 at 
294 K with some assignments. 
 
The I2”’6”’ quaterpyridine signal displays a small upfield shift (0.06 ppm) upon coordination 
of 4 to 9egua, whereas the I3”’5”’ resonance shifts more appreciably (0.25 ppm). The C2 
symmetry displayed in the 1H NMR spectrum of 6 suggests either a rigid structure of the 
adduct, or fast rotation of the coordinated DNA-model base. The conjugated π system of the 
quaterpyridine ligand probably prevents rotation within the ligand. The I2”’6”’–H8 NOE 
crosspeak indicates that 9egua is directed with the H8 proton towards the quaterpyridine 
ligand. This orientation is most likely stabilized by H bonding between the keto group of the 
base and the NH2 protons of the ethylene diamine ligand. Rotation around the platinum-
pyridine coordination bond is theoretically possible, but the platinum-9egua unit may also be 




The new complexes have been tested against human ovarian A2780 and mouse leukemia 
L1210 cisplatin sensitive and resistant cells. The mononuclear complex 2 and the dinuclear 
complex 4 do not display any toxicity against the A2780 cell lines at the tested concentrations 
(i.e. 100 µM), whereas the mononuclear bis(quaterpyridine)-ruthenium complex 3 inhibits 
50 % of cell growth of A2780 cells at a similar concentration. The trinuclear complex 5 
inhibits 50 % of cell growth of cisplatin sensitive A2780cis cells at a concentration of 
approximately 50 µM, and reaches 50 % of cell growth inhibition of cisplatin resistant 
A2780R cells at 100 µM. These results suggest that the quaterpyridine ligand affects the 






























general the complexes do not display significant cytotoxicity. The complexes are not toxic 
against the leukemia cell lines either. Cytotoxicity has been reported[23] for the mononuclear 




















Figure 6.7 2D 1H NOESY NMR spectrum of 6 in acetone-d6 at 294 K with some 
assignments and the I2”’6”’-H8 crosspeak indicated. 
 
 
6.4 Concluding remarks 
 
The paramagnetic complex [Ru(qpy)Cl3] (1) has been shown to display interesting 1H NMR 
features, which have been studied by different 1H NMR experiments. The alternating shifts of 
the central pyridine and the pendant pyridine protons stress that within these aromatic rings 
delocalization of spin density partly occurs by a spin polarization mechanism, as has been 
suggested for analogues paramagnetic trichlororuthenium complexes. The water soluble 
complexes [(tpy)Ru(qpy)]Cl2 (2) and [Ru(qpy)2]Cl2 (3) have been synthesized from 
[Ru(tpy)Cl3] and 1, respectively, for the assembly of the polynuclear ruthenium-platinum 




It has been shown that the platinum ethylene diamine moiety of 4 does not hydrolyze at 310 
K. Instead the platinum unit reacts with the DNA-model base 9-ethylguanine (9egua). It has 
been concluded that the base is coordinated to platinum via the N7 atom, and is pointing with 
the H8 proton towards the quaterpyridine ligand. This orientation is most probably stabilized 
by hydrogen bonding between the keto group of the base and the amine protons of the 
ethylene diamine ligand. Unfortunately, the complexes do not show significant cytotoxicity 
against a selection of cancer cell lines. 
Electronic spectra have shown that coordination of platinum to the 4’-pyridine ligand lowers 
the energy level of the ruthenium-centered MLTC band. It would be of interest to study 
whether the platinum moiety is more reactive towards biomolecules by light excitation of the 
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Cisplatin is successfully used in chemotherapy, but is effective only against a narrow range of 
tumors.[1] The development of analogues has resulted in a few clinically useful complexes, 
most of which, however, are cross-resistant to cisplatin.[2] Many cancers remain difficult to 
treat. Cisplatin derivatives probably lack activity against cancers, which are resistant to the 
parent drug, because they form a similar type of adducts to the DNA, the ultimate target of 
platinum drugs.[3] Therefore, a variety of platinum complexes have been synthesized, which 
are structurally distinct from cisplatin, and as a result bind to DNA in a fundamentally 
different manner.[4] A class of “non-classical” platinum compounds comprises polynuclear 
platinum complexes.[5] It is believed that these complexes can overcome cisplatin resistance, 
because they are capable of specific interactions with biomolecules, which cannot be achieved 
by their mononuclear counterparts. Next to platinum, ruthenium is also used for the 
construction of anticancer agents.[6] Because of the octahedral structure of ruthenium 
complexes, as opposed to the square-planar geometry of cisplatin, they interact differently 
with biological targets. The research described in this Thesis has been devoted to the design 
and development of polynuclear polypyridyl ruthenium and ruthenium-platinum complexes in 









7.2 Summary and general discussion 
 
Chapter 1 presents an introduction on the development of platinum and ruthenium anticancer 
complexes. The clinical success of cisplatin has been a tremendous impetus for the design of 
metal-based antitumor drugs. Its mechanism of action is therefore briefly discussed, as well as 
the toxic side effects of its clinical use and the cellular resistance to the drug. Cisplatin’s side 
effects have lead to the development of cisplatin analogues, whereas drug resistance has 
stimulated the construction of structurally different complexes. The main achievements in the 
development of mononuclear anticancer platinum and ruthenium complexes have been 
presented first. Of special interest are the polynuclear platinum compounds. An overview is 
given, and insight in their biological features is outlined. The last part of the introduction 
deals with the development of polynuclear ruthenium and polynuclear ruthenium-platinum 
DNA-binding complexes, the main topics of the research described in this Thesis. 
In Chapter 2 the synthesis of the dinuclear ruthenium(II)-ruthenium(III) complex 
[(tpy)Ru(dtdeg)RuCl3]Cl2, for which the long and flexible linker dtdeg has been used, is 
presented (dtdeg = bis[4’-(2,2’:6’,2”-terpyridyl)]-diethyleneglycolether, tpy = 2,2’:6’,2”-
terpyridine). The development of the complex has been inspired by the antitumor-active 
mononuclear complex[7] [Ru(tpy)Cl3]. The paramagnetic complex has been fully 
characterized in a straightforward manner by 1H NMR experiments, which include the use of 
1D 1H NOE difference techniques. The complex represents a prototype of the various 
trichlororuthenium(III) terpyridyl complexes, which are described in this Thesis. For these 
complexes dipolar and contact interactions are suggested to contribute to the hyperfine shift 
and nuclear relaxation. 
The dinuclear ruthenium(II) complexes [Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2, 
[(tpy)Ru(dtdeg)Ru(bpy)Cl]Cl3, and [(tpy)Ru(dtdeg)Ru(tpy)]Cl4 are described in Chapter 3 
(bpy = 2,2’-bipyridine). The complexes consist of two metal moieties, of which at least one is 
capable of monofunctional coordination to biomolecules. The bifunctional complex 
[Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2 has been studied for its hydrolysis, since it is generally 
believed that the chloride ligands of cisplatin are hydrolyzed before coordination to DNA.[8] 
The complex has also been shown to coordinate to the DNA-model base 9-ethylguanine 
(9egua). Its monoadduct and bisadduct have been characterized by variable temperature 1H 
NMR experiments. Free rotation of the base is hindered at room temperature. At 248 K 9egua 
is flipping between two enantiomeric rotamers. Despite the fact that the monofunctional metal 
moieties can coordinate to DNA, the complexes do not show cytotoxicity against different 
cancer cell lines. The complexes are taken up in the cell, but uptake is not related to 
cytotoxicity. 
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Variation of the metal may have an effect on the activity of the complexes against cancer 
cells. Therefore, the heterodinuclear ruthenium-platinum complex [Cl3Ru(dtdeg)PtCl]Cl, and 
its derivatives [Cl(bpy)Ru(dtdeg)PtCl]Cl2 and [(tpy)Ru(dtdeg)PtCl]Cl3, have been 
constructed, which is revealed in Chapter 4. The complexes vary in the structure of the 
ruthenium moiety. The platinum unit is derived from the cytotoxic[9] mononuclear complex 
[Pt(tpy)Cl]Cl·2H2O. The crystal structure of [(tpy)Ru(dtdeg)PtCl]Cl3 illustrates that the 
platinum moiety is capable of self-stacking interactions. DNA-model base studies show that 
the platinum moiety coordinates to a guanine derivative. The results imply that the platinum 
moiety is able to both intercalate and coordinate to the DNA, without being hindered by the 
dangling ruthenium moiety. The length of the linker can afford long-range DNA interactions 
of the dinuclear complexes. However, the complexes do not show cytotoxicity. Even complex 
[Cl3Ru(dtdeg)PtCl]Cl, in which two active units have been assembled, is deficient of any 
cytotoxicity. 
To examine the influence of the nature and length of the linker on biological activity, the 
complexes [(dtdeg)Ru(dtdeg)]Cl2 and [(dtdeg)Ru(dtdeg)Ru(dtdeg)]Cl4 have been developed. 
They have been produced to synthesize the trinuclear and tetranuclear ruthenium complexes 
[Cl3Ru(dtdeg)Ru(dtdeg)RuCl3]Cl2 and [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4, and the 
trinuclear and tetranuclear ruthenium-platinum analogues [ClPt(dtdeg)Ru(dtdeg)PtCl]Cl4 and 
[ClPt(dtdeg)Ru(dtdeg)Ru(dtdeg)PtCl]Cl6. The linkers most likely affect DNA affinity by 
electrostatic interactions. In general, the complexes show higher cytotoxicity then the 
dinuclear derivatives. The tetranuclear complex [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4 
displays interesting biological features. Human ovarian cisplatin sensitive carcinoma 
(A2780cis) cells adhere together and form clots upon incubation with this complex. The effect 
is characteristic for these ovarian cancer cells in particular, and is specific for the structure of 
the tetranuclear ruthenium complex. These results are presented in Chapter 5. 
In contrast to the long and flexible linker dtdeg, the short and semi-rigid bridging ligand 
4’-pyridyl-2,2’:6’,2”-terpyridine (qpy) has been used for the development of the 
heteropolynuclear ruthenium-platinum complexes [(tpy)Ru(qpy)Pt(en)Cl](NO3)3 and 
[Cl(en)Pt(qpy)Ru(qpy)Pt(en)Cl](NO3)4 (en = 1,2-ethylenediamine), which are described in 
Chapter 6. It has been demonstrated that the platinum moiety can coordinate to 
9-ethylguanine. The adduct is most probably stabilized by a hydrogen bond between the 
amine protons of the en ligand and the keto group of the base. The complexes do not show 
cytotoxicity against a variety of cancer cell lines. 
In conclusion, the research described in this Thesis has resulted in the synthesis of a class of 
polynuclear polypyridyl ruthenium and ruthenium-platinum complexes, for which the length 
of the linker appears to be of importance for biological activity. The work has lead to the 
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development of a complex, i.e. [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4, which shows an 
interesting effect against human ovarian carcinoma cells. Considering the urgent need for 
highly selective drugs, this complex may represent a novelty. Significant activity against 
cisplatin-resistant cancer cells has, however, not been achieved. Variation of the metal, 
terminal ligands and the linker within this group of polynuclear polypyridyl complexes can 
provide promising agents, which may specifically be cytotoxic against drug-resistant 
carcinomas. 
 
7.3 Future prospects 
 
Several routes can be taken to improve the activity of the complexes presented in this Thesis. 
The results described in Chapter 3 have indicated that the dinuclear ruthenium complexes are 
taken up by cancer cells. Subsequently, it would be of interest to know whether the complexes 
reach the DNA inside the cell. DNA binding studies have shown that the complexes associate 
fast with the isolated duplex[10] (data not shown), which is most likely due to electrostatic 
interactions. However, the DNA-model base studies described in Chapter 3 have shown 
flexible behavior of coordinated base, and even dissociation from ruthenium. DNA 
interactions can be enhanced by substitution of the terminal bipyridine ligand with a more 
extended aromatic ligand. Intercalation may then become feasible. Ongoing studies[11] have 
already demonstrated increased cytotoxicity of the dppz (dppz = dipyrido-[3,2-a:2’,3’-c]-
phenazine) derivative  of complex [Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2 (Figure 7.1). Extended 






Figure 7.1 The cationic dinuclear dppz complex [Cl(dppz)Ru(dtdeg)Ru(dppz)Cl]2+. 
 
For the dinuclear ruthenium-platinum complexes, with which Chapter 4 deals, self-stacking 
interactions of the platinum terpyridine moieties have been observed. It would be of interest to 
study the intercalation of the platinum moiety into DNA. Replacement of the platinum bound 
chloride ligand, with for example 4-picoline (Figure 7.2) may result in increased DNA 


























Figure 7.2 The 2+ charged dinuclear 4-picoline ruthenium(III)-platinum(II) complex 
[Cl3Ru(dtdeg)Pt(4-picoline)]2+. 
 
This strategy is especially attractive to apply to the water-insoluble complex 
[Cl3Ru(dtdeg)PtCl]Cl, in which two active mononuclear complexes are joined. The 2+ charge 
of the resulting platinum moiety most likely yields increased water solubility and DNA 
affinity, which may affect cytotoxicity. Introduction of thiolate ligands on the platinum-
terpyridine moiety represents a different approach. Interaction with DNA and the 
selenoenzyme thioredoxin reductase has been reported for thiolate platinum-terpyridine 
complexes.[13] It would also be interesting to use gold instead of platinum as the second metal, 
since gold(III) complexes represent another class of anticancer agents.[14] Gold-terpyridine 
complexes have already been reported to display significant cytotoxicity against cisplatin-
sensitive and -resistant human ovarian carcinoma cells.[15] 
The tetranuclear complex [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4 presented in Chapter 
5, has already been shown to induce clotting of human ovarian cancer cells. The effect 
indicates that the complex may inhibit cell migration and metastasis. The relation between 
clotting and invasion inhibition is currently under study. To better understand the effect of the 
nature and length of the linker in more detail, it would be of interest to synthesize the 
spermidine and spermine derivatives of these complexes (Figure 7.3). Spermidine and 
spermine are known to play essential roles in normal cell growth and differentiation.[16] They 
have already been used for the construction of polynuclear platinum complexes, which show 
promising anticancer activity.[17] In addition to electrostatic interactions, the polyamines can 
also hydrogen bond to the DNA, which may tune the biological properties of the polynuclear 
complexes. Variation of the metal and terminal ligands, as has been suggested for the 
dinuclear ruthenium and ruthenium-platinum complexes, can be extended to these trinuclear 
and tetranuclear complexes. 
To enhance cytotoxicity of the short-linked quaterpyridine complexes presented in Chapter 6, 
the number of labile chloride ligands on the platinum moieties may be varied. The synthesis 






















Figure 7.3 The spermidine analogue of the dinuclear cationic ruthenium(III) complex 
[Cl3Ru(dtdeg)Ru(dtdeg)RuCl3]2+. The spermidine linker will be protonated at physiological 
pH, which will result in a 3+ total charge for the complex. 
 
Attempts to vary the ruthenium unit of the dinuclear complex [(tpy)Ru(qpy)Pt(en)Cl](NO3)3 
have already been performed, but were unsuccessful so far. The poor solubility of the 
trichlororuthenium(III) quaterpyridine complex represented a major problem for the synthesis 
of polynuclear ruthenium(III)-platinum(II) derivatives. Preliminary results have indicated that 
synthesis of the bipyridine complex [Cl(bpy)Ru(qpy)Pt(en)Cl](NO3)3 is possible, but 
hydrolysis of the ruthenium moiety occurs. Substitution of the chloride ligand can provide a 
solution to this problem. The ligand can be chosen in a way to generate electron transfer from 
the ruthenium unit to the platinum moiety upon light excitation of the former, which may lead 
to increased reactivity of the latter towards biomolecules. A different strategy can be 
employed, in which platinum coordinates to the terpyridine part of the quaterpyridine ligand, 
and ruthenium to the fourth pyridine. It would for example be attractive to construct 
polynuclear ruthenium-platinum complexes, which resemble Keppler-type complexes with 
exception of the charge (Figure 7.4).[18] The Keppler-type complexes are of general formula 








Figure 7.4 A trinuclear ruthenium(III)-platinum(II) quaterpyridine complex, in which the 
ruthenium moiety resembles the promising anticancer agent (Hind)[RuCl4(ind)2] (KP1019, 






























Clearly, the above suggested variations of the metal, terminal ligands, or linker can provide a 
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Ontwerp en ontwikkeling van polynucleaire ruthenium-
complexen en ruthenium-platinacomplexen 
 
Op zoek naar nieuwe medicijnen tegen kanker 
 
 
Het antikankermedicijn cisplatina wordt succesvol gebruikt in chemotherapie maar is slechts 
actief tegen een klein aantal tumoren. Alhoewel de ontwikkeling van analoga wel heeft 
geresulteerd in een aantal klinisch waardevolle verbindingen, zijn veel vormen van kanker 
nog steeds moeilijk te behandelen. De meeste cisplatinaderivaten zijn alleen werkzaam tegen 
tumoren waartegen cisplatina ook actief is. Waarschijnlijk komt dit omdat ze soortgelijke 
adducten vormen met DNA, het doelwit van antikanker-platinamedicijnen. Daarom zijn 
platinacomplexen ontwikkeld die structureel niet gerelateerd zijn aan cisplatina en die op een 
fundamenteel verschillende wijze aan DNA binden. Polynucleaire platinacomplexen zijn een 
voorbeeld van een groep niet-klassieke platinaverbindingen. In vergelijking met 
mononucleaire complexen zijn deze verbindingen in staat tot unieke interacties met 
biomoleculen waardoor cisplatinaresistentie overwonnen kan worden. Naast platina wordt 
ruthenium ook gebruikt voor het ontwikkelen van antikankergeneesmiddelen. In tegenstelling 
tot de vlakvierkante geometrie van cisplatina hebben veel rutheniumcomplexen een 
octaëdrische structuur. Door deze structuur kunnen rutheniumverbindingen een andere 
werking hebben op cellulaire componenten. Het onderzoek dat in dit proefschrift is 
beschreven heeft zich gericht op de ontwikkeling van polynucleaire rutheniumcomplexen en 
ruthenium-platinacomplexen met als doel nieuwe medicijnen tegen kanker te ontdekken. 
Hoofdstuk 1 is een algemene inleiding waarin de ontwikkeling van antikanker-
platinacomplexen en -rutheniumverbindingen samengevat is. Het klinische succes van 
cisplatina is van enorme invloed geweest op het ontwerp van metaalgebaseerde 
antikankermedicijnen. Daarom wordt het mechanisme van cisplatina, de toxische bijeffecten 
en de cellulaire resistentie tegen het medicijn kort besproken. De toxische bijeffecten van het 
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medicijn hebben geresulteerd in de synthese van cisplatinaderivaten. Cisplatinaresistentie van 
verschillende kankers heeft geleid tot de constructie van complexen die structureel niet 
gerelateerd zijn aan cisplatina. De belangrijkste resultaten die behaald zijn in de ontwikkeling 
van mononucleaire platina- en rutheniumcomplexen worden gepresenteerd. Polynucleaire 
platinacomplexen zijn van speciale interesse geweest voor het onderzoek dat in dit 
proefschrift is beschreven. Een overzicht van deze groep van verbindingen wordt gegeven en 
biologische eigenschappen worden belicht. Omdat het in dit proefschrift gepresenteerde 
onderzoek zich heeft gericht op de synthese en evaluatie van polynucleaire 
rutheniumcomplexen en polynucleaire ruthenium-platinacomplexen worden deze twee 
klassen van verbindingen ook besproken. 
In Hoofdstuk 2 wordt de synthese van het dinucleaire ruthenium(II)-ruthenium(III)complex 
[(tpy)Ru(dtdeg)RuCl3]Cl2 beschreven waarvoor de lange en flexibele linker dtdeg is gebruikt 
(dtdeg = bis[4’-(2,2’:6’,2”-terpyridyl)]-diethyleenglycolether, tpy = 2,2’:6’,2”-terpyridine). 
De ontwikkeling van het complex is gebaseerd op het antitumor-active mononucleaire 
complex [Ru(tpy)Cl3]. In tegenstelling tot [Ru(tpy)Cl3] is [(tpy)Ru(dtdeg)RuCl3]Cl2 in water 
oplosbaar. Het paramagnetische dinucleaire complex wordt volledig gekarakteriseerd met 
behulp van 1H NMR, waaronder 1D 1H NOE difference experimenten. Het complex is een 
prototype voor de verschillende trichlororuthenium(III)complexen die in dit proefschrift zijn 
beschreven. Waarschijnlijk beïnvloeden dipolaire- en contactinteracties de hyperfine shift en 
nucleaire relaxatie van de verschillende protonen van deze verbindingen. 
De dinucleaire ruthenium(II)complexen [Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2, 
[(tpy)Ru(dtdeg)Ru(bpy)Cl]Cl3, en [(tpy)Ru(dtdeg)Ru(tpy)]Cl4 zijn behandeld in Hoofdstuk 3 
(bpy = 2,2’-bipyridine). Het eerste complex bestaat uit twee metaaleenheden, die elk in staat 
zijn om monofunctioneel te coördineren aan biomoleculen. De laatste twee complexen 
bestaan uit tenminste één substitutie-inerte rutheniumeenheid. Omdat men aanneemt dat de 
chlorideliganden van cisplatina hydrolyseren vóór coördinatie aan DNA is de hydrolyse van 
het bifunctionele complex [Cl(bpy)Ru(dtdeg)Ru(bpy)Cl]Cl2 bestudeerd. Het complex 
coördineert aan de DNA-modelbase 9-ethylguanine (9egua). Zowel het monoadduct als het 
bisadduct zijn gekarakteriseerd met behulp van 1H NMR experimenten bij verschillende 
temperaturen. De base wordt gehinderd in vrije rotatie bij kamertemperatuur. Bij 248 K flipt 
9egua tussen twee enantiomere rotameren. Ondanks het feit dat de monofunctionele 
metaalunits aan DNA kunnen coördineren zijn de complexen niet cytotoxisch. De complexen 
worden door de cel opgenomen maar de opname is duidelijk niet gecorreleerd aan 
cytotoxiciteit. 
Variatie van het metaal kan van invloed zijn op de cytotoxiciteit. Daarom zijn het 
heterodinucleaire ruthenium(III)-platina(II)complex [Cl3Ru(dtdeg)PtCl]Cl en de 
 161
ruthenium(II)derivaten [Cl(bpy)Ru(dtdeg)PtCl]Cl2 en [(tpy)Ru(dtdeg)PtCl]Cl3 
gesynthetiseerd. De synthese en karakterisering van de complexen zijn beschreven in  
Hoofdstuk 4. De complexen variëren in de structuur van de rutheniumeenheid. De platina-
unit is afgeleid van het cytotoxische mononucleaire complex [Pt(tpy)Cl]Cl. In de 
kristalstructuur van [(tpy)Ru(dtdeg)PtCl]Cl3 zijn self-stacking interacties van de platina-
eenheden te zien. DNA-modelbase studies geven aan dat het platinadeel kan coördineren aan 
een guaninederivaat. De resultaten impliceren dat de platina-eenheid zowel kan intercaleren 
als coördineren aan DNA zonder dat het daarbij gehinderd wordt door de verbonden 
rutheniumeenheid. De complexen kunnen mogelijk over een lange afstand aan DNA binden 
door de lengte van de flexibele linker (14.5 Å). Helaas is gebleken dat de complexen niet 
actief zijn tegen verschillende kankercellijnen. Zelfs het complex [Cl3Ru(dtdeg)PtCl]Cl, 
waarin twee active eenheden zijn verbonden, is niet cytotoxisch. 
De ruthenium(II)complexen [(dtdeg)Ru(dtdeg)]Cl2 en [(dtdeg)Ru(dtdeg)Ru(dtdeg)]Cl4 zijn 
ontwikkeld om de invloed van de lading en de lengte van de linker op de cytotoxiciteit van de 
polynucleaire complexen te bestuderen. Uitgaande van deze verbindingen zijn de trinucleaire 
en tetranucleaire ruthenium(II)-ruthenium(III)complexen [Cl3Ru(dtdeg)Ru(dtdeg)RuCl3]Cl2 
en [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4 gesynthetiseerd, evenals de trinucleaire en 
tetranucleaire ruthenium(II)-platina(II) analoga [ClPt(dtdeg)Ru(dtdeg)PtCl]Cl4 en 
[ClPt(dtdeg)Ru(dtdeg)Ru(dtdeg)PtCl]Cl6. De positieve lading van de linkers beïnvloedt 
hoogst waarschijnlijk DNA-affiniteit door elektrostatische interacties. In het algemeen zijn de 
complexen actiever dan de dinucleaire derivaten tegen verschillende kankercellijnen. Het 
tetranucleaire complex [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4 heeft een karakteristieke 
uitwerking op de groei van menselijke ovarium-kankercellen die gevoelig zijn voor cisplatina 
(A2780cis). Deze cellen klonteren samen als ze geïncubeerd worden met het tetranucleaire 
complex en overleven voor slechts 35 % bij een concentratie van 20 µM van 
[Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4. Het effect is karakteristiek voor deze ovarium-
kankercellen en is specifiek voor de structuur van het tetranucleaire rutheniumcomplex. Deze 
resultaten worden gepresenteerd in Hoofdstuk 5. 
In tegenstelling tot de lange en flexibele linker dtdeg, is de korte en semistarre linker 
4’-pyridyl-2,2’:6’,2”-terpyridine (qpy) gebruikt voor de ontwikkeling van de 
heteropolynucleaire ruthenium(II)-platinum(II)complexen [(tpy)Ru(qpy)Pt(en)Cl](NO3)3 en 
[Cl(en)Pt(qpy)Ru(qpy)Pt(en)Cl](NO3)4 (en = 1,2-ethyleendiamine). De synthese en 
karakterisering van deze complexen is beschreven in Hoofdstuk 6. Het is bewezen dat de 
platina-eenheid kan coördineren aan 9-ethylguanine. Het adduct wordt waarschijnlijk 
gestabiliseerd door een waterstofbinding tussen de amineprotonen van het 
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ethyleendiamineligand en de ketongroep van de base. De complexen zijn niet cytotoxisch 
voor verschillende kankercellijnen. 
In Hoofdstuk 7 wordt een samenvatting gegeven van het in dit proefschrift beschreven 
onderzoek en wordt vooruitgeblikt op mogelijke uitbreidingen op de gepresenteerde 
polynucleaire complexen. 
Samenvattend vormen de ontwikkelde polynucleaire rutheniumcomplexen en ruthenium-
platinacomplexen die in dit proefschrift zijn beschreven een waardevolle uitbreiding op het 
bestaande repertoire van potentiële anorganische antikankerverbindingen. Het onderzoek 
heeft geleid tot de synthese van een klasse van verbindingen waarvoor de lengte en misschien 
ook de lading van de linker van belang zijn voor biologische activiteit. Resultaten wijzen uit 
dat speciaal het tetranucleaire complex [Cl3Ru(dtdeg)Ru(dtdeg)Ru(dtdeg)RuCl3]Cl4 
interessante biologische eigenschappen bezit. Omdat er grote behoefte is aan selectieve 
geneesmiddelen vertegenwoordigt dit complex misschien een belangrijk nieuw 
antikankermedicijn. Helaas zijn de complexen niet actief tegen cisplatinaresistente 
kankercellen. Variatie van het metaal, de terminale liganden en de linker van deze groep van 
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